Himcare Excel Sheet

Package Package PackageID Governme
Category Category PackageN PackageD PackageId IsMedSur PreAuthS

SL# - Amount nt_
ame escription - PMJAY gical tatus
HIMCARE Reserved
Code Code
Docetaxel
+
Cyclophos
phamideDo
cetax el
CT for CA
521 MO MO001 75mg/m2 MO001E MO001E2 S 10200 Y N
Breast
D1Cycloph
osphamide
600 mg/m2
D1 every
21 days
Trastuzum
ab
Trastuzum
ab 8 mg/Kg
in Cycle 1
CT for CA
522 MO MO001 D1 MO001F MO001F1 S 21200 Y N
Breast
Trastuzum
ab 6 mg/kg
D1 from C2
every 21
days
Trastuzum
ab
Trastuzum
ab 8 mg/Kg
in Cycle 1
CT for CA
522 MO MO001 D1 MO001F MO001F1 S 21200 Y N
Breast
Trastuzum
ab 6 mg/kg
D1 from C2
every 21
days
Trastuzum
abTrastuzu
mab 8
mg/Kg in
Cycle 1
CT for CA
523 MO MO001 D1Trastuz MO001F MO001F2 S 23400 Y N
Breast
umab 6
mg/kg D1
from C2
every 21
days
Tamoxifen
CT for CA Tamoxifem
524 MO MO001 MO001G MO001G1 S 1300 Y N
Breast 20 mg
orally daily
Letrozole
CT for CA Letrozole
525 MO MO001 MO001H MO001H1 S 4300 Y N
Breast 2.5 mg
orally daily
Letrozole
CT for CA Letrozole
525 MO MO001 MO001H MO001H1 S 4300 Y N
Breast 2.5 mg
orally daily
Carboplati
n+
Paclitaxel
Paclitaxel
CT for CA 175mg/m2
526 MO MO001 MO001I MO001I1 S 16400 Y N
Breast D1Carbopl
atin AUC
5-6 D1
every 21
days
Capecitabi
ne
Capecitabi
ne -
CT for CA 1000mg/m
527 MO MO001 MO001J MO001J1 S 7400 Y N
Breast 2 orally
twice daily
D1-D14
every 21
days
Capecitabi
neCapecita
bine -
1000mg/m
CT for CA
528 MO MO001 2 orally MO001J MO001J2 S 8200 Y N
Breast
twice daily
D1-D14
every 21
days
Capecitabi
neCapecita
bine -
1000mg/m
CT for CA
528 MO MO001 2 orally MO001J MO001J2 S 8200 Y N
Breast
twice daily
D1-D14
every 21
days
Carboplati
n+
Gemcitabin
e
Gemcitabin
e-
1000mg/m
2 D1 D8
CT for CA Carboplati
529 MO MO001 MO001K MO001K1 S 13900 Y N
Breast n AUC 2
D1 D8
Gemcitabin
e-
1000mg/m
2 D1 D8
Carboplati
n AUC 5-6
D1 only
Carboplati
n+
Gemcitabin
eGemcitabi
ne -
1000mg/m
2 D1
D8Carbopl
CT for CA
530 MO MO001 atin AUC 2 MO001K MO001K2 S 15300 Y N
Breast
D1
D8Gemcita
bine -
1000mg/m
2 D1 D8
Carboplati
n AUC 5-6
D1 only
Cyclophos
phamide +
Adriamycin
Cyclophos
phamide -
CT for CA
531 MO MO001 600 mg MO001L MO001L1 S 4500 Y N
Breast
/m2 D1
Adriamycin
- 60mg/m2
D1 every
21 days
Cyclophos
phamide +
Adriamycin
Cyclophos
phamide -
CT for CA
531 MO MO001 600 mg MO001L MO001L1 S 4500 Y N
Breast
/m2 D1
Adriamycin
- 60mg/m2
D1 every
21 days
Cyclophos
phamide +
Adriamycin
Cyclophos
phami de -
CT for CA 600 mg
532 MO MO001 MO001L MO001L2 S 5000 Y N
Breast /m2
D1Adriamy
cin -
60mg/m2
D1 every
21 days
Fulvestrant
Fulvestrant
CT for CA 500 mg D1
533 MO MO001 MO001M MO001M1 S 11000 Y N
Breast D15 D28
then every
28 days
Fulvestrant
Fulvestrant
500 mg D1
D15 D28
then every
CT for CA 28
534 MO MO001 MO001M MO001M2 S 13200 Y N
Breast days.per
dose13200
(39600 in
cycle1 )
then 13200
per month
Fulvestrant
Fulvestrant
500 mg D1
D15 D28
then every
CT for CA 28
534 MO MO001 MO001M MO001M2 S 13200 Y N
Breast days.per
dose13200
(39600 in
cycle1 )
then 13200
per month
Paclitaxel
Paclitaxel
CT for CA
535 MO MO001 175 mg/m2 MO001N MO001N1 S 13000 Y N
Breast
D1 every
21 days
Exemestan
e
CT for CA
536 MO MO001 Exemestan MO001O MO001O1 S 10400 Y N
Breast
e 25 mg
orally daily
Exemestan
e
Exemestan
CT for CA
537 MO MO001 e 25 mg MO001O MO001O2 S 4300 Y N
Breast
orally daily
(q 3
monthsly)
Exemestan
e
Exemestan
CT for CA
537 MO MO001 e 25 mg MO001O MO001O2 S 4300 Y N
Breast
orally daily
(q 3
monthsly)
CT for
Metastatic Zoledronic
bone Acid
538 MO MO002 malignancy Zoledronic MO002A MO002A1 S 3900 Y N
and acid 4 mg
multiple IV Monthly
myeloma
Cisplatin +
Irinotecan
Cisplatin
60mg/m2
CT for CA D1Irinoteca
539 MO MO003 MO003A MO003A1 S 14400 Y N
Ovary n 60
mg/m2 D1
D8 D15
every 28
days
Lipodox +
Carboplati
n Lipopdox
30 mg/m2
CT for CA
540 MO MO003 D1 MO003B MO003B1 S 19000 Y N
Ovary
Carboplati
n AUC 5-6
D1 every
28 days
Lipodox +
Carboplati
n Lipopdox
30 mg/m2
CT for CA
540 MO MO003 D1 MO003B MO003B1 S 19000 Y N
Ovary
Carboplati
n AUC 5-6
D1 every
28 days
Etoposide
Etoposide
CT for CA 50 mg/m2
541 MO MO003 MO003C MO003C1 S 3400 Y N
Ovary OD D1-
D14 every
21 days
Etoposide
Etoposide
CT for CA 50 mg/m2
541 MO MO003 MO003C MO003C1 S 3400 Y N
Ovary OD D1-
D14 every
21 days
Etoposide
50 mg/m2
CT for CA
542 MO MO003 OD D1- MO003C MO003C2 S 3800 Y N
Ovary
D21 every
28 days
Etoposide
50 mg/m2
CT for CA
542 MO MO003 OD D1- MO003C MO003C2 S 3800 Y N
Ovary
D21 every
28 days
Irinotecan
Irinotecan
CT for CA 60 -90
543 MO MO003 MO003D MO003D1 S 12100 Y N
Ovary mg/m2 D1
D8 every
21 days
Irinotecan
Irinotecan
CT for CA 60 -90
543 MO MO003 MO003D MO003D1 S 12100 Y N
Ovary mg/m2 D1
D8 every
21 days
LipodoxLip
odox 40
CT for CA
544 MO MO003 mg/m2 IV MO003E MO003E1 S 19800 Y N
Ovary
every 28
days
LipodoxLip
odox 40
CT for CA
544 MO MO003 mg/m2 IV MO003E MO003E1 S 19800 Y N
Ovary
every 28
days
Carboplati
n+
Gemcitabin
eGemcitabi
ne -
1000mg/m
2 D1 D8
Carboplati
CT for CA
545 MO MO003 n AUC 2 MO003F MO003F1 S 15300 Y N
Ovary
D1
D8Gemcita
bine -
1000mg/m
2 D1
D8Carbopl
atin AUC
5-6 D1 only
Carboplati
n+
Gemcitabin
eGemcitabi
ne -
1000mg/m
2 D1 D8
Carboplati
CT for CA
545 MO MO003 n AUC 2 MO003F MO003F1 S 15300 Y N
Ovary
D1
D8Gemcita
bine -
1000mg/m
2 D1
D8Carbopl
atin AUC
5-6 D1 only
Carboplati
n+
Paclitaxel
Paclitaxel
CT for CA 175mg/m2
546 MO MO003 MO003G MO003G1 S 16400 Y N
Ovary D1
Carboplati
n AUC 5-6
D1 every
21 days
Carboplati
n+
Paclitaxel
Paclitaxel
CT for CA 175mg/m2
546 MO MO003 MO003G MO003G1 S 16400 Y N
Ovary D1
Carboplati
n AUC 5-6
D1 every
21 days
Cyclophos
phamide
CT for CA 50 mg/m2
547 MO MO003 MO003H MO003H1 S 3100 Y N
Ovary OD D1-
D21 every
28 days
Tamoxifen
Tamoxifem
CT for CA
548 MO MO003 20 mg MO003I MO003I1 S 1400 Y N
Ovary
orally daily
(3 months)
LetrozoleL
etrozole
CT for CA
549 MO MO003 2.5 mg MO003J MO003J1 S 4300 Y N
Ovary
orally daily
(3 months)
Carboplati
n (AUC
CT for
7)Carbopla
550 MO MO004 Germ Cell MO004A MO004A1 S 8100 Y N
tin AUC 7
Tumor
every 21
days
Carboplati
n (AUC
CT for
7)Carbopla
550 MO MO004 Germ Cell MO004A MO004A1 S 8100 Y N
tin AUC 7
Tumor
every 21
days
Bleomycin
+
Etoposide
+
CisplatinBl
eomycin 30
units D1
D8
CT for
D15Cisplat
551 MO MO004 Germ Cell MO004B MO004B1 S 13600 Y N
in 20
Tumor
mg/m2 IV
D1-
D5Etoposi
de
100mg/m2
D1-D5
every 21
days
Bleomycin
+
Etoposide
+
CisplatinBl
eomycin 30
units D1
D8
CT for
D15Cisplat
551 MO MO004 Germ Cell MO004B MO004B1 S 13600 Y N
in 20
Tumor
mg/m2 IV
D1-
D5Etoposi
de
100mg/m2
D1-D5
every 21
days
Etoposide
+
CisplatinCi
splatin 20
mg/m2 IV
CT for
D1-
552 MO MO004 Germ Cell MO004C MO004C1 S 12000 Y N
D5Etoposi
Tumor
de
100mg/m2
D1-D5
every 21
days
Etoposide
+
CisplatinCi
splatin 20
mg/m2 IV
CT for
D1-
552 MO MO004 Germ Cell MO004C MO004C1 S 12000 Y N
D5Etoposi
Tumor
de
100mg/m2
D1-D5
every 21
days
Gemcitabin
e+
Oxaliplatin
Gemcitabin
CT for e
553 MO MO004 Germ Cell 1000mg/m MO004D MO004D1 S 19300 Y N
Tumor 2 D1 D8
Oxaiplatin
130mg/m2
D1 every
21 days
Gemcitabin
e+
Oxaliplatin
Gemcitabin
CT for e
553 MO MO004 Germ Cell 1000mg/m MO004D MO004D1 S 19300 Y N
Tumor 2 D1 D8
Oxaiplatin
130mg/m2
D1 every
21 days
Gemcitabin
e+
PaclitaxelG
emcitabine
1000mg/m
CT for
2 D1 D8
554 MO MO004 Germ Cell MO004E MO004E1 S 19300 Y N
D15Paclita
Tumor
xel 100
mg/m2 D1
D8 D15
every 28
days
Gemcitabin
e+
PaclitaxelG
emcitabine
1000mg/m
CT for
2 D1 D8
554 MO MO004 Germ Cell MO004E MO004E1 S 19300 Y N
D15Paclita
Tumor
xel 100
mg/m2 D1
D8 D15
every 28
days
Vinblastin
+
Ifosfamide
+ Cisplatin
Vinblastine
0.11 mg/kg
IV D1-
D2Mesna
240mg/m2
CT for
0h 4h 8h
555 MO MO004 Germ Cell MO004G MO004G1 S 15000 Y N
D1-
Tumor
D5Ifosfami
de
1200mg/m
2 D1-
D5Cisplati
n 20
mg/m2 D1-
D5 every
21 days
Vinblastin
+
Ifosfamide
+ Cisplatin
Vinblastine
0.11 mg/kg
IV D1-
D2Mesna
240mg/m2
CT for
0h 4h 8h
555 MO MO004 Germ Cell MO004G MO004G1 S 15000 Y N
D1-
Tumor
D5Ifosfami
de
1200mg/m
2 D1-
D5Cisplati
n 20
mg/m2 D1-
D5 every
21 days
Etoposide
+
Methotrexa
te +
Dactinomy
cin-
Cyclophos
phamide +
Vincristine
Etoposide
100mg/m2
IV D1
D2Dactino
CT for mycin 0.5
Gestational mg IV push
556 MO MO005 Trophoblas D1 MO005A MO005A1 S 13300 Y N
tic D2Methotr
Neoplasia exate 300
mg /m2
D1Leucovo
rin 15 mg
PO every
12 hrs for 4
dosesCycl
ophospha
mide
600mg/m2
D8Vincrsti
ne 1
mg/m2 D8
ever
Etoposide
+
Methotrexa
te +
Dactinomy
cin +
CisplatinEt
oposide
100mg/m2
IV D1 D2
CT for
Gestational
557 MO MO005 Trophoblas MO005B MO005B1 S 14100 Y N
tic
Neoplasia
D8Dactino
mycin 0.5
mg IV push
D1 D2
Methotrexa
te 300
mg /m2
D1Leucovo
rin 15 mg
PO every
12 hrs for 4
doses
Cisplatin
75mg/m2
D8 every 2
weeks
Methotrexa
teMethotre
xate
1/mg/kg IM
every other
day x 4
CT for
days D1 3
Gestational
D5
558 MO MO005 Trophoblas MO005C MO005C1 S 1400 Y N
D7Alternati
tic
ng every
Neoplasia
other day
withLeucov
orin 15 mg
PO repeat
every 14
days
Dactinomy
CT for cinInj
Gestational Dactinomy
559 MO MO005 Trophoblas cin 0.5 mg MO005D MO005D1 S 7700 Y N
tic D1- D5
Neoplasia every 14
days
Carboplati
n+
PaclitaxelP
aclitaxel
CT for
175mg/m2
560 MO MO006 Cervical MO006A MO006A1 S 16400 Y N
D1Carbopl
Cancer
atin AUC
5-6 D1
every 21
days
Carboplati
n+
PaclitaxelP
aclitaxel
CT for
175mg/m2
560 MO MO006 Cervical MO006A MO006A1 S 16400 Y N
D1Carbopl
Cancer
atin AUC
5-6 D1
every 21
days
Cisplatin
CT for
Cisplatin
561 MO MO006 Cervical MO006B MO006B1 S 2600 Y N
40 mg/m2
Cancer
every week
Carboplati
n+
PaclitaxelP
CT for aclitaxel
562 MO MO007 Endometria 175mg/m2 MO007A MO007A1 S 16400 Y N
l Cancer D1Carbopl
atin AUC 5
D1 every
21 days
Cisplatin +
Doxorubici
nDoxorubic
CT for in 60
563 MO MO007 Endometria mg/m2 MO007B MO007B1 S 4900 Y N
l Cancer D1Cisplati
n 50mg/m2
every 3
weeks
Lipodox +
Carboplati
nLipopdox
CT for
30 mg/m2
564 MO MO007 Endometria MO007C MO007C1 S 19000 Y N
D1Carbopl
l Cancer
atin AUC 5
D1 every
28 days
Carboplati
n+
Gemcitabin
eGemcitabi
ne -
1000mg/m
2 D1
D8Carbopl
CT for atin AUC 2
565 MO MO007 Endometria D1 MO007D MO007D1 S 15300 Y N
l Cancer D8Gemcita
bine -
1000mg/m
2 D1 D8
Carboplati
n AUC 5-6
D1 only
every 3
weeks
Anastrozol
CT for e 1 mg
566 MO MO007 Endometria orally daily MO007E MO007E1 S 4300 Y N
l Cancer (for 3
months)
Cisplatin +
5 FU5 FU
1000mg/m
CT for
2 D1-
567 MO MO008 Vulvar MO008A MO008A1 S 9100 Y N
D4Cisplati
Cancer
n 75mg/m2
D1 every 3
weeks
CisplatinCi
CT for
splatin 40
568 MO MO008 Vulvar MO008B MO008B1 S 2600 Y N
mg/m2
Cancer
every week
Carboplati
n+
PaclitaxelP
CT for aclitaxel
569 MO MO008 Vulvar 175mg/m2 MO008C MO008C1 S 16000 Y N
Cancer D1Carbopl
atin AUC 5
D1 every
21 days
Vincristine
+
Topotecan
+
Cyclophos
phamide +
Irinotecan
+
Temozola
mideVincri
stine
1.5mg/m2(
day
1)Topoteca
n
1.5mg/m2
(day
5)Cyclopho
sphamide
250mg/m2
(days
5)Given
every 3
weeksIrinot
ecan 10-
CT for
570 MO MO009 Ewing MO009A MO009A1 S 25500 Y N
Sarcoma
50 mg/sqM
days 5 and
days
8-12
Temozola
mide
100mg/m2
5 of each
Vincristine
+
Ifosfamide
+
EtoposideV
incristine +
Doxorubici
n+
Cyclophos
phamideVi
ncristi ne +
Cyclophos
phamide +
Dactinomy
cin.4
CT for
cycles VIE,
571 MO MO009 Ewing MO009B MO009B1 S 10900 Y N
6 cycles
Sarcoma
VAC, 4
cycles
VCDVincri
stine
1.5mg/m2
(day 1, 8
and
15)Ifosfami
de:
1800mg/m
2
(days5)Etp
oside:
100mg/sq.
m(
Vincristine
+
Adriamycin
+
Cyclophos
phamideIfo
sfami de +
EtoposideIf
osfamide:
1800mg/m
2
(days5)Etp
oside:
100mg/sq.
CT for m (days
572 MO MO009 Ewing 5)Given MO009C MO009C1 S 14000 Y N
Sarcoma every 3
weeklyVinc
ristine
1.5mg/m2
(day 1 and
8)Adriamyi
cn:
75mg/m2
(day
1)Cyclopho
sphamide
1200mg/m
2 (day
Adriamycin
+
Cyclophos
phamideIfo
sfami de +
EtoposideIf
osfamide:
1800mg/m
2
(days5)Etp
oside:
100mg/sq.
CT for m (days
572 MO MO009 Ewing 5)Given MO009C MO009C1 S 14000 Y N
Sarcoma every 3
weeklyVinc
ristine
1.5mg/m2
(day 1 and
8)Adriamyi
cn:
75mg/m2
(day
1)Cyclopho
sphamide
1200mg/m
2 (day
1)Given 3
weekly
Doxorubici
n+
CisplatinCi
CT for splatin
573 MO MO010 Osteogenic 100mg/m2 MO010A MO010A1 S 13200 Y N
Sarcoma Doxorubici
n 75mg/m2
given every
3 weeks
Methotrexa
te +
Doxorubici
n
CT for
574 MO MO010 Osteogenic MO010B MO010B1 S 29700 Y N
Sarcoma
+ Cisplatin
for
Relapsed
Osteogenic
SarcomaCi
splatin
120mg/sq.
mDoxorubi
cin
75mg/m2M
ethotrexate
8-12
gram/m2E
ach cycle
for 5 weeks
OGS - 12
Ifosfamide
1800
mg/m2 D1-
D5Mesna
600mg/m2
0h 3h 6h
CT for 9h D1-
575 MO MO010 Osteogenic D5Adriamy MO010C MO010C1 S 32600 Y N
Sarcoma cin
25mg/m2
D1-
D3Cisplati
n 33
mg/m2 D1-
D3 every
21 days
OGS - 12
Ifosfamide
1800
mg/m2 D1-
D5Mesna
CT for 600mg/m2
576 MO MO010 Osteogenic 0h 3h 6h MO010D MO010D1 S 31500 Y N
Sarcoma 9h D1-
D5Cisplati
n 33
mg/m2 D1-
D3 every
21 days
Gemcitabin
e+
Docetaxel
Gemcitabin
CT for Soft e 900
577 MO MO011 Tissue mg/m2 D1 MO011A MO011A1 S 26400 Y N
Sarcoma D8Docetax
el 100
mg/m2 D8
every 21
days
Gemcitabin
e+
Docetaxel
Gemcitabin
CT for Soft e 900
577 MO MO011 Tissue mg/m2 D1 MO011A MO011A1 S 26400 Y N
Sarcoma D8Docetax
el 100
mg/m2 D8
every 21
days
Ifosfamide
+
Adriamycin
Doxorubici
n 30mg/m2
D1
CT for Soft D2Ifosfami
578 MO MO011 Tissue de 2000 to MO011B MO011B1 S 15100 Y N
Sarcoma 3000mg/m
2Mesna
400 to 600
mg/m2 0h
4h 8h D1 -
D3Every
21 days
Doxorubici
CT for Soft n
579 MO MO011 Tissue 60-75/m2, MO011C MO011C1 S 4400 Y N
Sarcoma every 21
days
Dacarbazin
e+
CisplatinD
acarbazine
CT for 250mg/m2
580 MO MO012 Metastatic D1- MO012A MO012A1 S 7900 Y N
Melanoma D5Cisplati
n 75
mg/m2
Dacarbazin
e+
CisplatinD
acarbazine
CT for 250mg/m2
580 MO MO012 Metastatic D1- MO012A MO012A1 S 7900 Y N
Melanoma D5Cisplati
n 75
mg/m2
Every 21
days
Temozola
mideTemo
CT for zolami de
581 MO MO012 Metastatic 200mg/m2 MO012B MO012B1 S 5500 Y N
Melanoma D1-D5
every 28
days
Imatinib
CT for Tab
582 MO MO012 Metastatic Imatinib MO012C MO012C1 S 5500 Y N
Melanoma 400/800
mg daily
5
Fluorouraci
l (FU)+
Mitomycin
C5
Fluorouraci
l(FU)
1000mg/m
2 D1-D4
D29-
CT for Anal
583 MO MO013 D32Mitomy MO013A MO013A1 S 12100 Y N
Cancer
cin
10mg/m2
D1
Capecitabi
ne +
Mitomycin
C
Capecitabi
ne
CT for Anal 825mg/m2
584 MO MO013 MO013B MO013B1 S 18600 Y N
Cancer PO twice
daily till
completion
of
RTMitomyc
in 10mg/2
D1
Cisplatin +
5 FU5 FU
1000mg/m
CT for Anal 2 D1-
585 MO MO013 MO013C MO013C1 S 9000 Y N
Cancer D4Cisplati
n 75mg/m2
D1 every 4
weeks
Carboplati
n+
PaclitaxelP
aclitaxel
586 MO MO013 MO013D MO013D1 S 16400 Y N
Cancer D1Carbopl
atin AUC
5-6 D1
every 21
days
Carboplati
n+
PaclitaxelP
aclitaxel
586 MO MO013 MO013D MO013D1 S 16400 Y N
Cancer D1Carbopl
atin AUC
5-6 D1
every 21
days
Cisplatin +
PaclitaxelP
aclitaxel
CT for Anal 175 mg/m2
587 MO MO013 MO013E MO013E1 S 14700 Y N
Cancer D1Cisplati
n 75mg/m2
D1 every
21 days
5 FU +
Leucovorin
5 FU
1200mg/m
CT for
2 D1
588 MO MO014 Colorectal MO014A MO014A1 S 6100 Y N
D2Leucovo
Cancer
rin
400mg/m2
D1 every
14 days
Capecitabi
ne +
IrinotecanC
apecitabin
e
CT for
1000mg/m
589 MO MO014 Colorectal MO014B MO014B1 S 13800 Y N
2 D1-
Cancer
D14Irinotec
an 200
mg/m2 D1
every 21
days
Capecitabi
ne +
IrinotecanC
apecitabin
e
CT for
1000mg/m
589 MO MO014 Colorectal MO014B MO014B1 S 13800 Y N
2 D1-
Cancer
D14Irinotec
an 200
mg/m2 D1
every 21
days
5 FU +
Leucovorin
+
Oxaliplatin
5 FU
1200mg/m
CT for 2 D1
590 MO MO014 Colorectal D2Leucovo MO014C MO014C1 S 15100 Y N
Cancer rin
400mg/m2
D1Oxalipla
tin 85
mg/m2 D1
every 14
days
5FU +
Leucovorin
+
Irinotecan5
FU
1200mg/m
2 D1
CT for
D2Leucovo
591 MO MO014 Colorectal MO014D MO014D1 S 10600 Y N
rin
Cancer
400mg/m2
D1Irinoteca
n
180mg/m2
85 mg/m2
D1 every
14 days
Capecitabi
ne +
Oxaliplatin
Capecitabi
ne
CT for
1000mg/m
592 MO MO014 Colorectal MO014E MO014E1 S 13800 Y N
2 D1-
Cancer
D14Oxalipl
atin 130
mg/m2 D1
every 21
days
Capecitabi
ne +
Oxaliplatin
Capecitabi
ne
CT for
1000mg/m
592 MO MO014 Colorectal MO014E MO014E1 S 13800 Y N
2 D1-
Cancer
D14Oxalipl
atin 130
mg/m2 D1
every 21
days
Capecitabi
ne along
CT for with
593 MO MO014 Colorectal RTCapecit MO014F MO014F1 S 8000 Y N
Cancer abine 825
mg/m2
twice daily
Capecitabi
neCapecita
CT for bine
594 MO MO014 Colorectal 1000mg/m MO014G MO014G1 S 8100 Y N
Cancer 2 D1-D14
every 21
days
5FU +
Leucovorin
+
Oxaliplatin
+
Irinotecan5
FU
1200mg/m
2 D1
CT for
D2Leucovo
595 MO MO014 Colorectal MO014H MO014H1 S 20700 Y N
rin
Cancer
400mg/m2
D1Oxalipla
tin 85
mg/m2
D1Irinoteca
5FU +
Leucovorin
+
Oxaliplatin
+
Irinotecan5
FU
1200mg/m
2 D1
CT for
D2Leucovo
595 MO MO014 Colorectal MO014H MO014H1 S 20700 Y N
rin
Cancer
400mg/m2
D1Oxalipla
tin 85
mg/m2
D1Irinoteca
n
180mg/m2
every 14
days
Carboplati
n+
PaclitaxelP
aclitaxel
CT for
175mg/m2
596 MO MO015 Esophagea MO015A MO015A1 S 16400 Y N
D1Carbopl
l Cancer
atin AUC
5-6 D1
every 21
days
Cisplatin +
5 FU5 FU
1000mg/m
CT for
2 D1-
597 MO MO015 Esophagea MO015B MO015B1 S 10700 Y N
D4Cisplati
l Cancer
n 75mg/m2
D1 every 4
weeks
Cisplatin +
5
FUCisplati
n 75mg/m2
D1
D295FU
CT for
598 MO MO015 Esophagea MO015C MO015C1 S 15600 Y N
l Cancer
CT for
598 MO MO015 Esophagea MO015C MO015C1 S 15600 Y N
l Cancer 1000mg/
m2 D1-D4
D29
D32 every
35
Paclitaxel
+
Carboplati
CT for nPaclitaxel
599 MO MO015 Esophagea 50mg/m2 MO015D MO015D1 S 29900 Y N
l Cancer D1Carbopl
atin AUC 2
D1 every
week
Paclitaxel
+
Carboplati
CT for nPaclitaxel
600 MO MO015 Esophagea 50mg/m2 MO015E MO015E1 S 29900 Y N
l Cancer D1Carbopl
atin AUC 2
D1 every
week
Cisplatin +
Docetaxel
Docetaxel
40mg/m2
D1Cisplati
n 40
CT for
mg/m2
Esophagea
601 MO MO016 D1Leucovo MO016A MO016A1 S 15300 Y N
l / Stomach
rin
Cancer
400mg/m2
D15FU
1000mg/m
2 D1 D2
every 14
days
Cisplatin +
Docetaxel
Docetaxel
40mg/m2
D1Cisplati
n 40
CT for
mg/m2
Esophagea
601 MO MO016 D1Leucovo MO016A MO016A1 S 15300 Y N
l / Stomach
rin
Cancer
400mg/m2
D15FU
1000mg/m
2 D1 D2
every 14
days
IrinotecanIr
CT for inotecan
Esophagea 60- 90
602 MO MO016 MO016B MO016B1 S 12100 Y N
l / Stomach mg/m2 D1
Cancer D8 every
21 days
5 FU5 FU
250 mg/m2
D1-
CT for
Esophagea
603 MO MO016 MO016C MO016C1 S 10400 Y N
l / Stomach D5 over 24
Cancer hrs every
week
Capecitabi
CT for
neCapecita
Esophagea
604 MO MO016 bine 825 MO016D MO016D1 S 8000 Y N
l / Stomach
mg/m2
Cancer
twice daily
Capecitabi
CT for
neCapecita
Esophagea
604 MO MO016 bine 825 MO016D MO016D1 S 8000 Y N
l / Stomach
mg/m2
Cancer
twice daily
Capecitabi
ne +
Oxaliplatin
Capecitabi
CT for ne
Esophagea 1000mg/m
605 MO MO016 MO016E MO016E1 S 13800 Y N
l / Stomach 2 D1-
Cancer D14Oxalipl
atin 130
mg/m2 D1
every 21
days
Docetaxel
+ Cisplatin
+5
FUDocetax
el
40mg/m2
D1Cisplati
n 40
mg/m2
D1Leucovo
rin
400mg/m2
D15FU
1000mg/m
2 D1 D2
CT for
Esophagea
606 MO MO016 MO016F MO016F1 S 16000 Y N
l / Stomach
Cancer
every 14
days
Docetaxel
+ Cisplatin
+
Capecitabi
neDocetax
el
CT for 40mg/m2
Esophagea D1Cisplati
607 MO MO016 MO016G MO016G1 S 16000 Y N
Docetaxel
+ Cisplatin
+
Capecitabi
neDocetax
el
CT for 40mg/m2
Esophagea D1Cisplati
607 MO MO016 MO016G MO016G1 S 16000 Y N
l / Stomach n 40
Cancer mg/m2
D1Capecit
abine
825mg/m2
twice daily
every 14
days
Docetaxel
+
Oxaliplatin
+5
FUDocetax
el
50mg/m2
D1Oxalipla
tin 85
mg/m2
D1Leucovo
rin
400mg/m2
D15FU
1200mg/m
2 D1 D2
CT for
Esophagea
608 MO MO016 MO016H MO016H1 S 20400 Y N
l / Stomach
Cancer
CT for
Esophagea
608 MO MO016 MO016H MO016H1 S 20400 Y N
l / Stomach
Cancer
every 14
days
Docetaxel
+
Oxaliplatin
+
Capecitabi
neDocetax
el
50mg/m2
D1Oxalipla
tin 85
CT for mg/m2
Esophagea D1Capecit
609 MO MO016 MO016I MO016I1 S 20400 Y N
l / Stomach abine 825
Cancer mg/m2
Twice daily
every 14
days
5FU +
Leucovorin
+
Irinotecan5
FU
1200mg/m
CT for 2 D1
Esophagea D2Leucovo
610 MO MO016 MO016J MO016J1 S 10600 Y N
l / Stomach rin
Cancer 400mg/m2
D1Irinoteca
n
180mg/m2
85 mg/m2
D1 every
14 days
5FU +
Leucovorin
+
Oxaliplatin
5 FU
1200mg/m
CT for
2 D1
Esophagea
611 MO MO016 D2Leucovo MO016K MO016K1 S 15100 Y N
l / Stomach
rin
Cancer
400mg/m2
D1Oxalipla
tin 85
mg/m2 D1
every 14
days
5FU +
Leucovorin
+
Oxaliplatin
5 FU
1200mg/m
CT for
2 D1
Esophagea
611 MO MO016 D2Leucovo MO016K MO016K1 S 15100 Y N
l / Stomach
rin
Cancer
400mg/m2
D1Oxalipla
tin 85
mg/m2 D1
every 14
days
CT for PaclitaxelP
Esophagea aclitaxel
612 MO MO016 MO016L MO016L1 S 6600 Y N
l / Stomach 80mg/m2
Cancer every week
Doxorubici
n
CT for
(TACE)Dox
Hepatocell
613 MO MO017 orubicin MO017A MO017A1 S 24800 Y N
ular
30-75
Carcinoma
mg/m2 one
course
CT for SorafenibS
Hepatocell orafenib
614 MO MO017 MO017B MO017B1 S 9900 Y N
ular 400mg PO
Carcinoma twice daily
CT for
Hepatocell Lenvatinib
615 MO MO017 MO017C MO017C1 S 18700 Y N
ular 12 mg daily
Carcinoma
Gemcitabin
e+
Nanopaclit
axelGemcit
abine
1000mg/m
CT for
2 D1 D8
616 MO MO018 Panceratic MO018A MO018A1 S 31300 Y N
D16Albumi
Cancer
n bound
Paclitaxel
125mg/m2
D1 D8 D15
every 28
days
Gemcitabin
e+
Nanopaclit
axelGemcit
abine
1000mg/m
CT for
2 D1 D8
616 MO MO018 Panceratic MO018A MO018A1 S 31300 Y N
D16Albumi
Cancer
n bound
Paclitaxel
125mg/m2
D1 D8 D15
every 28
days
Gemcitabin
e
CT for
1000mg
617 MO MO018 Panceratic MO018B MO018B1 S 9900 Y N
/m2 D1 D8
Cancer
every 21
days
Gemcitabin
CT for
e
618 MO MO018 Panceratic MO018C MO018C1 S 4400 Y N
300mg/m2
Cancer
weekly
5FU +
Leucovorin
+
Oxaliplatin
+
Irinotecan5
FU
1200mg/m
2 D1
CT for
D2Leucovo
619 MO MO018 Panceratic MO018D MO018D1 S 20800 Y N
rin
Cancer
400mg/m2
D1Oxalipla
tin 85
mg/m2
D1Irinoteca
5FU +
Leucovorin
+
Oxaliplatin
+
Irinotecan5
FU
1200mg/m
2 D1
CT for
D2Leucovo
619 MO MO018 Panceratic MO018D MO018D1 S 20800 Y N
rin
Cancer
400mg/m2
D1Oxalipla
tin 85
mg/m2
D1Irinoteca
n
180mg/m2
every 14
days
Capecitabi
CT for neCapecita
620 MO MO018 Panceratic bine 825 MO018E MO018E1 S 8000 Y N
Cancer mg/m2
twice daily
Capecitabi
ne +
Gemcitabin
eGemcitabi
ne
1000mg/m
CT for
2 D1 D8
621 MO MO018 Panceratic MO018F MO018F1 S 37600 Y N
D15Capeci
Cancer
tabine
830mg/m2
twice daily
D1- D21
every 28
days
CT for Gall
Bladder
Cancer
Capecitabi
neCapecita
bine 1000 -
1250
622 MO MO019 mg/m2 MO019A MO019A1 S 8100 Y N
twice daily
D1 -D14
every 21
days
Capecitabi
neCapecita
bine 1000 -
1250
622 MO MO019 mg/m2 MO019A MO019A1 S 8100 Y N
/ twice daily
Cholangioc D1 -D14
arcinoma every 21
days
CT for Gall
Bladder
Cancer
Cisplatin +
Gemcitabin
eGemcitabi
ne 1000
mg/m2 D1
623 MO MO019 / MO019B MO019B1 S 13400 Y N
D8Cisplati
Cholangioc n 25
arcinoma mg/m2 D1
D8 every
21 days
CT for Gall
Bladder
Cancer
5FU +
Leucovorin
+
Irinotecan5
FU
1200mg/m
2 D1
D2Leucovo
624 MO MO019 MO019C MO019C1 S 10600 Y N
/ rin
Cholangioc 400mg/m2
arcinoma D1Irinoteca
n
180mg/m2
85 mg/m2
D1 every
14 days
CT for Gall
Bladder
Cancer
Gemcitabin
eGemcitabi
ne 300
mg/m2 D
625 MO MO019 MO019D MO019D1 S 4400 Y N
1every
week (till
RT ends) -
per week
Gemcitabin
eGemcitabi
ne 300
mg/m2 D
625 MO MO019 MO019D MO019D1 S 4400 Y N
/ 1every
Cholangioc week (till
arcinoma RT ends) -
per week
CT for Gall
Bladder
Cancer
Gemcitabin
eGemcitabi
ne 1000mg
626 MO MO019 / MO019E MO019E1 S 9900 Y N
/m2 D1 D8
Cholangioc every 21
arcinoma days
Oxaliplatin
+
Gemcitabin
CT for Gall
eGemcitabi
Bladder
ne 1000
Cancer
mg/m2
D1Oxalipla
tin
627 MO MO019 MO019F MO019F1 S 19200 Y N

/ 100 mg/m2
Cholangioc D1 every
arcinoma 14 days
CT for Gall
Bladder
Cancer
Capecitabi
ne +
IrinotecanC
apecitabin
e
1000mg/m
628 MO MO019 MO019G MO019G1 S 13800 Y N
2 D1-
D14Irinotec
an 200
mg/m2 D1
every 21
days
Capecitabi
ne +
IrinotecanC
apecitabin
e
1000mg/m
628 MO MO019 MO019G MO019G1 S 13800 Y N
/ 2 D1-
Cholangioc D14Irinotec
arcinoma an 200
mg/m2 D1
every 21
days
CT for Gall
Bladder
Cancer
5FU +
Leucovorin
+
Oxaliplatin
5 FU
1200mg/m
2 D1
629 MO MO019 / D2Leucovo MO019H MO019H1 S 15100 Y N
Cholangioc rin
arcinoma 400mg/m2
D1Oxalipla
tin 85
mg/m2 D1
every 14
days
CT for
ImatinibIm
Gastointest
atinib 400
630 MO MO020 inal MO020A MO020A1 S 16500 Y N
mg once
stromal
daily
tumor
CT for
SunitinibSu
Gastointest
nitinb 37.5
631 MO MO020 inal MO020B MO020B1 S 11000 Y N
mg once
stromal
daily
tumor
Temozola
mideTemo
zolomi de
CT for CA 150 - 200
632 MO MO021 mg/m2 D1- MO021A MO021A1 S 5500 Y N
Brain
D5
every 28
days
Temozola
mideTemo
CT for CA
633 MO MO021 zolomi de MO021B MO021B1 S 33000 Y N
Brain
75mg/m2
once daily
Gemcitabin
e+
CisplatinG
emcitabine
CT for 1000
634 MO MO022 Mesothelio mg/m2 D1 MO022A MO022A1 S 13400 Y N
ma D8Cisplati
n 75
mg/m2 D1
every 21
days
Gemcitabin
e+
CisplatinG
emcitabine
CT for 1000
634 MO MO022 Mesothelio mg/m2 D1 MO022A MO022A1 S 13400 Y N
ma D8Cisplati
n 75
mg/m2 D1
every 21
days
Pemetrexe
d+
CisplatinPe
metrexed
CT for
500mg/m2
635 MO MO022 Mesothelio MO022B MO022B1 S 10400 Y N
D1Cisplati
ma
n 75
mg/m2 D1
every 21
days
Pemetrexe
d+
Carboplati
nPemetrex
CT for ed
636 MO MO022 Mesothelio 500mg/m2 MO022C MO022C1 S 11200 Y N
ma D1Carbopl
atin AUC
5-6 D1
every 21
days
Cisplatin +
EtoposideE
toposide
100mg/m2
CT for
D1 -
637 MO MO023 Thymic MO023A MO023A1 S 7800 Y N
D3Cisplati
Carcinoma
n 75-100
mg/m2 D1
every 21
days
Cisplatin +
EtoposideE
toposide
100mg/m2
CT for
D1 -
637 MO MO023 Thymic MO023A MO023A1 S 7800 Y N
D3Cisplati
Carcinoma
n 75-100
mg/m2 D1
every 21
days
Cisplatin +
Adriamycin
+
Cyclophos
phamideCi
splatin 50
mg/m2
D1Doxorub
icin
CT for
638 MO MO023 Thymic MO023B MO023B1 S 6500 Y N
Carcinoma
50 mg/m2
D1Cycloph
osphamide
500 mg/m2
D1 every
21 days
Cisplatin +
Docetaxel
Docetaxel
75
mg/m2
D1Cisplati
n 75
mg/m2 D1
every 21
days
CT for CA
639 MO MO024 Head & MO024A MO024A1 S 13700 Y N
Neck
CisplatinCi
CT for CA splatin
640 MO MO024 Head & 100mg/m2 MO024B MO024B1 S 10800 Y N
Neck every 21
days
CisplatinCi
CT for CA splatin
640 MO MO024 Head & 100mg/m2 MO024B MO024B1 S 10800 Y N
Neck every 21
days
Carboplati
n+
Gemcitabin
eGemcitabi
CT for CA ne 1000
641 MO MO024 Head & mg/m2 D1 MO024C MO024C1 S 15300 Y N
Neck D8Carbopl
atin AUC
5-6 D1
every 21
days
Docetaxel
+ Cisplatin
+5
FUDocetax
el 75
mg/m2
D1Cisplati
n 75
mg/m2
D15 FU
750 mg/m2
D1- D5
every 21
days
CT for CA
642 MO MO024 Head & MO024D MO024D1 S 16000 Y N
Neck
Docetaxel
CT for CA
Docetaxel
Docetaxel
CT for CA
Docetaxel
643 MO MO024 Head & MO024E MO024E1 S 3600 Y N
20mg/m2
Neck
every week
Docetaxel
CT for CA Docetaxel
644 MO MO024 Head & 75 mg/m2 MO024F MO024F1 S 9400 Y N
Neck D1 every
21 days
Etoposide
+
Carboplati
nEtoposide
CT for CA 100mg/m2
645 MO MO024 Head & D1 - MO024G MO024G1 S 8500 Y N
Neck D3Carbopl
atin AUC
5-6 D1
every 21
days
Etoposide
+
CisplatinEt
oposide
CT for CA 100mg/m2
646 MO MO024 Head & D1 - MO024H MO024H1 S 10200 Y N
Neck D3Cisplati
n 75-100
mg/m2 D1
every 21
days
Etoposide
+
CisplatinEt
oposide
CT for CA 100mg/m2
646 MO MO024 Head & D1 - MO024H MO024H1 S 10200 Y N
Neck D3Cisplati
n 75-100
mg/m2 D1
every 21
days
Gemcitabin
eGemcitabi
CT for CA
ne 1000
647 MO MO024 Head & MO024I MO024I1 S 9900 Y N
mg/m2 D1
Neck
D8 every
21 days
Gemcitabin
e+
CisplatinG
emcitabine
CT for CA 1000
648 MO MO024 Head & mg/m2 D1 MO024J MO024J1 S 13400 Y N
Neck D8Cisplati
n 75
mg/m2 D1
every 21
days
Paclitaxel
+
Carboplati
CT for CA nPaclitaxel
649 MO MO024 Head & 80mg/m2 MO024K MO024K1 S 8500 Y N
Neck D1Carbopl
atin AUC 2
D1 every
week
Paclitaxel
+
Carboplati
CT for CA nPaclitaxel
649 MO MO024 Head & 80mg/m2 MO024K MO024K1 S 8500 Y N
Neck D1Carbopl
atin AUC 2
D1 every
week
Paclitaxel
+
CT for CA Carboplati
650 MO MO024 Head & nPaclitaxel MO024L MO024L1 S 16000 Y N
Neck 175mg/m2
every 21
days
PaclitaxelP
CT for CA
aclitaxel
651 MO MO024 Head & MO024M MO024M1 S 6600 Y N
80mg/m2
Neck
every week
PaclitaxelP
CT for CA aclitaxel
652 MO MO024 Head & 175mg/m2 MO024N MO024N1 S 13000 Y N
Neck every 21
days
PaclitaxelP
CT for CA aclitaxel
652 MO MO024 Head & 175mg/m2 MO024N MO024N1 S 13000 Y N
Neck every 21
days
Carboplati
CT for CA
nCarboplat
653 MO MO024 Head & MO024O MO024O1 S 3000 Y N
in AUC 2
Neck
every week
CisplatinCi
CT for CA
splatin
654 MO MO024 Head & MO024P MO024P1 S 2600 Y N
40mg/m2
Neck
every week
Sunitinib50
CT for mg once
655 MO MO025 Renal Cell daily 4 MO025A MO025A1 S 11000 Y N
Cancer weeks on 2
weeks off
Sunitinib50
CT for mg once
655 MO MO025 Renal Cell daily 4 MO025A MO025A1 S 11000 Y N
Cancer weeks on 2
weeks off
Cabozantin
CT for ib 60 mg
656 MO MO025 Renal Cell od x 1 MO025B MO025B1 S 14300 Y N
Cancer
monthever
y 4 weeks
Cisplatin +
Methotrexa
te +
Vinblastin
Methotrexa
te
30mg/m2
D1
D8Vinblasti
ne 4
mg/m2 D1
D8Doxorub
icin 30
mg/m2
D2Cisplati
n 100
CT for
Ureter /
657 MO MO026 MO026A MO026A1 S 7500 Y N
Bladder /
Urethra
CT for
Ureter /
657 MO MO026 MO026A MO026A1 S 7500 Y N
Bladder /
Urethra
mg/m2
D2Leucovo
rin 15 mg
PO D2 D9
every 21
days
Carboplati
n+
Gemcitabin
eGemcitabi
CT for
ne 1000
Ureter /
658 MO MO026 mg/m2 D1 MO026B MO026B1 S 15300 Y N
Bladder /
D8Carbopl
Urethra
atin AUC
5-6 D1
every 21
days
Cisplatin +
Gemcitabin
eGemcitabi
CT for ne 1000
Ureter / mg/m2 D1
659 MO MO026 MO026C MO026C1 S 13400 Y N
Bladder / D8Cisplati
Urethra n 75
mg/m2 D1
every 21
days
Cisplatin +
5 FU5 FU
CT for 1000mg/m
Ureter / 2 D1-
660 MO MO026 MO026D MO026D1 S 9000 Y N
Urethra n 75mg/m2
D1 every 4
weeks
Cisplatin +
5 FU5 FU
CT for 1000mg/m
Ureter / 2 D1-
660 MO MO026 MO026D MO026D1 S 9000 Y N
Urethra n 75mg/m2
D1 every 4
weeks
Cisplatin +
PaclitaxelP
aclitaxel
175 mg
CT for
Ureter / /m2
661 MO MO026 D1Cisplati MO026E MO026E1 S 14700 Y N
Bladder /
Urethra n 75 mg
/m2 D1
every 21
days
Docetaxel
CT for
Docetaxel
Ureter /
662 MO MO026 75 mg/m2 MO026F MO026F1 S 9400 Y N
Bladder /
D1 every
Urethra
21 days
Gemcitabin
e+
PaclitaxelG
emcitabine
2500
CT for
Ureter /
663 MO MO026 MO026G MO026G1 S 17100 Y N
Bladder /
Urethra
CT for
Ureter / mg/m2
663 MO MO026 D1Paclitax MO026G MO026G1 S 17100 Y N
Bladder /
Urethra el 150
mg/m2 D1
every 14
days
Gemcitabin
CT for eGemcitabi
Ureter / ne 1000mg
664 MO MO026 MO026H MO026H1 S 9900 Y N
Bladder / /m2 D1 D8
Urethra every 21
days
Methotrexa
te +
Vinblastin
+
Doxorubici
n+
CisplatinM
ethotrexate
30mg/m2
D1Vinblasti
ne 3
CT for
Ureter / mg/m2
665 MO MO026 MO026I MO026I1 S 8300 Y N
Bladder / D2Doxorub
Urethra icin 30
mg/m2
D2Cuisplat
in 70
mg/m2 D2
every 14
days
Paclitaxel
+
Carboplati
CT for nPaclitaxel
Paclitaxel
+
Carboplati
CT for nPaclitaxel
Ureter / 175mg/m2
666 MO MO026 MO026J MO026J1 S 16000 Y N
Bladder / D1Carbopl
Urethra atin AUC
5-6 D1
every 21
days
CT for PaclitaxelP
Ureter / aclitaxel 80
667 MO MO026 MO026K MO026K1 S 7100 Y N
Bladder / mg/m2 D1
Urethra every week
Cisplatin +
PaclitaxelP
aclitaxel
175
CT for CA
668 MO MO027 MO027A MO027A1 S 14700 Y N
Penis mg/m2
D1Cisplati
n 75
mg/m2 D1
every 21
days
5 FU +
Cisplatin5
FU
1000mg/m
CT for CA
669 MO MO027 2 D1- MO027B MO027B1 S 9000 Y N
Penis
D4Cisplati
n 75mg/m2
D1 every 4
5 FU +
Cisplatin5
FU
1000mg/m
CT for CA
669 MO MO027 2 D1- MO027B MO027B1 S 9000 Y N
Penis
D4Cisplati
n 75mg/m2
D1 every 4
weeks
Capecitabi
neCapecita
bine 1000-
1250
CT for CA
670 MO MO027 mg/m2 PO MO027C MO027C1 S 8100 Y N
Penis
twice daily
D1 -D14
every 21
days
Paclitaxel
+
Carboplati
nPaclitaxel
CT for CA 175mg/m2
671 MO MO027 MO027D MO027D1 S 16000 Y N
Penis D1Carbopl
atin AUC
5-6 D1
every 21
days
PaclitaxelP
CT for CA aclitaxel 80
672 MO MO027 MO027E MO027E1 S 6600 Y N
Penis mg/m2 D1
every week
PaclitaxelP
CT for CA aclitaxel 80
672 MO MO027 MO027E MO027E1 S 6600 Y N
Penis mg/m2 D1
every week
PaclitaxelP
aclitaxel
CT for CA
673 MO MO027 175 mg/m2 MO027F MO027F1 S 13000 Y N
Penis
D1 every
21 days
Paclitaxel
+
Carboplati
nPaclitaxel
CT for CA
674 MO MO027 80 mg/m2 MO027G MO027G1 S 8500 Y N
Penis
D1Carbopl
atin AUC 2
D1 every
week
Docetaxel
Docetaxel
CT for CA
675 MO MO028 60 mg/m2 MO028A MO028A1 S 8800 Y N
Prostate
D1 every
14 days
Docetaxel
Docetaxel
CT for CA
Prostate
D1 every
14 days
Docetaxel
Docetaxel
CT for CA
676 MO MO028 75 mg/m2 MO028B MO028B1 S 9400 Y N
Prostate
D1 every
21 days
Etoposide
+
Carboplati
nEtoposide
100mg/m2
CT for CA
677 MO MO028 D1 - MO028C MO028C1 S 8500 Y N
Prostate
D3Carbopl
atin AUC
5-6 D1
every 21
days
LHRH
AgonistLeu
prolide
CT for CA
678 MO MO028 MO028D MO028D1 S 16900 Y N
Prostate
CT for CA
678 MO MO028 22.5 ug MO028D MO028D1 S 16900 Y N
Prostate
every 3
months
Mitoxantro
ne +
Prednisolo
neMitoxant
rone
12mg/m2
every 3
CT for CA
679 MO MO028 weeksPred MO028E MO028E1 S 4700 Y N
Prostate
nsiolone 10
mg daily
Paclitaxel
+
Carboplati
nPaclitaxel
CT for CA
680 MO MO028 80mg/m2 MO028F MO028F1 S 8500 Y N
Prostate
D1Carbopl
atin AUC 2
D1 every
week
Paclitaxel
+
Carboplati
nPaclitaxel
CT for CA 175mg/m2
681 MO MO028 MO028G MO028G1 S 16000 Y N
Prostate D1Carbopl
atin AUC
Paclitaxel
+
Carboplati
nPaclitaxel
CT for CA 175mg/m2
681 MO MO028 MO028G MO028G1 S 16000 Y N
Prostate D1Carbopl
atin AUC
5-6 D1
every 21
days
Docetaxel
Docetaxel
CT for CA
682 MO MO028 20mg/m2 MO028H MO028H1 S 3600 Y N
Prostate
D1 every
week
Abirateron
e 1000 mg
+
CT for CA Prednisolo
683 MO MO028 MO028I MO028I1 S 14300 Y N
Prostate ne 10mg
daily Once
every
month
Rituximab
+
Cyclophos
phamide +
Etoposide
+
CT for B - Prednsiolo
Cell NHL - neRituxima
High Grade b
375mg/m2
Cyclophos
phami de
750
mg/m2Vinc
ristine
684 MO MO029 1.4 mg/m2, MO029A MO029A1 S 28900 Y N

on
Day1Etopo
side
65mg/m2
(Except Day 1 to
Burkitt's & 3Prednisol
PCNSL) one 100
mg Day
5Total 6
cycles,
repeat 21
days
Rituximab
+
Cyclophos
phamide +
Doxorubici
n+
CT for B - Prednsiolo
Cell NHL - neRituxima
High Grade b
375mg/m2
Cyclophos
phami de
750
mg/m2Dox
orubicin
685 MO MO029 MO029B MO029B1 S 29700 Y N

50mg/
m2Vincristi
ne 1.4
mg/m2 on
(Except Day1Predn
Burkitt's & isolone 100
PCNSL) mg Day
5Total 6
cycles,
repeat 21
days
Rituxmab +
Dexametha
sone +
High Dose
Cytarabine
+
CisplatinRit
uximab
375mg/m2
Day
1Cytarabin
e 2g/m2
CT for High
BD on day
- Grade
Rituxmab +
Dexametha
sone +
High Dose
Cytarabine
+
CisplatinRit
uximab
375mg/m2
Day
1Cytarabin
e 2g/m2
CT for High
BD on day
- Grade
686 MO MO030 2Dexameth MO030A MO030A1 S 38400 Y N
NHL - B
asone 40
Cell
mg Day 1 -
4Cisplatin
75mg/m2
or
Carboplati
n AUC-5
on day
1Cycle to
be
repeated
every
21days
CT for
Relapsed
B - Cell
NHL - High
Grade
GDP -
RRituxima
b
375mg/m2
Day
1Gemcitabi
ne
1000mg/m
2 on day 1
and
8Dexameth
687 MO MO031 MO031A MO031A1 S 38900 Y N
asone 40
mg Day 1 -
4Cisplatin
75mg/m2
on day
1Cycle to
be
repeated
every
21daysTot
al- 6 cycles
GDP -
RRituxima
b
375mg/m2
Day
1Gemcitabi
ne
1000mg/m
2 on day 1
and
8Dexameth
687 MO MO031 MO031A MO031A1 S 38900 Y N
asone 40
mg Day 1 -
4Cisplatin
(Except 75mg/m2
Burkitt's & on day
PCNSL) 1Cycle to
be
repeated
every
21daysTot
al- 6 cycles
CT for
Relapsed
B - Cell
NHL - High
Grade
ICE -
RRituxima
b
375mg/m2I
fosfamide
1.66g/m2
on day 1 -
3Mesna
1.66g/m2
day 1 -
688 MO MO031 MO031B MO031B1 S 35100 Y N
3Carboplat
in AUC 5
on day
1Etoposide
100mg/m2
on day 1 -
3Cycle
every
21days for
6 cycles
ICE -
RRituxima
b
375mg/m2I
fosfamide
1.66g/m2
on day 1 -
3Mesna
1.66g/m2
day 1 -
688 MO MO031 MO031B MO031B1 S 35100 Y N
3Carboplat
in AUC 5
on day
(Except 1Etoposide
Burkitt's & 100mg/m2
PCNSL) on day 1 -
3Cycle
every
21days for
6 cycles
Etoposide
+
Prednsiolo
ne +
Vincristine
+
Cyclophos
phamide +
Doxorubici
nRituximab
375mg/m2
Day
CT for
1Etoposide
PMBCL /
50mg/m2V
Burkitt's
CR
Lymphoma
689 MO MO032 0.4mg/m2 MO032A MO032A1 S 34900 Y N
/
Doxorubici
Seropositiv
n 10mg/m2
e B - Cell
Day1 -
NHLR
4Cyclopho
sphamide
750mg/m2
on day 5
Prednisolo
ne 100 mg
day 5Every
21
daysDose
adjustment
each cycle
dep
Etoposide
+
Prednsiolo
ne +
Vincristine
+
Cyclophos
phamide +
Doxorubici
nRituximab
375mg/m2
Day
CT for
1Etoposide
PMBCL /
50mg/m2V
Burkitt's
CR
Lymphoma
689 MO MO032 0.4mg/m2 MO032A MO032A1 S 34900 Y N
/
Doxorubici
Seropositiv
n 10mg/m2
e B - Cell
Day1 -
NHLR
4Cyclopho
sphamide
750mg/m2
on day 5
Prednisolo
ne 100 mg
day 5Every
21
daysDose
adjustment
each cycle
dep
Codox - M
- IVAC-
cyclophosp
hamide,
vincristine,
doxorubici
n, high-
dose
methotrexa
te /
ifosfamide,
etoposide,
high- dose
CT for
cytarabine)
690 MO MO033 Burkitt's MO033A MO033A1 S 38000 Y N
GMALL
NHL
(German
multicenter
acute
lymphoblas
tic
leukemia)B
erlin-
Frankfurt -
MunsterHy
per CVAD
(cyclophos
phamide,
Vincristine,
Codox - M
- IVAC-
cyclophosp
hamide,
vincristine,
doxorubici
n, high-
dose
methotrexa
te /
ifosfamide,
etoposide,
high- dose
CT for
cytarabine)
690 MO MO033 Burkitt's MO033A MO033A1 S 38000 Y N
GMALL
NHL
(German
multicenter
acute
lymphoblas
tic
leukemia)B
erlin-
Frankfurt -
MunsterHy
per CVAD
(cyclophos
phamide,
Vincristine,
Bendamust
ine +
Rituximab
Bendamust
ine
90mg/m2
CT for Low
on day 1,
691 MO MO034 Grade B - MO034A MO034A1 S 27500 Y N
2Rituximab
Cell NHL
375mg/m2
on day
1Repeat
every 28
days, Total
6 cycles
Bendamust
ine +
Rituximab
Bendamust
ine
90mg/m2
CT for Low
on day 1,
691 MO MO034 Grade B - MO034A MO034A1 S 27500 Y N
2Rituximab
Cell NHL
375mg/m2
on day
1Repeat
every 28
days, Total
6 cycles
Lenalidomi
de +
Rituximab
Rituximab
CT for Low
375mg/m2
692 MO MO034 Grade B - MO034B MO034B1 S 24800 Y N
Day
Cell NHL
1Lenlidomi
de 25 mg
D1-28, for
8 cycles
Lenalidomi
de +
Rituximab
Rituximab
CT for Low
375mg/m2
692 MO MO034 Grade B - MO034B MO034B1 S 24800 Y N
Day
Cell NHL
1Lenlidomi
de 25 mg
D1-28, for
8 cycles
Rituximab
Rituximab
CT for Low
693 MO MO035 375mg/m2 MO035A MO035A1 S 17600 Y N
Grade NHL
per week
for 6 weeks
Rituximab
Rituximab
CT for Low
693 MO MO035 375mg/m2 MO035A MO035A1 S 17600 Y N
Grade NHL
per week
for 6 weeks
Rituximab
+
Cyclophos
phamide +
Vincristine
+
Prednisolo
neRituxima
b 375
mg/m2Cycl
ophospha
CT for Low mide
694 MO MO035 MO035B MO035B1 S 19300 Y N
Grade NHL 750mg/m2
Vincristine
1.4mg/m2
Day
1Prednisol
one 100
mg Day 1 -
5Repeat
every
21days.
Total 6
cycles
Rituximab
+
Cyclophos
phamide +
Vincristine
+
Prednisolo
neRituxima
b 375
mg/m2Cycl
ophospha
CT for Low mide
694 MO MO035 MO035B MO035B1 S 19300 Y N
Grade NHL 750mg/m2
Vincristine
1.4mg/m2
Day
1Prednisol
one 100
mg Day 1 -
5Repeat
every
21days.
Total 6
cycles
Fludarabin
e+
Cyclophos
phamideFl
udarab ine
CT for
25mg/m2
Chronic
695 MO MO036 D1- MO036A MO036A1 S 20000 Y N
Lymphocyti
3Cyclopho
c Leukemia
sphamide
250 mg/m2
D1-3 every
28 days for
6 cycles
Fludarabin
e+
Cyclophos
phamideFl
udarab ine
CT for
25mg/m2
Chronic
695 MO MO036 D1- MO036A MO036A1 S 20000 Y N
Lymphocyti
3Cyclopho
c Leukemia
sphamide
250 mg/m2
D1-3 every
28 days for
6 cycles
Rituxmab +
Chlorambu
cilRituxima
b
375mg/m2
CT for
Day
Chronic
696 MO MO036 1Chloramb MO036B MO036B1 S 18900 Y N
Lymphocyti
ucil 10
c Leukemia
mg/m2 D1-
7Repeat
every 28
days for 12
cycles
Rituxmab +
Chlorambu
cilRituxima
b
375mg/m2
CT for
Day
Chronic
696 MO MO036 1Chloramb MO036B MO036B1 S 18900 Y N
Lymphocyti
ucil 10
c Leukemia
mg/m2 D1-
7Repeat
every 28
days for 12
cycles
Rituximab
+
Fludarabin
e+
Cyclophos
phamideRit
uxima b
375mg/m2
CT for on day
Chronic 1Fludarabi
697 MO MO036 MO036C MO036C1 S 44800 Y N
Lymphocyti ne
c Leukemia 25mg/m2
D1 -
3Cyclopho
sphamide
250 mg/m2
D1 -
3Every 28
days for 6
cycles
Rituximab
+
Fludarabin
e+
Cyclophos
phamideRit
uxima b
375mg/m2
CT for on day
Chronic 1Fludarabi
697 MO MO036 MO036C MO036C1 S 44800 Y N
Lymphocyti ne
c Leukemia 25mg/m2
D1 -
3Cyclopho
sphamide
250 mg/m2
D1 -
3Every 28
days for 6
cycles
Lenalidomi
delenalido
mide- 10-
25 mg/day
day 1 to 21
CT for
Chronic
698 MO MO036 MO036D MO036D1 S 5300 Y N
Lymphocyti
c Leukemia
CT for
Chronic
698 MO MO036 MO036D MO036D1 S 5300 Y N
Lymphocyti
c Leukemia
every 28
days
CHOEPCy
clophospha
mide
750mg/m2
D1Vincristi
ne
1.4mg/m2
D1Adriamy
cin 50
CT for
mg/m2
Peripheral
699 MO MO037 D1Etoposi MO037A MO037A1 S 5800 Y N
T - Cell
de
Lymphoma
100mg/m2
D1-
3Prednisol
one 100
mg
D5Every
21days.
Total 6
cycles
CHOEPCy
clophospha
mide
750mg/m2
D1Vincristi
ne
1.4mg/m2
D1Adriamy
cin 50
CT for
mg/m2
Peripheral
699 MO MO037 D1Etoposi MO037A MO037A1 S 5800 Y N
T - Cell
de
Lymphoma
100mg/m2
D1-
3Prednisol
one 100
mg
D5Every
21days.
Total 6
cycles
CHOPCycl
ophospha
mide
750mg/m2
D1Vincristi
ne
1.4mg/m2
D1Adriamy
cin 50
CT for
Peripheral
700 MO MO037 MO037B MO037B1 S 5700 Y N
T - Cell
Lymphoma
CT for
Peripheral
700 MO MO037 MO037B MO037B1 S 5700 Y N
T - Cell
mg/m2
Lymphoma
D1Prednis
olone 100
mg
D5Every
21days.
Total 6
cycles
SMILEMet
hotrexate
2gm/m2
D1Ifosfami
de
1500mg/m
2 D2-
4Etoposide
100mg/m2
D2-4L-
CT for
Peripheral
701 MO MO037 MO037C MO037C1 S 21700 Y N
T - Cell
Lymphoma
CT for
Peripheral
701 MO MO037 MO037C MO037C1 S 21700 Y N
T - Cell
Lymphoma asparginas
e
6000U/m2
D8,10,12,1
4,16,18,20
Dexa
methasone
40mg D1-4
every 28
days
GELOXGe
mcitabine
1000mg/m
2 D1 and
D8Oxalipla
tin
CT for NK -
130mg/m2
702 MO MO038 T Cell MO038A MO038A1 S 21300 Y N
D1L-
Lymphoma
asparginas
e 6000
U/m2 D1-
7Repeat
every 21
days
GELOXGe
mcitabine
1000mg/m
2 D1 and
D8Oxalipla
tin
CT for NK -
130mg/m2
702 MO MO038 T Cell MO038A MO038A1 S 21300 Y N
D1L-
Lymphoma
asparginas
e 6000
U/m2 D1-
7Repeat
every 21
days
LVPL-
asparginas
e
6000U/m2
D5Vincristi
CT for NK - ne
703 MO MO038 T Cell 1.4mg/m2 MO038B MO038B1 S 8800 Y N
Lymphoma D1Prednis
olone
100mg
D5Repeat
every 21
days
LVPL-
asparginas
e
6000U/m2
D5Vincristi
CT for NK - ne
703 MO MO038 T Cell 1.4mg/m2 MO038B MO038B1 S 8800 Y N
Lymphoma D1Prednis
olone
100mg
D5Repeat
every 21
days
COPPCycl
ophospha
mide
650mg/m2
D1,
8Vincristin
e
1.4mg/m2
D1,
CT for
8Procarbaz
704 MO MO039 Hodgkin's MO039A MO039A1 S 4300 Y N
ine 100
Lymphoma
mg/m2 D1-
14Predniso
lone
40mg/m2
D1-
14Every
28days.
Total 6 - 8
cycles
COPPCycl
ophospha
mide
650mg/m2
D1,
8Vincristin
e
1.4mg/m2
D1,
CT for
8Procarbaz
704 MO MO039 Hodgkin's MO039A MO039A1 S 4300 Y N
ine 100
Lymphoma
mg/m2 D1-
14Predniso
lone
40mg/m2
D1-
14Every
28days.
Total 6 - 8
cycles
ABVDAdria
mycin
25mg/m2Bl
eomycin
10unit/m2V
CT for inblastine
705 MO MO039 Hodgkin's 6mg/m2Da MO039B MO039B1 S 11300 Y N
Lymphoma carbazine
375 mg/m2
Day
1,15Every
28 days for
6 cycles
ABVDAdria
mycin
25mg/m2Bl
eomycin
10unit/m2V
CT for inblastine
705 MO MO039 Hodgkin's 6mg/m2Da MO039B MO039B1 S 11300 Y N
Lymphoma carbazine
375 mg/m2
Day
1,15Every
28 days for
6 cycles
AEVDAdria
mycin
25mg/m2Vi
nblastine
6mg/m2Da
carbazine
375 mg/m2
Day
1,15Etopos
ide
65mg/m2
Day 1-3,
15-
CT for
706 MO MO039 Hodgkin's MO039C MO039C1 S 11300 Y N
Lymphoma
CT for
706 MO MO039 Hodgkin's MO039C MO039C1 S 11300 Y N
Lymphoma
17Every 28
days for 6
cycles
ICEIfosfam
ide 1.5
mg/m2 D1-
CT for 3Carboplat
Relapsed in AUC5
707 MO MO040 MO040A MO040A1 S 11600 Y N
Hodgkin D2Etoposi
Lymphoma de
100mg/m2
D1- 3Every
3 weeks
ICEIfosfam
ide 1.5
mg/m2 D1-
CT for 3Carboplat
Relapsed in AUC5
707 MO MO040 MO040A MO040A1 S 11600 Y N
Hodgkin D2Etoposi
Lymphoma de
100mg/m2
D1- 3Every
3 weeks
MINEIfosfa
mide 4
gm/m2
over 3days
CT for (D1-
Relapsed 3)Mitoxantr
708 MO MO040 MO040B MO040B1 S 11600 Y N
Hodgkin one
Lymphoma 8mg/m2Eto
poside
65mg/m2
D1-3Every
3 weeks
MINEIfosfa
mide 4
gm/m2
over 3days
CT for (D1-
Relapsed 3)Mitoxantr
708 MO MO040 MO040B MO040B1 S 11600 Y N
Hodgkin one
Lymphoma 8mg/m2Eto
poside
65mg/m2
D1-3Every
3 weeks
PTCL -
GDPGemci
tabine
1000mg/m
2 D1 and
D8Dexame
CT for
thasone
Relapsed
709 MO MO040 40mg D1- MO040C MO040C1 S 16300 Y N
Hodgkin
4Cisplatin
Lymphoma
75mg/m2
D1
orCacrbopl
atin AUC-
5Every 3
weeks
PTCL -
GDPGemci
tabine
1000mg/m
2 D1 and
D8Dexame
CT for
thasone
Relapsed
709 MO MO040 40mg D1- MO040C MO040C1 S 16300 Y N
Hodgkin
4Cisplatin
Lymphoma
75mg/m2
D1
orCacrbopl
atin AUC-
5Every 3
weeks
DHAPDexa
methasone
40mg D1-
4Cisplatin
100mg/m2
or
CT for
Carboplati
710 MO MO041 Relapsed MO041A MO041A1 S 13800 Y N
n AUC-
NHL & HL
5D1Cytara
bine 2
gm/m2 BD
D2Repeat
every 21
days
DHAPDexa
methasone
40mg D1-
4Cisplatin
100mg/m2
or
CT for
Carboplati
710 MO MO041 Relapsed MO041A MO041A1 S 13800 Y N
n AUC-
NHL & HL
5D1Cytara
bine 2
gm/m2 BD
D2Repeat
every 21
days
Lenalidomi
de +
Dexametha
soneLenali
domi de 25
CT for
mg daily
MM /
711 MO MO042 Day1- MO042A MO042A1 S 5800 Y N
Amyloidosi
21Dexamet
s / POEMS
hasone
40mg Day
1, 8, 15,
22Every
28days
Lenalidomi
de +
Dexametha
soneLenali
domi de 25
CT for
mg daily
MM /
711 MO MO042 Day1- MO042A MO042A1 S 5800 Y N
Amyloidosi
21Dexamet
s / POEMS
hasone
40mg Day
1, 8, 15,
22Every
28days
Pomalidom
ide +
Dexametha
sonePomal
idom ide 4
CT for
mg daily
MM /
712 MO MO042 Day 1- MO042B MO042B1 S 7900 Y N
Amyloidosi
21Dexamet
s / POEMS
hasone
40mg Day
1, 8, 15,
22Every 28
days
Pomalidom
ide +
Dexametha
sonePomal
idom ide 4
CT for
mg daily
MM /
712 MO MO042 Day 1- MO042B MO042B1 S 7900 Y N
Amyloidosi
21Dexamet
s / POEMS
hasone
40mg Day
1, 8, 15,
22Every 28
days
Cyclophos
phamide +
Thalidomid
e+
Dexametha
soneCyclo
phosp
hamide
CT for 100mg D1-
MM / D14Thalid
713 MO MO043 MO043A MO043A1 S 4500 Y N
Amyloidosi omide 100-
s 200 mg
daily Day
1-
28Dexamet
hasone
40mg Day
1, 8, 15,
22Every 28
days
Cyclophos
phamide +
Thalidomid
e+
Dexametha
soneCyclo
phosp
hamide
CT for 100mg D1-
MM / D14Thalid
713 MO MO043 MO043A MO043A1 S 4500 Y N
Amyloidosi omide 100-
s 200 mg
daily Day
1-
28Dexamet
hasone
40mg Day
1, 8, 15,
22Every 28
days
Melphalan
+
Thalidomid
e+
Prednisolo
neMelphal
an 9mg/m2
CT for
D1-
MM /
714 MO MO043 D4Thalido MO043B MO043B1 S 4600 Y N
Amyloidosi
mide
s
100mg D1-
28Predniso
lone
100mg
Day1-
4Every
28days
Melphalan
+
Thalidomid
e+
Prednisolo
neMelphal
an 9mg/m2
CT for
D1-
MM /
714 MO MO043 D4Thalido MO043B MO043B1 S 4600 Y N
Amyloidosi
mide
s
100mg D1-
28Predniso
lone
100mg
Day1-
4Every
28days
Bortezomib
+
Cyclophos
phamide +
Dexametha
sone
Cyclophos
p hamide -
300 mg/m2
day 1,
CT for
MM /
715 MO MO043 MO043C MO043C1 S 16100 Y N
Amyloidosi
s
CT for
MM /
715 MO MO043 MO043C MO043C1 S 16100 Y N
Amyloidosi 8, 15,
s 22Dexamet
hasone
40mg Day
1, 8, 15,
22Bortezo
mib 1.3
mg/m2
Day1, 8,
15,
22Every 28
days
Bortezomib
+
Dexametha
sone
Bortezomib
1.3 mg/m2
CT for
Day1, 8,
MM /
716 MO MO043 15, MO043D MO043D1 S 14700 Y N
Amyloidosi
22Dexamet
s
hasone
40mg
Day1, 8,
15,
22Every 28
day
Bortezomib
+
Dexametha
sone
Bortezomib
1.3 mg/m2
CT for
Day1, 8,
MM /
716 MO MO043 15, MO043D MO043D1 S 14700 Y N
Amyloidosi
22Dexamet
s
hasone
40mg
Day1, 8,
15,
22Every 28
day
Bortezomib
+
Melphalan
+
Prednsiolo
ne
Melphalan
9mg/m2
D1-
D4Prednis
olone
100mg Day
1-
4Bortezomi
b 1.3
CT for
MM /
717 MO MO043 MO043E MO043E1 S 13900 Y N
Amyloidosi
s
CT for
MM /
717 MO MO043 MO043E MO043E1 S 13900 Y N
Amyloidosi
s
mg/m2 Day
1, 8, 15,
22Every 28
days
Bortezomib
+
Lenalidomi
de
CT for
MM /
718 MO MO043 MO043F MO043F1 S 19600 Y N
Amyloidosi
s
+
CT for
MM /
718 MO MO043 MO043F MO043F1 S 19600 Y N
Amyloidosi
s
Dexametha
sone
Lenalidomi
de 25 mg
daily Day 1
-
21Dexamet
hasone
40mg Day
1, 8, 15,
22Bortezo
mib
1.3 mg/m2
Day 1, 8,
15,
22Every 28
days
Bortezomib
+
Thalidomid
e
+
CT for
MM /
719 MO MO043 MO043G MO043G1 S 16500 Y N
Amyloidosi
s
Dexametha
sone
Thalidomid
e 100 mg
daily Day 1
- 28
Dexametha
sone 40
mg Day 1,
8, 15,
22Bortezo
mib 1.3
mg/m2 Day
1, 8, 15,
22Every 28
days
Imatinib
Imatinib
400 mg,
CT for
Chronic
720 MO MO044 MO044A MO044A1 S 16500 Y N
Myeloid
Leukemia
CT for
Chronic
720 MO MO044 MO044A MO044A1 S 16500 Y N
Myeloid
Leukemia
600 mg,
800 mg(per
month
X 5 years)
CT for
Dasatinib
Chronic
721 MO MO044 100 mg MO044B MO044B1 S 5500 Y N
Myeloid
once a day
Leukemia
Hydroxure
a
Hydroxure
CT for
a
Myeloprolif
722 MO MO045 daily(Dose MO045A MO045A1 S 2500 Y N
erative
will be
Neoplasm
based on
blood
counts)
Hydroxure
a
Hydroxure
CT for
a
Myeloprolif
722 MO MO045 daily(Dose MO045A MO045A1 S 2500 Y N
erative
will be
Neoplasm
based on
blood
counts)
Cytarabine
CT for 2 gm / M2
Acute BD for
723 MO MO046 MO046A MO046A1 S 78400 Y N
Myeloid 5Every 21
Leukemia days for 3
cycles
Cytarabine
100 mg /
M2 7 days
Daunomyci
n 60 mg /
CT for M2 3 ( this
Acute does not
724 MO MO046 MO046B MO046B1 S 116200 Y N
Myeloid include
Leukemia antibiotics,
antifungals
, blood and
platelets
transfusion
)
Berlin-
Frankfurt -
Munster-
90, Berlin-
Frankfurt -
Munster-
95, Berlin-
Frankfurt -
Munster-
2000Hyper
(cyclophos
phamide,
Vincristine,
Adriamycin
,Dexameth
asone
UKALL
(United
kingdom
acute
lymphoblas
ticleukaemi
a)
GMALL
(German
CT for multicenter
Acute acute
725 MO MO047 Lymphobla lymphoblas MO047A MO047A1 S 176000 Y N
stic tic
Leukemia
Berlin-
Frankfurt -
Munster-
90Berlin-
Frankfurt -
Munster
95Berlin-
Frankfurt -
Munster
2000Hyper
(cyclophos
phamide,
Vincristine,
Adriamycin
,Dexameth
asone
UKALL
(United
kingdom
acute
lymphoblas
tic
leukaemia)
GMALL
(German
multicenter
CT for acute
Acute lymphoblas
726 MO MO047 Lymphobla tic leukem MO047B MO047B1 S 136200 Y N
stic
Leukemia
6
Mercaptop
urine 50
mg /
M2 daily
CT for
Acute
727 MO MO047 Lymphobla MO047C MO047C1 S 4400 Y N
stic
Leukemia
Methotrexa
te 25 mg /
M2 Weekly
for 2 years
Berlin-
Frankfurt -
Munster-
90Berlin-
Frankfurt -
Munster
95Berlin-
Frankfurt -
Munster
2000Hyper
CVAD
(cyclophos
phamide,
Vincristine,
Adriamycin
,
CT for
Lymphobla
728 MO MO048 MO048A MO048A1 S 176000 Y N
stic
Lymphoma
CT for
Lymphobla
728 MO MO048 MO048A MO048A1 S 176000 Y N
stic Dexametha
Lymphoma sone
UKALL
(United
kingdom
acute
lymphoblas
tic
leukaemia)
GMALL
(German
multicenter
acute
lymphoblas
tic
Berlin-
Frankfurt -
Munster-
90Berlin-
Frankfurt -
Munster 95
Berlin-
Frankfurt -
Munster-
2000Hyper
CVAD
(cyclophos
phamide,
Vincristine,
Adriamycin
,
CT for
Lymphobla
729 MO MO048 MO048B MO048B1 S 136200 Y N
stic
Lymphoma
CT for
Lymphobla Dexametha
729 MO MO048 sone MO048B MO048B1 S 136200 Y N
stic
Lymphoma UKALL
(United
kingdom
acute
lymphoblas
tic
leukaemia)
GMALL
(German
multicenter
acute
lymphoblas
tic
6
Mercaptop
urine 50
CT for mg/M2
Lymphobla daily and
730 MO MO048 MO048C MO048C1 S 4400 Y N
stic Methotrexa
Lymphoma te 25
mg/M2
Weekly for
2 Years
6
Mercaptop
urine 50
CT for mg/M2
Lymphobla daily and
730 MO MO048 MO048C MO048C1 S 4400 Y N
stic Methotrexa
Lymphoma te 25
mg/M2
Weekly for
2 Years
CT for
Acute
Arsenic
Promyeloc
trioxide
ytic
Leukemia
731 MO MO049 MO049A MO049A1 S 79200 Y N

(High Risk) ATRA
Daunomyci
n or
Idarubcin
Cytarabine
-
multiagent
- vary in
each
protocol
CT for
Acute
Arsenic
Promyeloc
trioxide
ytic
Leukemia
ATRADaun
omycin or
732 MO MO049 IdarubcinC MO049B MO049B1 S 106500 Y N
(High Risk) ytarabine -
multiagent
- vary on
protocol
CT for
Acute
6 MP 50
Promyeloc
mg / day
ytic
Leukemia
(High Risk) Daily
733 MO MO049 MO049C MO049C1 S 8800 Y N
Methotrexa
te 15 mg
WeeklyAT
RA 45 mg /
M2 for 14
days Every
three
months for
18 Months
ATO:
Arsenic
CT for trioxide
Acute 0.15 mg /
Promyeloc kg day 1-
ytic Day 5, day
Leukemia 8- 12, day
15-19, day
22-26
every 56
days for 4
cyclesATR
A : All trans
734 MO MO050 (Low Risk) retinoic MO050A MO050A1 S 60500 Y N
acid 45 mg
/ M2 day 1-
Day 14 and
Day 29-
43 every
56 days for
4 cycles -
(per 56 day
cycle)
CT for
Acute
Promyeloc
ytic
Leukemia
ATO:
Arsenic
trioxide
0.15 mg /
kg day 1-
45 or
735 MO MO050 MO050B MO050B1 S 89100 Y N
60ATRA:
(Low Risk) All trans
retinoic
acid 45 mg
/ M2 - day
1-45 or 60
Cefoperaz
one +
Sulbactum
Piperalicilli
n+
Tazobactu
mCefopera
Cefoperaz
one +
Sulbactum
Piperalicilli
n+
Tazobactu
mCefopera
zoneP
iperacillinA
Febrile mikacinGe
736 MO MO051 MO051A MO051A1 S 36600 Y N
Neutopenia ntami
cinCefipim
eLevofloxa
cinAm
oxycillin
and
clavulanate
Teicoplani
nVanc
omycin
Meropene
mImipene
mColisti
nTigecyclin
Febrile
737 MO MO051 LinezolidV MO051B MO051B1 S 86700 Y N
Neutopenia
oricon
azoleCaspf
unginAmph
oteri cin - B
Chemother
apy Rasburicas
Complicati eFebuxost
738 MO MO052 ons - atAllo MO052A MO052A1 S 26400 Y N
Tumor purinolSev
Lysis elamer
Syndrome
5
microgram
/ kg /
5
microgram
/ kg /
day(max
300
Granulocyt microgram
e Colony per day) for
739 MO MO053 MO053A MO053A1 S 5000 Y N
Stimulating 7 days
Factor Use orPEG -
GCSF 6mg
one single
dose per
chemother
apy cycle
Langerhan
CT for s Cell
Langerhan Histiocytosi
740 MO MO054 s Cell s(Histiocyt MO054A MO054A1 S 27900 Y N
Histiocytosi osis
s Protocol -
Induction)
Langerhan
s Cell
CT for
Histiocytosi
Langerhan
s(Histiocyt
741 MO MO054 s Cell MO054B MO054B1 S 31800 Y N
osis
Histiocytosi
Protocol -
s
Maintenan
ce)
Vincristine
+
Carboplati
nVincristin
e
1.5mg/m2
(day 1, 8
and 15 for
CT for Low first 4
742 MO MO055 Grade cycles and MO055A MO055A1 S 6500 Y N
Glioma then only
day 1 from
cycle 5 to
17)Carbopl
atin
550mg/m2
every 3
weeks (all
cycles)
VinblastinV
CT for Low
inblastine 6
743 MO MO055 Grade MO055B MO055B1 S 3700 Y N
mg/m2
Glioma
every week
CT for
Medullobla
744 MO MO056 stoma / PACKER MO056A MO056A1 S 7000 Y N
Brain
PNET
Cisplatin +
Cyclophos
phamide +
Vincristine
Cyclophos
phami de
1000mg/m
2 (2 every
CT for cycles)Vinc
Medullobla ristine
745 MO MO056 MO056B MO056B1 S 9200 Y N
stoma / 1.5mg/m2
CNS PNET (days 1
and
8)Cisplatin
100mg/m2
(1 day per
cycle)Cycl
es given
every 3
weekly
Cabroplati
n+
Etoposide
+
Cyclophos
phamide +
Doxorubici
CT for
nCarboplat
746 MO MO057 Neuroblast MO057A MO057A1 S 9500 Y N
in
oma
600mg/m2
Etoposide
100mg/m2
(days
5)Cyclopho
sphamideD
oxor ubicin
Carboplati
n+
Cisplatin +
CT for
Cyclophos
747 MO MO057 Neuroblast MO057B MO057B1 S 8400 Y N
phamide +
oma
Vincristine
+
Etoposide
13-cis
retinoic
acid
CT for 160mg/m2
748 MO MO057 Neuroblast per day for MO057C MO057C1 S 2300 Y N
oma 2
weeksEach
cycle given
4 weekly
Vincristine
+
Carboplati
n+
Etoposide
Carboplati
CT for n
749 MO MO058 Retinoblast 600mg/m2 MO058A MO058A1 S 8200 Y N
oma day
1Etoposide
150mg/m2
1-3
Vincristine
1.5mg/m2
day 1
Vincristine
+
Cyclophos
phamide +
Dactinomy
cinVincristi
ne
1.5mg/m2
(day 1, 8
and
CT for
750 MO MO059 Rhabdomy MO059A MO059A1 S 6300 Y N
osarcoma
15)Cycloph
osphamie
1200 -
2200
mg/m2
(day
1)Dactinom
ycin
1.5mg / m2
(day 1)3
weekly
cycle
Vincristine
+
Ifosfamide
+
EtoposideV
incristine
1.5mg/m2
(days 1, 8
and
CT for
15)Ifosfami
751 MO MO059 Rhabdomy MO059B MO059B1 S 17900 Y N
de
osarcoma
1.8gm/m2
(days
5)Etoposid
e
100mg/m2
(days
5)Each
cycle every
3 weeks
Vincristine
+
Topotecan
+
Cyclophos
phamide
andVincrist
ine +
Adriamycin
CT for
Relapse
752 MO MO060 MO060A MO060A1 S 13700 Y N
Rhabdomy
osarcoma
Cyclophos
phamideVi
ncristi ne
1.5mg/m2
(day
1)Topoteca
n
1.5mg/m2
(day
5)Cyclopho
sphamide
250mg/m2
(days 5)3 -
weeklyVinc
ristine
1.5mg/m2A
driamyicn
60mg/m2C
yclophosph
amid e
600mg/m2
(all
Vincristine
+
Actinomyci
n
DVincristin
e 1.5
mg/m2
weekly for
CT for 12 weeks
753 MO MO061 Wilms and then 3 MO061A MO061A1 S 4200 Y N
Tumor weeklyActi
nomycin D
45
microgram
/ kg 3
weekly
for 24
weeks
Vincristine
+
Actinomyci
nD
CT for
754 MO MO061 Wilms MO061B MO061B1 S 5500 Y N
Tumor
+
Doxorubici
nVincristin
e 1.5
mg/m2
weekly for
12 weeks
and then 3
weeklyActi
nomycin D
45
microgram/
kg 3
weeklyDox
orubicin
60mg/m2
for 24
weeks
Cyclophos
phamide +
Doxorubici
n+
Etoposide
+
Vincristine
+
Dactinomy
cinVincristi
ne 1.5
CT for
755 MO MO061 Wilms MO061C MO061C1 S 16800 Y N
Tumor
mg/
m2Dactino
mycin 45
microgram/
kgAdriamyi
cn
60mg/m2C
yclophosph
amid
eEtoposide
Weekly
chemother
apy -
varying
hybrid
regimen
CT for Consolidati
Pediatric on (Phase
Acute II, CNS
756 MO MO062 MO062A MO062A1 S 263700 Y N
Lymphobla Therapy
stic Reinductio
Leukemia n)
India
collaborativ
e childhood
leukaemia
group
Berlin-
CT for
Frankfurt -
Pediatric
Munster
Acute
757 MO MO062 Kill acute MO062B MO062B1 S 95700 Y N
Lymphobla
lymphocyti
stic
c leukemia
Leukemia
cells
Mitroxantro
ne,Chlora
mbucil,
Prednisolo
ne: 841
6-
Mercaptop
urine
75mg/m2
dailyMetho
CT for
trexate
Pediatric
20mg/m2
Acute
758 MO MO062 weeklyVinc MO062C MO062C1 S 3000 Y N
Lymphobla
ristine
stic
1.5mg/m2
Leukemia
monthlyIntr
athecal
methotrexa
te 12 mg 3
monthly
Pediatric
chemo (to
Acute
be used
Lymphobla
759 MO MO062 only with MO062D MO062D1 S 5500 Y N
stic
ALL
Leukemia
therapy)-
for adult
CT for
Ph+ve
Imatinib +
Pediatric
chemo ((to
Acute
be used
Lymphobla
760 MO MO062 only with MO062E MO062E1 S 5500 Y N
stic
ALL
Leukemia
therapy)
for adult
and
paediatric -permonth
Consolidati
CT for
on (Phase
Pediatric
II, CNS
761 MO MO063 Lymphobla MO063A MO063A1 S 263700 Y N
Therapy
stic
Reinductio
Lymphoma
n)
India
collaborativ
e childhood
leukaemia
group
Berlin-
CT for Frankfurt -
Pediatric Munster
762 MO MO063 Lymphobla Kill acute MO063B MO063B1 S 95700 Y N
stic lymphocyti
Lymphoma c leukemia
cellsMitrox
antrone,Ch
loram
bucil,Predn
isolone:
841
6-
Mercaptop
urine
75mg/m2
dailyMetho
CT for trexate
Pediatric 20mg/m2
763 MO MO063 Lymphobla weeklyVinc MO063C MO063C1 S 3000 Y N
stic ristine
Lymphoma 1.5mg/m2
monthlyIntr
athecal
methotrexa
te 12 mg 3
monthly
CT for Cytrabine 3
Pediatric gram/m2
764 MO MO064 Acute twice a MO064A MO064A1 S 63400 Y N
Myeloid dayDays 1,
Leukemia 3 and 5
Cytrabine
200mg/m2/
day days
CT for 1-10 and
Pediatric
765 MO MO064 Acute MO064B MO064B1 S 115800 Y N
Myeloid
Leukemia
Daunorubic
in
50mg/m2
1, 3 and
5Etposide
100mg/m2
5
Cytrabine
100-
CT for
Pediatric
766 MO MO064 Acute MO064C MO064C1 S 115400 Y N
Myeloid
Leukemia
200mg/
m2/day
days 1-7
and
Daunorubic
in
50mg/m2
1, 3 and 5
CT for
Pediatric
Acute Consolidati
767 MO MO065 MO065A MO065A1 S 64700 Y N
Promyeloc on
ytic
Leukemia
CT for
Pediatric
Acute
768 MO MO065 Induction MO065B MO065B1 S 142400 Y N
Promyeloc
ytic
Leukemia
CT for
Pediatric Maintenan
Acute ce (18
769 MO MO065 MO065C MO065C1 S 43300 Y N
Promyeloc months
ytic total cost)
Leukemia
COPDAC:
CT for
Pediatric
770 MO MO066 MO066A MO066A1 S 10400 Y N
Hodgkins
Lymphoma
Cyclophos
phamide,
Vincristine
sulfate,Pre
dnisone,Da
carba zine
Oncovin,Et
oposide,Pr
CT for
ednis
Pediatric
771 MO MO066 one,doxoru MO066B MO066B1 S 14300 Y N
Hodgkins
bicin
Lymphoma
hydrochlori
de
CT for
Pediatric ifosfamide,
772 MO MO067 Hodgkins carboplatin MO067A MO067A1 S 15400 Y N
Lymphoma , etoposide
Relapse
DECA:
CT for
Pediatric
773 MO MO067 Hodgkins MO067B MO067B1 S 15400 Y N
Lymphoma
Relapse
Dexametha
sone,Etopo
side,
Cytarabine,
Cisplatin
CT for
Pediatric IGVD:
774 MO MO067 Hodgkins Need to MO067C MO067C1 S 37400 Y N
Lymphoma check
Relapse
Lymphoma
CT for
malign B
Pediatric
89-96
775 MO MO068 Non MO068A MO068A1 S 46900 Y N
Consolidati
Hodgkins
on (second
Lymphoma
month)
Lymphoma
CT for
malign B
Pediatric
89-96
776 MO MO068 Non MO068B MO068B1 S 46700 Y N
Consolidati
Hodgkins
on (First
Lymphoma
month)
CT for Lymphoma
Pediatric malign B
777 MO MO068 Non 89-96 - MO068C MO068C1 S 72400 Y N
Hodgkins Maintenan
Lymphoma ce
CT for Mitroxantro
Pediatric ne,Chlora
778 MO MO068 Non mbucil, MO068D MO068D1 S 108600 Y N
Hodgkins Prednisolo
Lymphoma ne: 842
PEDIATRI PEDIATRI
779 MO MO069 C-GCT/ C-GCT/ MO069A MO069A1 S 11800 Y N
JEB JEB
Carboplati
CT for
n+
Pediatric
780 MO MO070 Cisplatin + MO070A MO070A1 S 6200 Y N
Hepatoblas
Doxorubici
toma
n
CT for
Pediatric
781 MO MO070 Cisplatin MO070B MO070B1 S 6200 Y N
Hepatoblas
toma
Docetaxel
Docetaxel
CT for CA
Lung
D1 every
21 days
Docetaxel
Docetaxel
CT for CA
Lung
D1 every
21 days
ErlotinibErl
CT for CA otinib 150
783 MO MO071 MO071B MO071B1 S 5000 Y N
Lung mg once
daily
GefitnibGef
CT for CA itinib 250
784 MO MO071 MO071C MO071C1 S 2800 Y N
Lung mg once
daily
Paclitaxel
+
Carboplati
nPaclitaxel
CT for CA 175mg/m2
785 MO MO071 MO071D MO071D1 S 16000 Y N
Lung D1Carbopl
atin AUC
5-6 D1
every 21
days
Paclitaxel
+
Carboplati
nPaclitaxel
CT for CA 175mg/m2
785 MO MO071 MO071D MO071D1 S 16000 Y N
Lung D1Carbopl
atin AUC
5-6 D1
every 21
days
Pemetrexe
d+
Carboplati
nPemetrex
ed
CT for CA
786 MO MO071 500mg/m2 MO071E MO071E1 S 11200 Y N
Lung
D1Carbopl
atin AUC
5-6 D1
every 21
days
Topotecan
Topotecan
CT for CA 1.5 mg/m2
787 MO MO071 MO071F MO071F1 S 27100 Y N
Lung D1-D5
every 21
days
Docetaxel
Docetaxel
CT for CA
Lung
D1 every
week
Docetaxel
Docetaxel
CT for CA
Lung
D1 every
week
Etoposide
+
Carboplati
nEtoposide
100mg/m2
CT for CA
789 MO MO071 D1 - MO071H MO071H1 S 8500 Y N
Lung
D3Carbopl
atin AUC
5-6 D1
every 21
days
Etoposide
+
CisplatinEt
oposide
100mg/m2
CT for CA
790 MO MO071 D1 - MO071I MO071I1 S 7500 Y N
Lung
D3Cisplati
n 75-100
mg/m2 D1
every 21
days
Gemcitabin
eGemcitabi
CT for CA ne 1000mg
791 MO MO071 MO071J MO071J1 S 9900 Y N
Lung /m2 D1 D8
every 21
days
Gemcitabin
eGemcitabi
CT for CA ne 1000mg
791 MO MO071 MO071J MO071J1 S 9900 Y N
Lung /m2 D1 D8
every 21
days
Gemcitabin
e+
Carboplati
nGemcitabi
ne 1000
CT for CA
792 MO MO071 mg/m2 D1 MO071K MO071K1 S 15300 Y N
Lung
D8Carbopl
atin AUC
5-6 D1
every 21
days
Gemcitabin
e+
CisplatinG
emcitabine
1000
CT for CA
793 MO MO071 mg/m2 D1 MO071L MO071L1 S 13400 Y N
Lung
D8Cisplati
n 75
mg/m2 D1
D8 every
21 days
PaclitaxelP
CT for CA aclitaxel
794 MO MO071 MO071M MO071M1 S 6600 Y N
Lung 80mg/m2
every week
PaclitaxelP
CT for CA aclitaxel
794 MO MO071 MO071M MO071M1 S 6600 Y N
Lung 80mg/m2
every week
PaclitaxelP
aclitaxel
CT for CA
795 MO MO071 175mg/m2 MO071N MO071N1 S 13000 Y N
Lung
every 21
days
Paclitaxel
+
Carboplati
nPaclitaxel
CT for CA
796 MO MO071 50mg/m2 MO071O MO071O1 S 8500 Y N
Lung
D1Carbopl
atin AUC 2
D1 every
week
Paclitaxel
+
CisplatinPa
clitaxel 175
CT for CA
797 MO MO071 mg/m2 MO071P MO071P1 S 14700 Y N
Lung
D1Cisplati
n 75mg/m2
D1 every
21 days
Paclitaxel
+
CisplatinPa
clitaxel 175
CT for CA
797 MO MO071 mg/m2 MO071P MO071P1 S 14700 Y N
Lung
D1Cisplati
n 75mg/m2
D1 every
21 days
Pemetrexe
d+
CisplatinPe
metrexed
CT for CA 500mg/m2
798 MO MO071 MO071Q MO071Q1 S 10400 Y N
Lung D1Cisplati
n 75
mg/m2 D1
every 21
days
Pemetrexe
dPemetrex
CT for CA ed
799 MO MO071 MO071R MO071R1 S 8400 Y N
Lung 500mg/m2
D1 every
21 days
Vinorelbine
+
Carboplati
nVinorelbin
e 25mg/m2
D1
D8Carbopl
atinAUC 5-
6 D1
CT for CA
800 MO MO071 MO071S MO071S1 S 18700 Y N
Lung
CT for CA
800 MO MO071 MO071S MO071S1 S 18700 Y N
Lung
every 21
days
Vinorelbine
+
CisplatinVi
norelbine
CT for CA 25mg/m2
801 MO MO071 MO071T MO071T1 S 18700 Y N
Lung D1
D8Cisplati
n 75mg/m2
D1 every
21 days
Carboplati
n
CT for CA
802 MO MO072 Carboplati MO072A MO072A1 S 3000 Y N
Cervix
n AUC 2
every week
CT for De-
primary Angelis/
803 MO MO073 MO073A MO073A1 S 39600 Y N
CNS Methotrexa
lymphoma te
SA
Carboplati
n AUC 7
once every
804 MO MO074 GCT Testis 3 weeks - MO074A MO074A1 S 6600 Y N
Max 4
cycles
(price per
cycle)
Denosuma
b
Denosuma
b 120 mg
CT for s/c D1, 8,
805 MO MO075 GCT of 15 then MO075A MO075A1 S 19800 Y N
bone
every 28
days-
19800 per
dose. Max
6 dose
150mg/m2
GEP NET
D9-14 +
Neuroendo
806 MO MO076 Capecitabi MO076A MO076A1 S 8800 Y N
crine
ne 1gm/me
carcinoma
D1-14
GEP NET n AUC 5 +
high grade Etoposide
807 MO MO076 Neuroendo 100mg/m2 MO076B MO076B1 S 14800 Y N
crine D1- D3
carcinoma every 21
Induction
cycles
(PC)Rate
Intravesical
per dose -
808 MO SU060 BCG / SU060A SU060A1 S 3200 N N
Rs 5000
Mitomycin
max no- 06
(including
drug)
Intravesical
Maintenan
809 MO SU060 BCG / SU060B SU060B1 S 30000 Y N
ce
Mitomycin
Whole
Blood
910 MP MG074 Blood MG074A MG074A1 M 2000 N N
transfusion
transfusion
Blood
component
including
Blood
911 MP MG074 platelet MG074B MG074B1 M 2000 N N
transfusion
transfusion
(RDP, PC,
SDP)
ogy ogy
(Biopsies) (Biopsies)
912 MP MG076 and and MG076A MG076A1 M 5000 Y N
advanced advanced
serology serology
Per Day
Bed
Category-
HDU(3300)
,,Bed
913 MP MG098 PET scan PET scan MG098A MG098A1 M Y N

Category-
ICU -
913 MP MG098 PET scan PET scan MG098A MG098A1 M Without Y N
Ventilator(
8500),Bed
Category-
ICU - With
Ventilator(
9000),Bed
Category-
Routine
Ward(2100
)
Platelet Platelet
914 MP MG099 MG099A MG099A1 M 11000 Y N
pheresis pheresis
Linear
Accelerator
, External
Beam
Radiothera
py 3D CRT
1015 MR MR001 (6 Radical MR001A MR001A1 M 23100 Y N
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
2D
External
Beam
Radiothera
py
(Telecobalt
/ Strock
1016 MR MR001 LA) Adjuvant MR001B MR001B1 M 12100 Y N
(6
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
2D
External
Beam
Radiothera
py
(Telecobalt
/ Strock
LA) Neoadjuva
1017 MR MR001 MR001C MR001C1 M 12100 Y N
nt
(6
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
2D Additional
External fractions -
Beam 18 Max
Radiothera upto (Every
1018 MR MR001 MR001D MR001D1 M 18900 Y N
py additional
(Telecobalt fraction at
/ Strock Rs.500 per
LA) Fraction)
(6
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
2D
External
Beam
Radiothera
py -
Palliative
(Telecobalt
/ Strock
1019 MR MR002 Palliative MR002A MR002A1 M 11000 Y N
LA) (Upto
10
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
2D
External
Beam
Radiothera
1020 MR MR003 Radical MR003A MR003A1 M 22000 Y N
py
(Telecobalt
/ Strock
LA)
(25
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
2D
External
Beam
Radiothera
1021 MR MR003 Adjuvant MR003B MR003B1 M 22000 Y N
py
(Telecobalt
/ Strock
LA)
(25
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
2D
External
Beam
Radiothera Neoadjuva
1022 MR MR003 MR003C MR003C1 M 22000 Y N
py nt
(Telecobalt
/ Strock
LA)
(25
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Additional
2D fractions -
External 10 Max
Beam upto
Radiothera (additional
1023 MR MR003 MR003D MR003D1 M 10500 Y N
py fraction at
(Telecobalt Rs.500 per
/ Strock Fraction
LA) upto a
max)
(25
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
2D
External
Beam
Radiothera
py
(Telecobalt
/ Strock
LA)
(6
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
, External
Beam
Radiothera
py 3D CRT
1025 MR MR004 (6 Adjuvant MR004B MR004B1 M 23100 Y N
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
, External
Beam
Radiothera
py 3D CRT
Neoadjuva
1026 MR MR004 (6 MR004C MR004C1 M 23100 Y N
nt
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
, External Additional
Beam fractions -
Radiothera 18 Max
py 3D CRT upto (Every
1027 MR MR004 (6 additional MR004D MR004D1 M 37800 Y N
Fractions) fraction at
(Inclusive Rs.1000
of per
Simulation Fraction)
& Planning
Cost)
Linear
Accelerator
, External
Beam
Radiothera
py 3D CRT
1028 MR MR005 (25 Radical MR005A MR005A1 M 44000 Y N
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
, External
Beam
Radiothera
py 3D CRT
1029 MR MR005 (25 Adjuvant MR005B MR005B1 M 44000 Y N
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
, External
Beam
Radiothera
py 3D CRT
Neoadjuva
1030 MR MR005 (25 MR005C MR005C1 M 44000 Y N
nt
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
Beam fractions -
Radiothera 10 Max
1031 MR MR005 (25 additional MR005D MR005D1 M 21000 Y N
(Inclusive Rs.1000
of per
& Planning
Cost)
Linear
Accelerator
, External
Beam
Radiothera
py IMRT
(Intensity
Modulated
Radiothera
py)
(20
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
, External
Beam
Radiothera
py IMRT
(Intensity
Modulated
Radiothera
py)
(20
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
, External
Beam
1034 MR MR006 MR006C MR006C1 M 77000 Y N
py IMRT nt
(Intensity
Modulated
Radiothera
py)
(20
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator Additional
, External fractions -
Beam 15 (Every
Radiothera additional
1035 MR MR006 MR006D MR006D1 M 63000 Y N
py IMRT fraction at
(Intensity Rs.2000
Modulated per
Radiothera Fraction)
py)
(20
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
, External
Beam
Radiothera
py IMRT
(Intensity
Modulated
Radiothera
py)
(6
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
, External
Beam
Radiothera
py IMRT
(Intensity
Modulated
Radiothera
py)
(6
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
, External
Beam
1038 MR MR007 MR007C MR007C1 M 46200 Y N
py IMRT nt
(Intensity
Modulated
Radiothera
py)
(6
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Additional
Accelerator
fractions -
, External
18 Max
Beam
upto (Every
Radiothera
1039 MR MR007 additional MR007D MR007D1 M 75600 Y N
py IMRT
fraction at
(Intensity
Rs.2000
Modulated
per
Radiothera
Fraction)
py)
(6
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
External
Beam
Radiothera
py IGRT
(Image
Guided
radiotherap
y) with 3D
CRT or
IMRT
(20
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
External
Beam
Radiothera
py IGRT
(Image
Guided
radiotherap
y) with 3D
CRT or
IMRT
(20
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
External
Beam
Radiothera
py IGRT Neoadjuva
1042 MR MR008 MR008C MR008C1 M 99000 Y N
(Image nt
Guided
radiotherap
y) with 3D
CRT or
IMRT
(20
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
Additional
External
fractions -
Beam
15 Max
Radiothera
upto(Every
py IGRT
(Image
fraction at
Guided
Rs.2500
radiotherap
per
y) with 3D
Fraction)
CRT or
IMRT
(20
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
External
Beam
Radiothera
py IGRT
(Image
Guided
radiotherap
y) with 3D
CRT or
IMRT
(6
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
External
Beam
Radiothera
py IGRT
(Image
Guided
radiotherap
y) with 3D
CRT or
IMRT
(6
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
External
Beam
Radiothera
py IGRT Neoadjuva
1046 MR MR009 MR009C MR009C1 M 60500 Y N
(Image nt
Guided
radiotherap
y) with 3D
CRT or
IMRT
(6
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
Additional
External
fractions -
Beam
18 Max
Radiothera
uptoEvery
py IGRT
(Image
fraction at
Guided
Rs.2500
radiotherap
per
y) with 3D
Fraction
CRT or
IMRT
(6
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
SRT /
SRT /
SBRT with
SBRT with
IGRT
IGRT
(Stereotac
1048 MR MR010 (Stereotac MR010A MR010A1 M 90200 Y N
atic
atic
radiotherap
radiotherap
y) (4
y)
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
SRT / Additional
SBRT with fractions -
IGRT 4Every
(Stereotac additional
1049 MR MR010 MR010B MR010B1 M 92400 Y N
atic fraction at
radiotherap Rs.11000
y) (4 per
Fractions) Fraction
(Inclusive
of
Simulation
& Planning
Cost)
SRS with
IGRT
(Stereotac
SRS with
atic
IGRT
radiotherap
(Stereotac
1050 MR MR011 y) MR011A MR011A1 M 77000 Y N
atic
(Inclusive
radiotherap
of
y)
Simulation
& Planning
Cost)
Respiratory
Gating
along with
Linear Respiratory
Accelerator Gating
planning (5 along with
1051 MR MR012 MR012A MR012A1 M 71500 Y N
Fractions) Linear
(Inclusive Accelerator
of planning
Simulation
& Planning
Cost)
Respiratory
Gating
Additional
along with
fractions -
Linear
10 Max
Accelerator
uptoEvery
planning (5
1052 MR MR012 additional MR012B MR012B1 M 73500 Y N
Fractions)
fraction at
(Inclusive
Rs.3500
of
per
Simulation
Fraction
& Planning
Cost)
Brachyther
apy High
Dose
Radiation Intracavitor
1053 MR MR013 MR013A MR013A1 M 3900 Y N
(2D/X-ray) y
(Maximum
of 4
session)
Brachyther
apy High
Dose
Radiation Intralumina
1054 MR MR013 MR013B MR013B1 M 3900 Y N
(2D/X-ray) l
(Maximum
of 4
session)
Brachyther
apy High
Dose
Radiation
1055 MR MR013 Endobiliary MR013C MR013C1 M 3900 Y N
(2D/X-ray)
(Maximum
of 4
session)
Brachyther
apy High
Dose
Radiation Endobronc
1056 MR MR013 MR013D MR013D1 M 3900 Y N
(2D/X-ray) hial
(Maximum
of 4
session)
Brachyther
apy High
Dose
Radiation
1057 MR MR013 CVS MR013E MR013E1 M 3900 Y N
(2D/X-ray)
(Maximum
of 4
session)
Brachyther
apy High
Dose
Radiation Interstitial /
(5 doses) Intracavitar
(Inclusive y complex
1058 MR MR014 MR014A MR014A1 M 46200 Y N
of planning
Simulation, like CT or
Planning MR
Cost, OT &
other
charges )
Brachyther
apy High
Dose
Surface
Radiation
Mould /
(5 doses)
Intracavitar
(Inclusive
1059 MR MR014 y complex MR014B MR014B1 M 46200 Y N
of
planning
Simulation,
like CT or
Planning
MR
Cost, OT &
other
charges )
Brachyther
apy High
Dose
Radiation
(5 doses)
Additional
(Inclusive
1060 MR MR014 fractions - MR014C MR014C1 M 39450 Y N
of
11
Simulation,
Planning
Cost, OT &
other
charges )
large Dose
iodine scan/ Pre
1061 MR MR015 treatment 3 Ablation - MR015A MR015A1 M 11400 Y N
mCi calculation
of
treatment
Ablation of
iodine
residual
1062 MR MR015 treatment MR015B MR015B1 M 16900 Y N
disease
30 mCi
any risk
Ablation of
residual
Iodine
neck
1063 MR MR016 treatment MR016A MR016A1 M 18000 Y N
disease
50 mCi
low/interm
ediate
Ablation for
Iodine
metastatic
1064 MR MR020 treatment MR020A MR020A1 M 40000 Y N
disease,
250 mCi
High risk
Chemo
Chemo
Port
1393 SC SC076 Port SC076A SC076A2 S 49000 Y N
Insertion
Insertion
(Pediatric)
Lymph
1757 SG SG096 Biopsy SG096A SG096A1 S 5000 Y N
Node
Endometria
1758 SG SG096 Biopsy SG096B SG096B1 S 2700 Y N
l Aspiration
Cervix
Cancer
screening
1759 SG SG096 Biopsy SG096C SG096C1 S 2500 Y N
(PAP +
Colposcop
y)
Cervical Cervical
1760 SG SG096 SG096D SG096D1 S 1500 N N
(Neck) (Neck)
1761 SG SG096 Biopsy Vulval SG096E SG096E1 S 2500 Y N

Stoma
Stoma Manageme
1762 SG SG097 Manageme nt follow up SG097A SG097A1 S 5500 Y N
nt of
Ileostomy
Stoma
Stoma Manageme
1763 SG SG097 Manageme nt follow up SG097B SG097B1 S 5500 Y N
nt of
Colostomy
Induction
cycles
(PC)Rate
Intravesical
per dose -
2658 SU SU060 BCG / SU060A SU060A1 S 3200 N N
Rs 5000
Mitomycin
max no- 06
(including
drug)
Intravesical
Maintenan
2659 SU SU060 BCG / SU060B SU060B1 S 30000 Y N
ce
Mitomycin
Unspecifie Unspecifie
to be
3227 US US100 d Surgical d Surgical US100A US100A1 S Y N
negotiated
Package Package
Unspecifie Unspecifie
to be
3228 US US100 d Medical d Medical US100B US100B1 M Y N
negotiated
Package Package
Mandatory
Document
Mandatory Documents (Pre Authorization) s (Claim
Processin
g)
Barcode of
the
2D ECHO,Biopsy/ pathology report of Modified
drug,BAR
radical mastectomy or breast conservation
CODE OF
surgery,Biopsy report or surgical pathology
THE
report of Modified radical mastectomy or breast
DRUGS,C
conservation surgery,Blood investigation (CBC,
HARTS OF
LFT,RFT),CBC,Clinical notes
CHEMOTH
ERAPY
REGIMEN,
Charts of
Chemother
apy
regimen &
transfusion
slips,Clinic
al
notes,Detai
ls of
/
Follow-up
and
Supportive
care that
may be
required &
indications
for it eg. for
Neutropeni
a, Growth
facto
Barcode of
the
drug,BAR
CODE OF
2D ECHO,2D-ECHO,Biopsy/ THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
Chemother
apy
regimen &
transfusion
slips,Clinic
pathology report of Modified radical mastectomy al
or breast conservation surgery,Biopsy report or notes,Detai
surgical pathology report of Modified radical ls of
mastectomy or breast conservation Follow-up
surgery,Blood investigation (CBC, and
LFT,RFT),CBC,Clinical Supportive
care that
may be
required &
indications
for it eg. for
Neutropeni
a, Growth
facto
Barcode of
the
drug,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
Chemother
apy
regimen &
transfusion
slips,Clinic
care that
may be
required &
indications
for it eg. for
Neutropeni
a, Growth
facto
Barcode of
the
drug,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
Chemother
apy
regimen &
transfusion
slips,Clinic
al
notes,Detai
ls of
/
Follow-up
and
Supportive
care that
may be
required &
indications
for it eg. for
Neutropeni
a, Growth
facto
Barcode of
the
drug,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
Chemother
apy
regimen &
transfusion
slips,Clinic
al
notes,Detai
ls of
/
Follow-up
and
Supportive
care that
may be
required &
indications
for it eg. for
Neutropeni
a, Growth
facto
Barcode of
the
drug,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
Chemother
apy
regimen &
transfusion
slips,Clinic
al
notes,Detai
ls of
/
Follow-up
and
Supportive
care that
may be
required &
indications
for it eg. for
Neutropeni
a, Growth
facto
Barcode of
the
drug,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
Chemother
apy
regimen &
transfusion
slips,Clinic
al
notes,Detai
ls of
/
Follow-up
and
Supportive
care that
may be
required &
indications
for it eg. for
Neutropeni
a, Growth
facto
Barcode of
the
drug,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
Chemother
apy
regimen &
transfusion
slips,Clinic
al
notes,Detai
ls of
/
Follow-up
and
Supportive
care that
may be
required &
indications
for it eg. for
Neutropeni
a, Growth
facto
Barcode of
the
drug,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
Chemother
apy
regimen &
transfusion
slips,Clinic
al
notes,Detai
ls of
/
Follow-up
and
Supportive
care that
may be
required &
indications
for it eg. for
Neutropeni
a, Growth
Barcode of
the
drug,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
Chemother
apy
regimen &
transfusion
slips,Clinic
al
notes,Detai
ls of
/
Follow-up
and
Supportive
care that
may be
required &
indications
for it eg. for
Neutropeni
a, Growth
facto
Barcode of
the
drug,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
Chemother
apy
regimen &
transfusion
slips,Clinic
care that
may be
required &
indications
for it eg. for
Neutropeni
a, Growth
facto
Barcode of
the
drug,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
Chemother
apy
regimen &
transfusion
slips,Clinic
care that
may be
required &
indications
for it eg. for
Neutropeni
a, Growth
facto
Barcode of
the
drug,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
Chemother
apy
regimen &
transfusion
slips,Clinic
al
notes,Detai
ls of
/
Follow-up
and
Supportive
care that
may be
required &
indications
for it eg. for
Neutropeni
a, Growth
facto
Barcode of
the
drug,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
Chemother
apy
regimen &
transfusion
slips,Clinic
al
notes,Detai
ls of
/
Follow-up
and
Supportive
care that
may be
required &
indications
for it eg. for
Neutropeni
a, Growth
facto
Barcode of
the
drug,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
Chemother
apy
regimen &
transfusion
slips,Clinic
al
notes,Detai
ls of
/
Follow-up
and
Supportive
care that
may be
required &
indications
for it eg. for
Neutropeni
a, Growth
facto
Barcode of
the
drug,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
Chemother
apy
regimen &
transfusion
slips,Clinic
al
notes,Detai
ls of
/
Follow-up
and
Supportive
care that
may be
required &
indications
for it eg. for
Neutropeni
a, Growth
facto
Barcode of
the
drug,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
Chemother
apy
regimen &
transfusion
slips,Clinic
al
notes,Detai
ls of
/
Follow-up
and
Supportive
care that
may be
required &
indications
for it eg. for
Neutropeni
a, Growth
facto
Bar code of
the
drugs,BAR
CODE OF
Blood Investigations such as CBC, LFT, RFT,
THE
Ca, Viral
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
markers (HBsAg, HCV, HIV), calculated
T
creatinine clearance, Beta2 microglobulin,
DEPARTM
SPEP+IFE, S.FLC assay, Urine Bence Jones
ENT /
Protein (BJP) ( may not be done if SPEP and
DISCHAR
FLC assay show M band or abnormal f
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
Admission/clinical notes with planned line of the
treatment,Biochemistry reports (LFT, RFT and drugs ,BAR
RBS),CA-125,CA-125 CODE OF
THE
DRUGS,C
harts of
chemother
apy
regimen,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
,CBC,CBC ,CECT Thorax,
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
abdomen and Pelvis,Chest X- ray/ CECT Thorax
tests
,HPE or cytology suggestive of ovarian
(pathology,
adenocarcinoma,LFT,RBS,R FT,USG/ CT/ MRI
radiology,
microbiolo
gy,
hemat
Bar code of
THE
DRUGS,C
harts of
chemother
apy
regimen,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
microbiolo
gy,
hemat
Bar code of
THE
DRUGS,C
harts of
chemother
apy
regimen,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
microbiolo
gy,
hemat
Bar code of
THE
DRUGS,C
harts of
chemother
apy
regimen,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
microbiolo
gy,
hemat
Bar code of
THE
DRUGS,C
harts of
chemother
apy
regimen,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
microbiolo
gy,
hemat
Bar code of
THE
DRUGS,C
harts of
chemother
apy
regimen,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
microbiolo
gy,
hemat
Bar code of
THE
DRUGS,C
harts of
chemother
apy
regimen,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
microbiolo
gy,
hemat
Bar code of
THE
DRUGS,C
harts of
chemother
apy
regimen,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
microbiolo
gy,
hemat
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
CA-125,CBC,CECT Thorax, SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
abdomen and Pelvis,HPE or cytology suggestive NFUSION

of ovarian adenocarcinoma,LFT,RBS,R FT SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA

BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA

Bar code of
Admission/clinical notes with planned line of
the
treatment,AFP,Beta- HCG,Biochemistry reports
drugs ,BAR
(LFT, RFT and RBS),Blood Investigations: Beta
CODE OF
HCG, AFP, LDH,CBC,CBC ,CECT
THE
DRUGS,C
harts of
chemother
apy
regimen,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
Thorax, abdomen and Pelvis,CECT Thorax, GE
abdomen and Pelvis SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
,ECG,ECG ,Histopathology - testi
(pathology,
radiology,
microbiolo
gy,
hemat
Bar code of
the
drugs ,BAR
CODE OF
THE
DRUGS,C
harts of
chemother
apy
regimen,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
,ECG,ECG ,Histopathology - Ovari
(pathology,
radiology,
microbiolo
gy,
hemat
Bar code of
the
drugs ,BAR
CODE OF
THE
DRUGS,C
harts of
chemother
apy
regimen,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
microbiolo
gy,
hemat
Bar code of
the
drugs ,BAR
CODE OF
THE
DRUGS,C
harts of
chemother
apy
regimen,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
microbiolo
gy,
hemat
Bar code of
the
drugs ,BAR
CODE OF
THE
DRUGS,C
harts of
chemother
apy
regimen,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
microbiolo
gy,
hemat
Bar code of
the
drugs ,BAR
CODE OF
THE
DRUGS,C
harts of
chemother
apy
regimen,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
microbiolo
gy,
hemat
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
Admission Or Clinical Notes,Beta- CARE
HCG,CBC,CECT Thorax, abdomen and DEPARTM
Pelvis,LFT,RBS,RFT ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
Admission Or Clinical Notes,Beta- (PATHOLO
HCG,CBC,CECT Thorax, abdomen and GY,
Pelvis,LFT,RBS,RFT RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
Admission Or Clinical Notes,Beta- SUMMARY
HCG,CBC,CECT Thorax, abdomen and OF DAY
Pelvis,LFT,RBS,RFT CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
Beta- HCG,CBC,CECT SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
Thorax, abdomen and Pelvis,LFT,RBS,RFT
SLIPS
Bar code of
the
Biochemistry reports (RBS,LFT,RFT, Na,
drugs ,BAR
K),CBC,CBC ,CECT Thorax,
CODE OF
THE
DRUGS,C
abdomen and Pelvis,Clinical notes with Details
harts of
of pelvic examination (Per speculum and
chemother
pervaginal examination), planned line of
apy
treatment
regimen
,CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
,ECG
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
,ECHO,histopathology,Histop athology tests
report,LFT,M (pathology,
radiology,
microbiolo
gy,
hema
Bar code of
the
Biochemistry reports (LFT,RFT, Na,K),CBC,CBC drugs ,BAR
CODE OF
THE
DRUGS,C
,CECT Thorax, abdomen and Pelvis,Clinical
harts of
notes with Details of pelvic examination (Per
chemother
speculum and pervaginal examination), planned
apy
line of treatment
regimen
,CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
,ECG
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
,ECHO,histopathology,Histop athology tests
report,LFT,Metast (pathology,
radiology,
microbiolo
gy,
hema
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
Admission Or Clinical Notes,CBC,CECT Thorax, SUMMARY
abdomen and Pelvis,histopathology,LFT,RB OF DAY
S,RFT CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
2D ECHO,Admission Or Clinical SUMMARY
Notes,CBC,CECT Thorax, abdomen and OF DAY
Pelvis,ECG,histopathology,L FT,RBS,RFT CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
Admission Or Clinical SUMMARY
Notes,CBC,histopathology,LF T,MRI OF DAY
pelvis,RBS,RFT CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
pelvis,RBS,RFT CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
CBC,LFT,RBS,RFT DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,RBS,
RFT,TR
ANFUSIO
N SLIPS
Barcode of
drugs
used,BAR
2D ECHO,Admission /clinical notes with history CODE OF
and indication for the procedure, planned line of THE
management DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
,Biochemistry,Biopsy,Bone marrow
SUMMARY
studies,CBC,Chest x- ray/ CECT report ,CT/
OF
USG guided biospy report,ECG,Histopathology
INPATIEN
report,PET-CT (for lymphoma/
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
(pathology,
radiology,
Barcode of
drugs
used,BAR
management DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
(pathology,
radiology,
Barcode of
drugs
used,BAR
management DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
(pathology,
radiology,
Bar code of
2D ECHO,Audiometry,Blood investigations- the
CBC,LFT, RFT, RBS,Bone scan or F18 PET drugs,BAR
Scan,CBC,CECT CODE OF
THE
DRUGS,C
harts of
chemother
apy
regimen,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
chest,Clinical notes with documentation of
GE
relevant history Bone imaging (local and chest x-
SUMMARY
ray),Core needle biopsy,DTPA GFR,ECG
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
,ECHO,GFR
(pathology,
radiology,
microbiolo
gy,
,histopathology,Histo hemato
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
2D ECHO,Admission Or Clinical (PATHOLO
Notes,AUDIOMETRY,Bioche GY,
mistry,Biopsy,BONE SCAN,CBC,CT RADIOLO
CHEST,ECG,GFR GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
Bar code of
2D ECHO,Audiometry,Blood investigations- the
CBC,LFT, RFT, RBS,Bone scan or F18 PET drugs,BAR
Scan,CBC,CECT CODE OF
THE
DRUGS,C
harts of
chemother
apy
regimen,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
chest,Clinical notes with documentation of T
relevant history Bone imaging (local and chest x- DEPARTM
ray),Core needle biopsy,DTPA GFR,ECG ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
,ECHO,GFR LOGY,
HEMATO
,histopathology,Histo
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
2D ECHO,Admission Or Clinical SUMMARY
Notes,CBC,DTPA GFR,histopathology,LFT,Pur OF DAY
e tone,RBS,RFT CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
Bar code of
the
drugs,BAR
CODE OF
Blood investigations- CBC,LFT, RFT, THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
RBS,CBC,CECT/ MRI thorax, abdomen,
HARGE
pelvis,CECT Thorax, abdomen and Pelvis,Chest
SUMMARY
X-ray,Clinical notes with documentation of
OF
relevant history, signs, symptoms, indication
INPATIEN
including stage,ECHO,ECHO
T
report,histopathology,LFT
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
RBS,CBC,CECT/ MRI thorax, abdomen,
HARGE
pelvis,CECT Thorax, abdomen and Pelvis,Chest
SUMMARY
X-ray,Clinical notes with documentation of
OF
relevant history, signs, symptoms, indication
INPATIEN
including stage,ECHO,ECHO
T
report,histopathology,LFT
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of
the tests
(pathology,
radiology,
m
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
CBC,CECT Thorax, abdomen and SUMMARY
Pelvis,ECHO,histopathology, LFT,MRI of the OF DAY
involved part CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
Bar code of
Admission/ clinical notes with complete history,
the
physical examinations, indications and plan of
drugs,BAR
treatment,Biochemistry (RBS, LFT, RFT,
CODE OF
LDH) ,CBC,CBC
THE
DRUGS,C
harts of
,CECT/ PET-CT Chest, chemother
apy
regimen
,CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
Abdomen and Pelvis/Chest X- ray ,CECT
OF
Thorax, abdomen and
INPATIEN
Pelvis,histopathology,LFT,Pe
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
microbiolo
gy,
hemat
Bar code of
the
drugs,BAR
treatment,Biochemistry (RBS, LFT, RFT,
CODE OF
LDH) ,CBC,CBC
THE
DRUGS,C
harts of
,CECT/ PET-CT Chest, chemother
apy
regimen
,CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
Abdomen and Pelvis/Chest X- ray ,CECT
OF
Thorax, abdomen and Pelvis,LFT,Peripheral
INPATIEN
blood
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
microbiolo
gy,
hemat
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
CBC,CECT Thorax, abdomen and SUMMARY
Pelvis,histopathology,LFT,RB S,RFT OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
Bar code of
the
drugs,BAR
CODE OF
Biopsy/ Histopathology report,Blood
THE
investigations- CBC,LFT, RFT, RBS, HIV
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
testing, CD4 counts,Carcinoembryonic antigen
OF
(CEA),CBC,CEA,CECT
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
Thorax, abdomen,Clinical notes with ENT,Repor
documentation of relevant history (anal growth or ts of the
mass/ bleeding per rectum) and tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
(CEA),CBC,CEA,CECT
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
Thorax, abdomen,Clinical notes with DEPARTM

documentation of relevant history (anal growth or ENT,Repor
mass/ bleeding per rectum) and ts of
the tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
(CEA),CBC,CEA,CECT
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
Thorax, abdomen, Pelvis,Clinical notes with ENT,Repor
mass/ bleeding per rect tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
(CEA),CBC,CEA,CECT
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
Thorax, abdomen, Pelvis,Clinical notes with ENT,Repor
mass/ bleeding per rect tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
(CEA),CBC,CEA,CECT
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
Thorax, abdomen, Pelvis,Clinical notes with DEPARTM

documentation of relevant history (anal growth or ENT,Repor
mass/ bleeding per rect ts of
the tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
RBS,Carcinoembryonic antigen
OF
(CEA),CBC,CEA,CECT
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
Thorax, abdomen, Pelvis,CECT Thorax,
ENT,Repor
abdomen & Pelvis; Chest X- ray,Clinical notes
ts of the
with documentation of relevant history, signs,
tests
symptoms, indication including stage,Colono
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
(CEA),CBC,CEA,CECT
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
(CEA),CBC,CEA,CECT
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE

DEPARTM
ENT,Repor
ts of
the tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
(CEA),CBC,CEA,CECT
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
(CEA),CBC,CEA,CECT
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
(CEA),CBC,CEA,CECT
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE

DEPARTM
ENT,Repor
ts of
the tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
(CEA),CBC,CEA,CECT
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
(CEA),CBC,CEA,CECT
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
m
Barcode of
drugs
used,BAR
Biopsy/ histopathology report,Blood investigation CODE OF
reports such as CBC, LFT, RFT, THE
RBS,CBC,CECT DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
abdomen, pelvis reports,Clinical notes with
OF
indications including stage, signs, symptoms,
INPATIEN
relevant history/ risk factors, pl
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
(pathology,
radiology,
Barcode of
drugs
used,BAR
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
(pathology,
radiology,
Barcode of
drugs
used,BAR
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
(pathology,
radiology,
Barcode of
drugs
used,BAR
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
(pathology,
radiology,
Barcode of
drugs
used,BAR
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
(pathology,
radiology,
Bar code of
the
drugs,BAR
CODE OF
Biopsy/Histopathology report,Blood
THE
investigations- CBC,LFT, RFT,
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
RBS,CBC,CECT thorax, abdomen, pelvis,CECT HARGE
Thorax, abdomen, Pelvis,Clinical notes with SUMMARY
documentation of relevant history, risk OF
factors,signs, symptoms, indication including INPATIEN
staging of treatmen T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of
the tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of
the tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of
the tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
Biopsy, Histopathology report,Blood
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
staging of treatme T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
Biopsy, Histopathology report,Blood
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
staging of treatme T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of
the tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
AFP,Blood investigations- CBC,LFT, RFT, THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
RBS,CBC,Clinical notes with documentation of HARGE
relevant history, signs, symptoms, indication SUMMARY
including stage,Documentation of Child scoring OF
and BCLC scoring,Gadolinium enhanced MRI of INPATIEN
the abdomen (in cirrhotics and sus T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
2D ECHO,AFP,Blood GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
investigations-CBC,LFT, RFT, RBS,CBC,Clinical tests
notes with documentation of relevant history, (pathology,
signs, symptoms, indication including radiology,
stage,Documentation of Child scoring and BCLC microbiolo
scoring,Gadolinium enhanced MRI of the gy,
abdomen (in cirrhotics hematolog
y,
biochemist
ry,
etc.),REPO
R
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
AFP,CBC,CECT Thorax, SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
abdomen and Pelvis,histopathology,LFT,M NFUSION

RI,RBS,RFT SLIPS
Bar code of
the
drugs,BAR
CODE OF
Blood investigations- CBC,LFT, RFT, RBS, THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
Coagulation profile,CA19.9,CBC,CECT Thorax, HARGE
abdomen, Pelvis,Chest X-ray,Clinical notes with SUMMARY
documentation of relevant history, signs, OF
symptoms, indication including staging of INPATIEN
treatment,CT/ USG guided FNAC / Biopsy T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of
the tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of
the tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
Blood investigations- CBC,LFT, RFT,
THE
RBS,CA19.9,CA 19.9
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
report,Carcinoembryonic antigen (CEA) report OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
,CBC,CECT Abdomen &Pelvis ,CECT Thorax,
ENT,Repor
abdomen, Pelvis,Clinical notes with
ts of the
documentation of relevant history, signs,
tests
symptoms, indication including staging
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
THE
RBS,CA19.9,CA 19.9
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE

DEPARTM
ENT,Repor
ts of
the tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
THE
RBS,CA19.9,CA 19.9
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
THE
RBS,CA19.9,CA 19.9
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
THE
RBS,CA19.9,CA 19.9
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE

DEPARTM
ENT,Repor
ts of
the tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
THE
RBS,CA19.9,CA 19.9
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
THE
RBS,CA19.9,CA 19.9
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
THE
RBS,CA19.9,CA 19.9
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE

DEPARTM
ENT,Repor
ts of
the tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
THE
RBS,CBC,CECT Thorax,
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,Disch
arge
summary
of
inpatient/d
aycare
department
abdomen, Pelvis,CECT Thorax, Abdomen
,DISCHAR
&Pelvis
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPAR
,Chest X-ray,Ckit-mutation (not mandatory),C-kit

(positivity) on Immunohistochemistry (IHC)
,Clinical notes with documentation of relevant
history, signs,
Bar code of
the
drugs,BAR
CODE OF
THE
RBS,CBC,CECT Thorax,
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,Disch
arge
summary
of
inpatient/d
aycare
department
abdomen, Pelvis,CECT Thorax, Abdomen
,DISCHAR
&Pelvis
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPAR
,Chest X-ray,Ckit-mutation (not mandatory),C-kit

(positivity) on Immunohistochemistry (IHC)
,Clinical notes with documentation of relevant
history, signs,
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
brain,RBS,RFT CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
brain,RBS,RFT CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
Barcode of
drugs
used,BAR
CODE OF
THE
treatment,Blood Investigations: CBC, RBS, LFT,
DRUGS,C
RFT, LDH,CBC,CECT/
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
PET-CT Chest, Abdomen and Pelvis,CECT SUMMARY
Thorax, abdomen, Pelvis,Chest X- ray,FNAC of OF
pleural/ pe INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
(pathology,
radiology,
Barcode of
drugs
used,BAR
CODE OF
THE
DRUGS,C
RFT, LDH,CBC,CECT/
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
(pathology,
radiology,
Barcode of
drugs
used,BAR
CODE OF
THE
DRUGS,C
RFT, LDH,CBC,CECT/
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
(pathology,
radiology,
Barcode of
drugs
used,BAR
CODE OF
Physical examinations, Indications and plan of
THE
treatment.,Blood Investigations: CBC, RBS, LFT,
DRUGS,C
RFT, LDH,CBC,CECT
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
Thorax, abdomen, Pelvis,CECT Thorax, SUMMARY
abdomen, pelvis reports,CT guided biopsy to be OF
done only INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
(pathology,
radiology,
Barcode of
drugs
used,BAR
CODE OF
Physical examinations, Indications and plan of
THE
treatment.,Blood Investigations: CBC, RBS, LFT,
DRUGS,C
RFT, LDH,CBC,CECT
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
Thorax, abdomen, Pelvis,CECT Thorax, SUMMARY
abdomen, pelvis reports,CT guided biopsy to be OF
done only INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
(pathology,
radiology,
Barcode of
drugs
Blood investigations- CBC, RFT, LFT,
used,BAR
RBS,CBC,CECT
CODE OF
THE
DRUGS,Bl
/MR face & Neck,CECT/MRI Face and
ood
neck,Chest X-ray report,Clinical notes with
investigatio
complete history, risk factors, staging with
ns- CBC,
subsite involvement, physical examinations,
RFT, LFT,
indications including signs, symptoms,
S.
Creatinine,
CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF
DAY CARE
DEPA
Barcode of
drugs
used,BAR
RBS,CBC,CECT
CODE OF
THE
DRUGS,Bl
ood
investigatio
ns- CBC,
RFT, LFT,
S.
Creatinine,
CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF
DAY CARE
DEPA
Barcode of
drugs
used,BAR
RBS,CBC,CECT
CODE OF
THE
DRUGS,Bl
/MR face & Neck,Chest X-ray report,Clinical
ood
notes with complete history, risk factors, staging
investigatio
with subsite involvement, physical examinations,
ns- CBC,
indications including signs, symptoms, stage and
RFT, LFT,
planned line
S.
Creatinine,
CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF
DAY CARE
DEPA
Barcode of
drugs
used,BAR
RBS,CBC,CECT
CODE OF
THE
DRUGS,Bl
ood
investigatio
ns- CBC,
RFT, LFT,
planned line
S.
Creatinine,
CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF
DAY CARE
DEPA
Barcode of
drugs
used,BAR
RBS,CBC,CECT
CODE OF
THE
DRUGS,Bl
ood
investigatio
ns- CBC,
RFT, LFT,
planned line
S.
Creatinine,
CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF
DAY CARE
DEPA
Barcode of
drugs
used,BAR
RBS,CBC,CECT
CODE OF
THE
DRUGS,Bl
ood
investigatio
ns- CBC,
RFT, LFT,
S.
Creatinine,
CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF
DAY CARE
DEPA
Barcode of
drugs
used,BAR
RBS,CBC,CECT
CODE OF
THE
DRUGS,Bl
ood
investigatio
ns- CBC,
RFT, LFT,
planned line
S.
Creatinine,
CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF
DAY CARE
DEPA
Barcode of
drugs
used,BAR
RBS,CBC,CECT
CODE OF
THE
DRUGS,Bl
ood
investigatio
ns- CBC,
RFT, LFT,
planned line
S.
Creatinine,
CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF
DAY CARE
DEPA
Barcode of
drugs
used,BAR
RBS,CBC,CECT
CODE OF
THE
DRUGS,Bl
ood
investigatio
ns- CBC,
RFT, LFT,
planned line
S.
Creatinine,
CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF
DAY CARE
DEPA
Barcode of
drugs
used,BAR
RBS,CBC,CECT
CODE OF
THE
DRUGS,Bl
ood
investigatio
ns- CBC,
RFT, LFT,
planned line
S.
Creatinine,
CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF
DAY CARE
DEPA
Barcode of
drugs
used,BAR
RBS,CBC,CECT
CODE OF
THE
DRUGS,Bl
ood
investigatio
ns- CBC,
RFT, LFT,
planned line
S.
Creatinine,
CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF
DAY CARE
DEPA
Barcode of
drugs
used,BAR
RBS,CBC,CECT
CODE OF
THE
DRUGS,Bl
ood
investigatio
ns- CBC,
RFT, LFT,
planned line
S.
Creatinine,
CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF
DAY CARE
DEPA
Barcode of
drugs
used,BAR
RBS,CBC,CECT
CODE OF
THE
DRUGS,Bl
ood
investigatio
ns- CBC,
RFT, LFT,
planned line
S.
Creatinine,
CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF
DAY CARE
DEPA
Barcode of
drugs
used,BAR
RBS,CBC,CECT
CODE OF
THE
DRUGS,Bl
ood
investigatio
ns- CBC,
RFT, LFT,
planned line
S.
Creatinine,
CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF
DAY CARE
DEPA
Barcode of
drugs
used,BAR
RBS,CBC,CECT
CODE OF
THE
DRUGS,Bl
ood
investigatio
ns- CBC,
RFT, LFT,
S.
Creatinine,
CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF
DAY CARE
DEPA
Barcode of
drugs
used,BAR
RBS,CBC,CECT
CODE OF
THE
DRUGS,Bl
ood
investigatio
ns- CBC,
RFT, LFT,
S.
Creatinine,
CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF
DAY CARE
DEPA
Bar code of
the
drugs,BAR
24 hour urine protein,24-hour urine protein,2 D CODE OF
ECHO,Blood investigations: CBC, LFT, RFT, THE
RBS; lipid DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
profile, , TFT ,CBC,CECT Thorax, abdomen and
SUMMARY
Pelvis,chest X-ray,Clinical notes with
OF
documentation of relevant history,Histopathology
INPATIEN
report
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
,If pseudo tum ts of the
tests
(pathology,
radiology,
m
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
24 hour urine protein,2D ECHO,CBC,LFT,Lipid SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
Profile,RBS,RFT,TFT
SLIPS
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
RBS,CBC,CECT thorax, abdomen and HARGE
pelvis ,CECT Thorax, abdomen and SUMMARY
Pelvis,Chest X-ray,Clinical notes with OF
documentation of relevant history,CT-IVU or INPATIEN
MRU ,cystoscopy + RGP T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
,histopathology,LFT,Metastati c work-up (Bone
ts of the
sca
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
sca
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
2D-ECHO,Blood investigations- CBC,LFT, RFT,
THE
RBS,CBC,CECT thorax,
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
abdomen and pelvis ,CECT Thorax, abdomen
SUMMARY
and Pelvis,Chest X-ray,Clinical notes with
OF
documentation of relevant history,CT-IVU or
INPATIEN
MRU ,cystoscopy + RGP
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
,ECG,histopathology,LFT,Met astatic work- ENT,Repor
ts of
the tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
sca
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
sca
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
sca
ts of
the tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
sca
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
sca
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
,ECG,ECHO,histopathology,L FT,Metastatic
ENT,Repor
work-up
ts of
the tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
sca
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
sca
tests
(pathology,
radiology,
m
Bar code of
the
drugs,BAR
CODE OF
Blood Investigation reports: CBC, RFT,
THE
LFT,CBC,CECT
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
Thorax, abdomen and Pelvis,Clinical notes with
OF
documentation of relevant
INPATIEN
history,histopathology,Histop athology
T
report,LFT,MRI/ CT scan (for nodal staging in
DEPARTM
obese, with prior groin surgery and assess pel
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,FNAC
report
in cases
with
palpable/
suspected
Bar code of
the
drugs,BAR
CODE OF
THE
LFT,CBC,CECT
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,FNAC
report
in cases
with
palpable/
suspected
Bar code of
the
drugs,BAR
CODE OF
THE
LFT,CBC,CECT
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,FNAC
report
in cases
with
palpable/
suspected
Bar code of
the
drugs,BAR
CODE OF
THE
LFT,CBC,CECT
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,FNAC
report
in cases
with
palpable/
suspected
Bar code of
the
drugs,BAR
CODE OF
THE
LFT,CBC,CECT
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,FNAC
report
in cases
with
palpable/
suspected
Bar code of
the
drugs,BAR
CODE OF
THE
LFT,CBC,CECT
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,FNAC
report
in cases
with
palpable/
suspected
Bar code of
the
drugs,BAR
CODE OF
THE
LFT,CBC,CECT
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,FNAC
report
in cases
with
palpable/
suspected
Bar code of
the
drugs,BAR
Blood Investigations: CBC, RFT, LFT, Prostate
CODE OF
Specific Antigen (PSA),BONE SCAN,Bone scan
THE
in locally advanced prostate cancer (T3b-
DRUGS,C
T4)},CBC,CECTThorax,
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
abdomen and Pelvis,CECT- Thorax, Abdomen, SUMMARY
Pelvis/ Transrectal Ultrasound (TRUS)/ MRI OF
pelvis ,Clinical no INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Evide
nce of
Biophosph
onates
(Zoledronic
Acid)
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Evide
nce of
Biophosph
onates
(Zoledronic
Acid)
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Evide
nce of
Biophosph
onates
(Zoledronic
Acid)
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Evide
nce of
Biophosph
onates
(Zoledronic
Acid)
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Evide
nce of
Biophosph
onates
(Zoledronic
Acid)
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Evide
nce of
Biophosph
onates
(Zoledronic
Acid)
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Evide
nce of
Biophosph
onates
(Zoledronic
Acid)
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Evide
nce of
Biophosph
onates
(Zoledronic
Acid)
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
BONE SCAN,CBC,CECT SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
Thorax, abdomen and NFUSION

Pelvis,ECG,histopathology,L FT,PSA,RFT SLIPS
Bar code of
the
drugs,BAR
CODE OF
2D THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
ECHO,Biochemistry,Biopsy or fluid flow/PB
DEPARTM
cytometry,Biopsy report,Bone marrow
ENT /
studies,CBC,CBC, LFT, RFT, Viral markers .
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
HbsAg , HCV and HIV,CECT (chest +abdomen

RADIOLO
+Pelvis) or PET-CT,Clinical notes with evidence
GY, M
to support indication for therapy, stage o
Bar code of
the
drugs,BAR
CODE OF
2D THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
ECHO,Biochemistry,Biopsy or fluid flow/PB
DEPARTM
cytometry,Biopsy report,Bone marrow
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,

RADIOLO
GY, M
to support indication for therapy, stage o
Bar code of
the
drugs,BAR
Biochemistry,Biopsy or fluid flow CODE OF
cytometry,Biopsy report,Bone marrow THE
studies,CBC,CBC, LFT, RFT, DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
Viral markers . HbsAg , HCV and HIV,CECT DEPARTM
(chest ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
+abdomen +Pelvis) or PET- CT,Clinical notes

RADIOLO
with evidence to support indication for therapy,
GY, M
stage of disease,
Bar code of
the
drugs,BAR
Biochemistry,Biopsy or fluid flow
CODE OF
cytometry,Biopsy report documenting the
THE
relapse of HL or NHL and subtype,Bone marrow
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
+Pelvis) or PET-CT report,Clinical notes with
ENT /
perfor
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
the
drugs,BAR
Biochemistry,Biopsy or fluid flow
CODE OF
cytometry,Biopsy report documenting the
THE
relapse of HL or NHL and subtype,Bone marrow
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
perfor
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
the
drugs,BAR
CODE OF
2D THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
ECHO,Biochemistry,Biopsy or bone marrow or T
peripheral blood flow cytometry report,Biopsy or DEPARTM
fluid flow cytometry,Bone marrow ENT /
studies,CBC,CBC, LFT, RFT, DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
Viral markers . HbsAg , HCV and HIV,CECT RADIOLO

(chest GY, M
with evid
Bar code of
the
drugs,BAR
CODE OF
2D THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
ECHO,Biochemistry,Biopsy or bone marrow or T
peripheral blood flow cytometry report,Biopsy or DEPARTM
fluid flow cytometry,Bone marrow ENT /
studies,CBC,CBC, LFT, RFT, DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
Viral markers . HbsAg , HCV and HIV,CECT RADIOLO

(chest GY, M
with evid
Bar code of
the
drugs,BAR
Biochemistry,Biopsy or bone marrow or
CODE OF
peripheral blood flow cytometry report,Biopsy or
THE
fluid flow cytometry,Bone marrow
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
HbsAg , HCV and HIV,CECT (chest +abdomen DEPARTM
+Pelvis) or PET-CT,Clinical notes . ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
Performance sta
GY, M
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
HbsAg , HCV and HIV,CECT (chest +abdomen DEPARTM
+Pelvis) or PET-CT,Clinical notes . ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
Performance sta
GY, M
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
HbsAg , HCV and HIV,CECT Chest abdomen DEPARTM
and pelvis,CECT (chest ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
+abdomen +Pelvis) or PET- CT,Cl
GY, M
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
HbsAg , HCV and HIV,CECT Chest abdomen DEPARTM
and pelvis,CECT (chest ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
+abdomen +Pelvis) or PET- CT,Cl
GY, M
Bar code of
the
drugs,BAR
CODE OF
Biochemistry,Biopsy or fluid flow cytometry,Bone
THE
marrow studies,CBC,Chest X ray,Clinical notes .
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
Performance status, PREsence or absence of B T
symptoms, lymphadenopathy with size, DEPARTM
splenomegaly with size comorbidities and ENT /
indication for therapy, Prior treat DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
Biochemistry,Biopsy,Bone marrow
to support indication for therapy, stage of
disease, performance status and disease sites i
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
Biochemistry,Biopsy,Bone marrow slips,DISC
studies,CBC,CBC, LFT, RFT, Viral markers . HARGE
HbsAg , HCV and HIV,CECT (chest +abdomen SUMMARY
+Pelvis) or PET-CT,Clinical notes with evidence OF
to support indication for therapy, stage of INPATIEN
disease, performance status and disease sites i T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
the
drugs,BAR
CODE OF
2D- THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen
with dates
and dose,
transfusion
slips,DISC
HARGE
SUMMARY
ECHO,Biochemistry,Biopsy to confirm diagnosis OF
of HL INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS
,Bone marrow studies,CBC,CBC, ESR,

LFT,RFT,Clinical notes with Indications, history, OF THE
Performance status, Stage, Age, comorbidities, TESTS
any prior chemotherapy and response to it,node (PAT
Biopsy,PET CT or CECT
Bar code of
the
drugs,BAR
2D-ECHO (repeated after cycle CODE OF
4 ),Biochemistry,Biopsy to confirm diagnosis of THE
HL DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen
with dates
and dose,
transfusion
slips,DISC
HARGE
,Bone marrow studies,CBC,CBC, ESR, SUMMARY
LFT,RFT,Clinical notes with Indications, history, OF
Performance status, Stage, Age, comorbidities, INPATIEN
any prior chemotherapy and response to it, T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS
OF THE
TESTS
(PAT
Bar code of
the
drugs,BAR
2D-ECHO (repeated after cycle CODE OF
4 ),Biochemistry,Biopsy to confirm diagnosis of THE
HL DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen
with dates
and dose,
transfusion
slips,DISC
HARGE
,Bone marrow studies,CBC,CBC, ESR, SUMMARY
LFT,RFT,Clinical notes with Indications, history, OF
Performance status, Stage, Age, comorbidities, INPATIEN
any prior chemotherapy and response to it, T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS
OF THE
TESTS
(PAT
Bar code of
the
drugs,BAR
Biochemistry,Biopsy,Biopsy report documenting CODE OF
the relapse of HL or NHL and subtype,Bone THE
marrow studies,CBC,CBC, LFT, RFT, DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
(chest ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
+abdomen +Pelvis) or PET- CT report,Clinical RADIOLO

notes with performance status and disease GY, M
Bar code of
the
drugs,BAR
Biochemistry,Biopsy,Biopsy report documenting CODE OF
the relapse of HL or NHL and subtype,Bone THE
marrow studies,CBC,CBC, LFT, RFT, DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
(chest ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
+abdomen +Pelvis) or PET- CT report,Clinical RADIOLO

notes with performance status and disease GY, M
Bar code of
the
drugs,BAR
Biochemistry,Biopsy report documenting the CODE OF
relapse of HL or NHL and subtype,Bone marrow THE
studies,CBC,CBC, LFT, RFT, Viral markers . DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
performance status and disease sites
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
the
drugs,BAR
Biochemistry,Biopsy report documenting the CODE OF
relapse of HL or NHL and subtype,Bone marrow THE
studies,CBC,CBC, LFT, RFT, Viral markers . DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
performance status and disease sites
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
the
drugs,BAR
Biochemistry,Blood Investigations such as CBC, CODE OF
LFT, RFT, Ca, Viral markers (HBsAg, HCV, THE
HIV), DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
calculated creatinine clearance, Beta2 T
microglobulin, SPEP+IFE, S.FLC assay, Urine DEPARTM
Bence Jones Protein (BJP) ( may not be done if ENT /
SPEP and FLC assay show M band DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
the
drugs,BAR
HIV), DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
the
drugs,BAR
HIV), DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
the
drugs,BAR
HIV), DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
the
drugs,BAR
HIV), DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
the
drugs,BAR
HIV), DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
the
drugs,BAR
HIV), DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
the
drugs,BAR
HIV), DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
the
drugs,BAR
HIV), DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
Biopsy,BONE MARROW,Bone marrow

aspiration and biopsy (if done), Conventional
cytogenetics or FISH on bone marrow or RT-
PCR on peripheral blood or bone
marrow,CBC,CBC, Peripheral smear, LFT,
RFT,Clinical notes with mention of prior
REGIMEN,
Charts of
chemother
apy
regimen,
Biopsy,BONE MARROW,Bone marrow transfusion
aspiration and biopsy (if done), Conventional slips,DISC
cytogenetics or FISH on bone marrow or RT- HARGE
PCR on peripheral blood or bone SUMMARY
marrow,CBC,CBC, Peripheral smear, LFT, OF
RFT,Clinical notes with mention of prior INPATIEN
treatment if any with re T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
Biopsy,BONE MARROW,CBC,CYTOGENE OF DAY
TICS,LFT,MDC,RFT,RQ PCR BCR ABL CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
2D ECHO or NCCT Chest/ CECT Chest, Bar code of
Abdomen and Pelvis.,Admission/ clinical notes the
with complete history, physical examinations, drugs,BAR
indications and plan of treatment.,Biochemistry CODE OF
(RBS, LFT, RFT, LDH, SE, Ca, PO4) ,BONE THE
DRUGS,C
harts of
MARROW,Bone marrow aspiration/ biopsy an chemother
apy
regimen
,CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
microbiolo
gy,
hemat
Barcode of
the
drugs ,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
Blood tests including Complete blood counts, transfusion
renal function tests, liver function tests,Bone slips,DISC
marrow aspiration,Bone marrow report HARGE
confirming complete remission after induction SUMMARY
(typically done on day 21-28 after the start date OF
of induction chemotherapy),CB INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Perio
dic CBC
reports
(once a
week
minimum
dur
Barcode of
the
drugs ,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
AML for reinduction cases: Clinical notes stating transfusion
date of start of induction therapy (should be slips,DISC
atleast 3 weeks before),AML for reinduction HARGE
cases: Peripheral blood or bone marrow showing SUMMARY
persistent of disease (second BM or PB . after OF
day 21 of first BM te INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Perio
dic CBC
reports
(once a
week
minimum
dur
BAR
Biochemistry,Bone marrow report ,CBC,CBC,
CODE OF
LFT, RFT,
THE
DRUGS,Ba
rcodes of
the
random blood sugar, CSF cytology
drugs,CHA
report,Clinical notes
RTS OF
CHEMOTH
ERAPY
REGIMEN,
Copy of
treatment
protocol
with dates
and doses
which were
delivered
at the end
of each
month,DIS
. Performance status and any infections, if yes - CHARGE
site,Documentation of induction dates . start and SUMMARY
end date along with the name of regimen OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,R
BAR
2D ECHO,Biopsy,BONE CODE OF
THE
DRUGS,Ba
rcodes of
the
MARROW or Peripheral blood FLOW
drugs,CHA
CYTOMETRY,CBC,CBC,
RTS OF
CHEMOTH
ERAPY
REGIMEN,
Copy of
treatment
protocol
with dates
and doses
which were
delivered
at the end
of each
peripheral smear, LFT, RFT, Blood sugar, SE, month,DIS
Ca, Po4, 2D-ECHO if age>30 years, Peripheral CHARGE
blood or Bone marrow aspiration with SUMMARY
immunophenotyping to confirm the diagnosis as OF
ALL,Clinica INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,R
Admission Or Clinical
Notes,Biochemistry,Biopsy,Bl ood BAR
investigations- CBC, LFT,RFT,BONE CODE OF
MARROW,CBC,CSF THE
CYTOMORPHOLOGY,CYTO
DRUGS,Ba
rcodes of
GENETICS,Documentation of consolidation the
dates . start and end date along with the name of drugs,CHA
regimen,Documentation of induction dates . RTS OF
CHEMOTH
ERAPY
REGIMEN,
Copy of
treatment
protocol
with dates
and doses
which were
delivered
at the end
of each
month,DIS
CHARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,R
Bar code of
the
drugs,BAR
CODE OF
Biochemistry,CBC,CBC, LFT, RFT, Viral
THE
markers . HbsAg , HCV and HIV,CECT (chest
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
+abdomen +Pelvis) or PET- CT,Clinical notes T
with evidence to support indication for therapy, DEPARTM
stage of disease, performance status and ENT /
disease sites including extranodal sites DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY, M
Bar code of
the
drugs,BAR
CODE OF
2D ECHO,Biopsy,BONE THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
MARROW or Peripheral blood FLOW DEPARTM
CYTOMETRY,CBC,CBC, ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
LFT, RFT, Viral markers . HbsAg , HCV and

HIV,CECT (chest +abdomen +Pelvis) or PET-
RADIOLO
CT,Clinical notes with evidence to support
GY, M
indication for therapy, stage of disease,
performance stat
Bar code of
the
drugs,BAR
CODE OF
Biochemistry,Biopsy,BONE
THE
MARROW,CBC,CBC, LFT,
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
RFT, Viral markers . HbsAg , HCV and DEPARTM
HIV,CECT (chest ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,

with evidence to support indication for therapy, RADIOLO
stage of disease, performance status and GY, M
disease sites including
Barcode of
the
drugs ,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
Biochemistry,BONEMARRO W,CBC,Clinical slips,DISC
notes containing patient Age, Performance HARGE
status, comorbidities, extramedullary disease SUMMARY
sites if any; any infections, performance OF
status,Complete blood counts, renal function INPATIEN
tests, liver function tests, ECG, coagulati T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Perio
dic CBC
reports
(once a
week
minimum
dur
Barcode of
the
drugs ,BAR
CODE OF
2D THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
ECHO,APTT,Biochemistry,Bi opsy,BONE
HARGE
MARROW,CBC,Clinical notes containing patient
SUMMARY
Age, Performance status, comorbidities,
OF
extramedullary disease sites if any; any
INPATIEN
infections, performance status,Complete blood
T
counts, renal function tests, liver function
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Perio
dic CBC
reports
(once a
week
minimum
dur
Barcode of
the
drugs,BAR
CODE OF
2D THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
ECHO,APTT,Biochemistry,Bi opsy,BONE
HARGE
MARROW,CBC,Clinical notes containing patient
SUMMARY
Age, Performance status, comorbidities,
OF
INPATIEN
T
counts, renal function tests, liver function
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Perio
dic CBC
reports
(once a
week
minimum
duri
Barcode of
the
drugs,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
transfusion
slips,DISC
CBC,Clinical notes containing patient Age,
HARGE
Performance status, comorbidities,
SUMMARY
OF
INPATIEN
counts, renal function tests, liver function tests,
T
ECG, coagulation profile,Documentation
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Perio
dic CBC
reports
(once a
week
minimum
duri
Barcode of
the
drugs ,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen,
Biochemistry,CBC,Clinical notes containing transfusion
patient Age, Performance status, comorbidities, slips,DISC
extramedullary disease sites if any; any HARGE
infections, performance status,Complete blood SUMMARY
counts, renal function tests, liver function tests, OF
ECG, coagulation profile, INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Perio
dic CBC
reports
(once a
week
minimum
dur
Bar code of
the
drugs ,BAR
CODE OF
THE
DRUGS,C
harts of
chemother
apy
regimen
,CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
Biochemistry,BONE MARROW,CBC,Clinical
GE
notes/ Admission notes including Indications,
SUMMARY
Stage it needs to be used, pre/ post- surgical,
OF
along with Radiation therapy, recurrence,
INPATIEN
etc.,ECG,PML RARA,RQ PCR
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
microbiolo
gy,
hema
Bar code of
the
drugs ,BAR
CODE OF
THE
DRUGS,C
harts of
chemother
apy
regimen
,CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
CBC,Clinical notes/ Admission notes including GE
Indications, Stage it needs to be used, pre/ post- SUMMARY
surgical, along with Radiation therapy, OF
recurrence, etc.,LFT,PML RARA,RQ PCR INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
microbiolo
gy,
hema
Bar code of
the
drugs ,BAR
CODE OF
THE
DRUGS,C
harts of
chemother
apy
regimen
,CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
Blood Phosphate levels,BUN,CBC,Clinical
GE
notes/ Admission notes including Indications,
SUMMARY
Stage it needs to be used, pre/ post- surgical,
OF
along with Radiation therapy, recurrence,
INPATIEN
etc.,LFT,Serum Electrolytes,Uric Acid
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
microbiolo
gy,
hema
Bar code of
the
BONE drugs ,BAR
CODE OF
THE
DRUGS,C
MARROW,CBC,Clinical notes/ Admission notes
harts of
including Indications, Stage it needs to be used,
chemother
pre/ post- surgical, along with Radiation therapy,
apy
recurrence, etc.,LFT,RFT
regimen
,CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
microbiolo
gy,
hema
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
Admission Or Clinical Notes,Biopsy,BONE SUMMARY
MARROW,CBC,LFT,MDC,R FT,SKELETAL OF DAY
SURVEY OR PET CECT CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
Admission Or Clinical Notes,BONE SUMMARY
MARROW,CBC,LFT,MDC,R FT,SKELETAL OF DAY
SURVEY OR PET CECT CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
Admission Or Clinical OF DAY
Notes,Biochemistry,Biopsy,C BC,MRI CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
Admission Or Clinical OF DAY
Notes,Biochemistry,Biopsy,C BC,MRI CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
Notes,Biochemistry,Biopsy,C BC,CSF OF DAY
CYTOLOGY,MRI (BRAIN AND SPINE) CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
Notes,Biochemistry,Biopsy,C BC,CSF OF DAY
CYTOLOGY,MRI (BRAIN AND SPINE) CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
Admission Or Clinical GE
Notes,Biochemistry,Biopsy,B one marrow SUMMARY
studies,CBC,CECT/MRI,FISH OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
,MIBG OR BONE OR PET CT SCAN
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
Admission Or Clinical GE
Notes,Biochemistry,Biopsy,B one marrow SUMMARY
studies,CBC,CECT/MRI,FISH OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
,MIBG OR BONE OR PET CT SCAN
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
Admission Or Clinical Notes,Biochemistry,CBC OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
Admission Or Clinical Notes,Biochemistry,BONE OF DAY
MARROW,CBC,CSF STUDIES,MRI/CT (BRAIN CARE
AND ORBITS),ULTRASONOGRA PHY DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
Admission Or Clinical RTS OF
Notes,Biochemistry,Biopsy,B one marrow THE
studies,BONE SCAN OR PET CT,CBC,MRI OR TESTS
CECT (PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
Notes,Biochemistry,Biopsy,B one marrow OF DAY
studies,BONE SCAN OR PET CT,CBC,MRI OR CARE
CECT DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
2D ECHO,Admission Or Clinical MICROBIO
Notes,Biochemistry,Biopsy,B one marrow LOGY,
studies,BONE SCAN OR PET CT,CBC,MRI OR HEMATOL
CECT OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
Notes,Biochemistry,Biopsy,C BC,CT CHEST OF DAY
ABDOMEN,ULTRASONOGR APHY CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
2D ECHO,Admission Or Clinical GY,
Notes,Biochemistry,Biopsy,C BC,CT CHEST RADIOLO
ABDOMEN,ULTRASONOGR APHY GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
2D ECHO,Admission Or Clinical (PATHOLO
Notes,Biochemistry,Biopsy,C BC,CT CHEST GY,
ABDOMEN,ULTRASONOGR APHY RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
Admission Or Clinical Notes,Biochemistry,CBC OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
2D ECHO,Admission Or Clinical ENT /
Notes,Biopsy,BONE MARROW or Peripheral DISCHAR
blood FLOW CYTOMETRY,CBC,CYTOGE GE
NETICS,HBSAG,HCV,HIV,M SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
DC,NCCT chest,PET-CT or CECT chest
STRY,ETC
abdomen and Pelvis(if LBL)
.)
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
Admission Or Clinical DISCHAR
Notes,Biochemistry,Biopsy,B ONE GE
MARROW,CBC,CSF SUMMARY
CYTOMORPHOLOGY,CYTO GENETICS,FLOW OF DAY
CYTOMETRY,HBSAG,HCV, HIV,MDC,NGS CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.)
BONE MARROW or ,,Discharge
Summary,I
Peripheral blood FLOW nvoice /
CYTOMETRY,CBC,ECG,FIS Receipt of
H,LFT,RFT,TUMOR BORD REPORT drugs and
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
Admission Or Clinical Notes,Biochemistry,CBC SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.)
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
2D ECHO,Admission Or Clinical ENT /
Notes,Biopsy,BONE MARROW or Peripheral DISCHAR
blood FLOW CYTOMETRY,CBC,CYTOGE GE
NETICS,HBSAG,HCV,HIV,M SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
DC,NCCT chest,PET-CT or CECT chest
STRY,ETC
abdomen and Pelvis(if LBL)
.)
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
Admission Or Clinical DISCHAR
Notes,Biochemistry,Biopsy,B ONE GE
MARROW,CBC,CSF SUMMARY
CYTOMORPHOLOGY,CYTO GENETICS,FLOW OF DAY
CYTOMETRY,HBSAG,HCV, HIV,MDC,NGS CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.)
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
Admission Or Clinical Notes,Bone marrow GE
aspiration,CBC,CYTOGENET ICS,flow SUMMARY
cytometry or Peripheral blood flow OF DAY
cytometry,LFT,RBS,RFT CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.)
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
Admission Or Clinical Notes,Bone marrow OF DAY
aspiration,CBC,CYTOGENET ICS,flow CARE
cytometry or Peripheral blood flow DEPARTM
cytometry,LFT,RBS,RFT ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.)
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
Admission Or Clinical Notes,Bone marrow OF DAY
aspiration,CBC,CYTOGENET ICS,flow CARE
cytometry or Peripheral blood flow DEPARTM
cytometry,LFT,RBS,RFT ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.)
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
Notes,Biochemistry,BONEMA OF DAY
RROW,CBC,ECG,PML,RAR A,RQPCR CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
Admission Or Clinical Notes,Biochemistry,CBC SUMMARY
OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.)
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
2D ECHO,Admission Or Clinical GE
Notes,APTT,Biochemistry,Bio psy,BONE SUMMARY
MARROW FLOW CYTOMETRY,CBC,CYTOGE OF DAY
NETICS,FIBRINOGEN,HBSA CARE
G,HCV,HIV,MDC,NCCT DEPARTM
chest,PML,PT,RARA,RQPCR ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
Admission Or Clinical Notes,Biochemistry,Bone OF DAY
marrow studies,CBC,node Biopsy,PET CT or CARE
CECT Chest abdomen and pelvis DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.)
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
Admission Or Clinical Notes,Biochemistry,Bone GE
marrow studies,CBC,node Biopsy,PET CT or SUMMARY
CECT Chest abdomen and pelvis OF DAY
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.)
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.)
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
Admission Or Clinical Notes,Biochemistry,Bone SUMMARY
marrow studies,CBC,node Biopsy,PET CT or OF DAY
CECT Chest abdomen and pelvis CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.)
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.)
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
2D-ECHO,Admission Or Clinical GE
Notes,Biochemistry,Biopsy or fluid flow SUMMARY
cytometry,Bone marrow studies,CBC,ECG,PET OF DAY
CT or CECT Chest abdomen and pelvis CARE
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.)
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.)
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.)
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.)
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
Notes,AUDIOMETRY,Bioche OF DAY
mistry,Biopsy,CBC,CECT CHEST AND CARE
ABDOMEN,GFR,TUMOR MARKERS DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
2D-ECHO,Admission Or Clinical SUMMARY
ABDOMEN,ECG,GFR DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
ABDOMEN,GFR,S. AFP DEPARTM
ENT,REPO
RTS OF
THE
TESTS
(PATHOLO
GY,
RADIOLO
GY,
MICROBIO
LOGY,
HEMATOL
OGY,
BIOCHEMI
STRY,ETC
.),TRA
NFUSION
SLIPS
Barcode of
drugs
used,BAR
CODE OF
Blood investigation reports such as CBC, LFT,
THE
RFT, RBS,CBC,CECT Thorax,
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
abdomen and Pelvis,CECT Thorax, abdomen,
OF
pelvis reports,Chest x-ray report
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
,Clinical notes with indications including stage,
s of the
signs, symptoms, relevant history/ risk factors,
tests
planned l
(pathology,
radiology,
Barcode of
drugs
used,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
planned l
(pathology,
radiology,
Barcode of
drugs
used,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
planned l
(pathology,
radiology,
Barcode of
drugs
Blood investigation reports such as CBC, LFT, used,BAR
RFT, RBS, LDH,Bronchoscopy (If CODE OF
available),CBC,CECT Thorax, abdomen and THE
Pelvis,CECT Thorax, abdomen, pelvis DRUGS,C
reports,Chest x-ray report HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
signs, symptoms, relevant
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
Barcode of
drugs
used,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
planned l
(pathology,
radiology,
Barcode of
drugs
used,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
planned l
(pathology,
radiology,
Barcode of
drugs
used,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
planned l
(pathology,
radiology,
Barcode of
drugs
used,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
planned l
(pathology,
radiology,
Barcode of
drugs
RFT, RBS,Bronchoscopy (If CODE OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
signs, symptoms, relevant hist
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
Barcode of
drugs
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
Barcode of
drugs
used,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
planned l
(pathology,
radiology,
Barcode of
drugs
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
Barcode of
drugs
used,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
planned l
(pathology,
radiology,
Barcode of
drugs
used,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
planned l
(pathology,
radiology,
Barcode of
drugs
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
Barcode of
drugs
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
Barcode of
drugs
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of
the tests
(pathology,
radiology,
Barcode of
drugs
used,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
planned l
(pathology,
radiology,
Barcode of
drugs
used,BAR
CODE OF
THE
DRUGS,C
HARTS OF
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,report
s of the
tests
planned l
(pathology,
radiology,
Barcode of
drugs
CHEMOTH
ERAPY
REGIMEN,
Charts of
chemother
apy
regimen &
transfusion
slips,DISC
HARGE
SUMMARY
OF
INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Histop
atholo gy
report,repo
rts of the
tests (
Bar code of
the
Biochemistry reports (RBS,LFT,RFT, Na,
drugs ,BAR
K),CBC,CBC ,CECT/MRI
CODE OF
THE
DRUGS,C
Face and neck,Clinical notes with Details of
harts of
pelvic examination (Per speculum and
chemother
pervaginal examination), planned line of
apy
treatment
regimen
,CHARTS
OF
CHEMOTH
ERAPY
REGIMEN,
DISCHAR
GE
SUMMARY
,ECG ,ECHO,Histopathology OF
report,histopathology - squamous carc INPATIEN
T
DEPARTM
ENT /
DISCHAR
GE
SUMMARY
OF DAY
CARE
DEPARTM
ENT,Repor
ts of the
tests
(pathology,
radiology,
microbiolo
gy,
hema
Clinical
photograph
,,Discharge
BONE MARROW BIOPSY
Summary,I
nvoice /
Receipt of
drugs and
,Clinical notes,CT Scan,EXAMINATION
consumabl
FINDINGS
es
Clinical
photograph
Clinical notes,CT Scan,EXAMINATION ,,Discharge
FINDINGS,TUMOR Summary,I
nvoice /
Receipt of
drugs and
MARKERS consumabl
es
Clinical
photograph
,,Discharge
Summary,I
nvoice /
Clinical notes,CT/MRI,EXAMINATIO N Receipt of
FINDINGS,X Ray
drugs and
consumabl
es
All investigations reports including ,,Discharge

CBC,Biopsy,Clinical notes,EXAMINATION Summary,I
FINDINGS,Urine nvoice /
Receipt of
Routine,USG/CT/MRI report drugs and
All investigations reports including ,,Discharge
CBC,Biopsy,Clinical notes,EXAMINATION Summary,I
FINDINGS,Urine nvoice /
Receipt of
Routine,USG/CT/MRI report drugs and
Detailed
discharge
summary,
Detailed
Procedure
Clinical notes and Histopathology/ biopsy / Operative
confirming the diagnosis of bladder cancer Notes,
original
bills of
medicines
administer
ed
Detailed
discharge
summary,D
etailed
Procedure
Clinical notes,Histopathology/ biopsy / Operative
Notes,origi
nal bills of
medicines
administer
ed
Detailed
discharge
summary,D
etailed
ICPs,Detail
ed Indoor
case
Blood Group,Blood grouping (ABO and Rh) papers
report,Clinical notes including evaluation (ICPs)
findings, indication for procedure, and planned including
line of management ,Clinical notes with planned treatment
line of treatment,Complete Hemogram,Complete details,Pos
hemogram report,Planned line of t
Transfusio
n
hemogram
report,Post
treatment
Complete
hemogram
Detailed
discharge
summary,D
etailed
ICPs,Detail
ed Indoor
case
Blood Group,Blood grouping (ABO and Rh) papers
report,Clinical notes including evaluation (ICPs)
findings, indication for procedure, and planned including
line of management ,Clinical notes with planned treatment
line of treatment,Complete Hemogram,Complete details,Pos
hemogram report,Planned line of t
Transfusio
n
hemogram
report,Post
treatment
Complete
hemogram
reports,Det
any investigations done,Clinical notes detailing ailed
history and Admission notes showing vitals and discharge
summary,D
examination findings etailed
All
investigatio
ns
reports,Det
any investigations done,Clinical notes detailing
ailed
history and Admission notes showing vitals and
discharge
examination findings,Planned line of
summary,D
management,X Ray/CT Scan
etailed
ICPs,Treat
ment
details
All
investigatio
ns
reports,Det
ailed
discharge
summary,D
etailed
ICPs,Treat
ment
details
All
investigatio
ns
reports,Det
ailed
discharge
summary,D
etailed
ICPs,Treat
ment
details
Detailed
Discahrge
Clinical notes with planned line of treatment Summary
(documents confirming the Procedure indicated (with RT
and details of RT treatment plan),HPE report treatment
and doses
given)
Detailed
Discahrge
and doses
given)
Detailed
Discahrge
and doses
given)
Detailed
Discahrge
and doses
given)
Detailed
Clinical notes with Indications (such as patient
Discahrge
age, general condition, staging, tumour size,
Summary
nodal status, presence of enlarged internal
(with RT
mammary nodes at baseline, Neoadjuvant CT
treatment
received, Margin status, pre-/ post- surgery),
and doses
planned line of treatment (
given)
Detailed
Discahrge
Summary
(with RT
treatment
and doses
given)
Detailed
Discahrge
Summary
(with RT
treatment
and doses
given)
Detailed
Discahrge
Summary
(with RT
treatment
and doses
given)
Detailed
Discahrge
and doses
given)
Detailed
Discahrge
and doses
given)
Detailed
Discahrge
Summary
(with RT
treatment
and doses
given)
Detailed
Discahrge
and doses
given)
Detailed
Discahrge
and doses
given)
Detailed
Discahrge
and doses
given)
Detailed
Discahrge
Summary
(with RT
treatment
and doses
given)
Detailed
Discahrge
Summary
(with RT
treatment
and doses
given)
Detailed
Discahrge
and doses
given)
Detailed
Discahrge
and doses
given)
Detailed
Discahrge
Summary
(with RT
treatment
and doses
given)
Detailed
Discahrge
Summary
(with RT
treatment
and doses
given)
Detailed
Discahrge
and doses
given)
Detailed
Discahrge
and doses
given)
Detailed
Discahrge
Summary
(with RT
treatment
and doses
given)
Detailed
Discahrge
and doses
given)
Detailed
Discahrge
and doses
given)
Detailed
Discahrge
Summary
(with RT
treatment
and doses
given)
Detailed
Discahrge
Summary
(with RT
treatment
and doses
given)
Detailed
Discahrge
Summary
(with RT
treatment
and doses
given)
Detailed
Discahrge
and doses
given)
Detailed
Discahrge
and doses
given)
Detailed
Discahrge
Summary
(with RT
treatment
and doses
given)
Detailed
Discahrge
and doses
given)
Detailed
Discahrge
and doses
given)
Detailed
Discahrge
Summary
(with RT
treatment
and doses
given)
Detailed
Discahrge
and doses
given)
Detailed
Biopsy/ HPE report of malignancy,Clinical notes
Discahrge
with Indications of SRS (such as patient age,
Summary
general condition, staging, tumour size, nodal
(with RT
status, presence of enlarged internal mammary
treatment
nodes at baseline, Neoadjuvant CT received,
and doses
Margin status, pre-/ pos
given)
Detailed
Clinical notes and Documentary evidence
Discahrge
confirming the need of Respiratory-gated
Summary
radiotherapy (tumours that move with respiration
(with RT
during radiotherapy (lung, breast and upper
treatment
abdominal tumpurs),Clinical notes and
and doses
documentary evidence
given)
confirming the need of

Detailed
Clinical notes and Documentary evidence Discahrge
confirming the need of Respiratory-gated Summary
radiotherapy (tumours that move with respiration (with RT
during radiotherapy (lung, breast and upper treatment
abdominal and doses
given)
tumpurs)
Detailed
Discahrge
and doses
given)
Detailed
Discahrge
and doses
given)
Detailed
Discahrge
and doses
given)
Detailed
Discahrge
and doses
given)
Detailed
Discahrge
and doses
given)
Detailed
Discahrge
Summary
(with RT
treatment
and doses
given)
Detailed
Discahrge
Summary
(with RT
treatment
and doses
given)
Detailed
Discahrge
and doses
given)
Biopsy/
HPE,Radio
Biopsy/FNAC iodine
original
treatment
chart,THY
ROID
SCAN
Biopsy/
HPE,Radio
Biopsy/FNAC iodine
original
treatment
chart,THY
ROID
SCAN
Biopsy/
Biopsy/FNAC HPE,Radio
iodine
original
treatment
chart,THY
ROID
SCAN
Biopsy/
Biopsy/FNAC HPE,Radio
iodine
original
treatment
chart,THY
ROID
SCAN
Discharge
summary,I
nvoice of
Chemo
port
Clinical notes with planned line of treatment used,Proce
dure /
Operative
Notes,Proc
edure /
Operative
Notes
Detailed
Indoor
case
papers
(ICPs),deta
iled
operative
notes,Detai
led
Procedure
/ operative
notes,Histo
pathologic
Clinical notes,Clinical notes with supporting al
investigations,Clinical photograph,Clinical examinatio
Photograph of Enlarged lymph nodes +/- FNAC n
report report,Hist
opathology
report,Othe
r
Investigatio
n reports if
done,Post
Procedure
clinical
photograph
,Post-
procedure
photograph
s(
Detailed
Indoor
case
papers
(ICPs),Det
ailed
Procedure
/ operative
notes,Disc
harge
Clinical notes with history, indications, summary,H
symptoms, signs, examination findings and istopatholo
advice for admission,Clinical notes with gical
supporting investigations examinatio
n
report,Hist
opathology
report,Intra
-procedure
photograph
s
(optional),
Pic of
specimen,
Detailed
Indoor
case
papers
(ICPs),Det
ailed
Procedure
/ operative
notes,Disc
harge
n
report,Hist
opathology
report,Intra
-procedure
photograph
s
(optional),
Pic of
specimen
Discharge
summary,H
istopatholo
Clinical notes with supporting investigations gy
report,Pic
of
specimen
Detailed
Indoor
case
papers
(ICPs),Det
ailed
Procedure
/ operative
notes,Disc
harge
n
report,Hist
opathology
report,Intra
-procedure
photograph
s
(optional),
Pic of
specimen
Invoice/
receipt of
consumabl
es
(optional) if
colostomy
bag
changed,In
voice /
Receipt of
drugs and
consumabl
es,Photogr
Clinical notes,Clinical notes including aphic
examination findings, investigation of the current evidence of
visit, follow-up advice,Discharge summary of the stoma
last admission,Earlier discharge summary complicatio
n, if
any,Signed
statement
from
patient that
s/he has
received
the
consumabl
es:
Ileostomy /
Colostomy
-
Invoice/
receipt of
consumabl
es
(optional) if
colostomy
bag
changed,In
voice /
Receipt of
drugs and
consumabl
es,Photogr
Clinical notes,Clinical notes including aphic
examination findings, investigation of the current evidence of
visit, follow-up advice,Discharge summary of the stoma
last admission,Earlier discharge summary complicatio
n, if
any,Signed
statement
from pt.
that s/he
has
received
the
consumabl
es:
Ileostomy /
Colostomy
- bag
Detailed
discharge
summary,
Detailed
Procedure
Clinical notes and Histopathology/ biopsy / Operative
confirming the diagnosis of bladder cancer Notes,
original
bills of
medicines
administer
ed
Detailed
discharge
summary,D
etailed
Procedure
Clinical notes,Histopathology/ biopsy / Operative
Notes,origi
nal bills of
medicines
administer
ed
Evidence
of
treatment
incluidng
Clinical note and diagnostic reports justifying the
discharge
treamment
summary
and
diagnostic
reports etc.
Evidence
of
treatment
incluidng
Clinical note and diagnostic reports justifying the
discharge
treamment
summary
and
diagnostic
reports etc.
Package
Code PackageName
Code
MO MO001 CT for CA Breast

CT for Metastatic bone

MO MO002 malignancy and multiple
myeloma
MO MO003 CT for CA Ovary


MO MO004 CT for Germ Cell Tumor
CT for Gestational
MO MO005
Trophoblastic Neoplasia
CT for Gestational
MO MO005
CT for Gestational
MO MO005
CT for Gestational
MO MO005
MO MO006 CT for Cervical Cancer
MO MO006 CT for Cervical Cancer
CT for Endometrial
MO MO007
Cancer
CT for Endometrial
MO MO007
Cancer
CT for Endometrial
MO MO007
Cancer
CT for Endometrial
MO MO007
Cancer
CT for Endometrial
MO MO007
Cancer
MO MO008 CT for Vulvar Cancer
MO MO009 CT for Ewing Sarcoma
CT for Osteogenic
MO MO010
Sarcoma
CT for Osteogenic
MO MO010
Sarcoma
CT for Osteogenic
MO MO010
Sarcoma
CT for Osteogenic
MO MO010
Sarcoma
CT for Soft Tissue

MO MO011
Sarcoma
CT for Soft Tissue
MO MO011
Sarcoma
CT for Soft Tissue
MO MO011
Sarcoma
CT for Metastatic
MO MO012
Melanoma
CT for Metastatic
MO MO012
Melanoma
CT for Metastatic
MO MO012
Melanoma
MO MO013 CT for Anal Cancer
MO MO014 CT for Colorectal Cancer
CT for Esophageal
MO MO015
Cancer
CT for Esophageal
MO MO015
Cancer
CT for Esophageal
MO MO015
Cancer
CT for Esophageal
MO MO015
Cancer
CT for Esophageal
MO MO015
Cancer
CT for Esophageal /
MO MO016
Stomach Cancer
CT for Esophageal /
MO MO016
Stomach Cancer
CT for Esophageal /
MO MO016
Stomach Cancer
CT for Esophageal /
MO MO016
Stomach Cancer
CT for Esophageal /
MO MO016
Stomach Cancer
CT for Esophageal /
MO MO016
Stomach Cancer
CT for Esophageal /
MO MO016
Stomach Cancer
CT for Esophageal /
MO MO016
Stomach Cancer
CT for Esophageal /
MO MO016
Stomach Cancer
CT for Esophageal /
MO MO016
Stomach Cancer
CT for Esophageal /
MO MO016
Stomach Cancer
CT for Esophageal /
MO MO016
Stomach Cancer
CT for Hepatocellular
MO MO017
Carcinoma
MO MO017
Carcinoma
MO MO017
Carcinoma
MO MO018 CT for Panceratic Cancer
CT for Gall Bladder

MO MO019
Cancer
MO MO019 / Cholangiocarcinoma
CT for Gall Bladder

MO MO019
Cancer
CT for Gall Bladder

MO MO019
Cancer
CT for Gall Bladder

MO MO019
Cancer
CT for Gall Bladder

MO MO020
Cancer
CT for Gall Bladder

MO MO021
Cancer
CT for Gall Bladder

MO MO022
Cancer
CT for Gall Bladder

MO MO022
Cancer
CT for Gastointestinal
MO MO023
stromal tumor
CT for Gastointestinal
MO MO024
stromal tumor
MO MO024 CT for CA Brain

MO MO024 CT for CA Brain
MO MO024 CT for Mesothelioma
MO MO024 CT for Thymic Carcinoma
MO MO024 CT for Thymic Carcinoma
MO MO024 CT for CA Head & Neck

MO MO026 CT for Renal Cell Cancer
MO MO026 CT for Renal Cell Cancer
CT for Ureter / Bladder /

MO MO026
Urethra
MO MO026
Urethra
MO MO026
Urethra
MO MO027
Urethra
MO MO027
Urethra
MO MO027
Urethra
MO MO027
Urethra
MO MO027
Urethra
MO MO027
Urethra
MO MO027
Urethra
MO MO028
Urethra
MO MO028 CT for CA Penis
MO MO028 CT for CA Prostate

CT for B - Cell NHL - High

MO MO034
Grade
(Except Burkitt's &

MO MO035
PCNSL)
CT for B - Cell NHL - High

MO MO035
Grade
(Except Burkitt's &

MO MO036
PCNSL)
CT for High - Grade NHL -

MO MO036
B Cell
CT for Relapsed B - Cell

MO MO036
NHL - High Grade
(Except Burkitt's &

MO MO036
PCNSL)
CT for Relapsed B - Cell
MO MO037
NHL - High Grade
(Except Burkitt's &
MO MO037
PCNSL)
CT for PMBCL / Burkitt's

MO MO037 Lymphoma / Seropositive
B - Cell NHLR
MO MO038 CT for Burkitt's NHL
CT for Low Grade B - Cell

MO MO038
NHL
CT for Low Grade B - Cell

MO MO039
NHL
MO MO039 CT for Low Grade NHL
MO MO039 CT for Low Grade NHL
CT for Chronic
MO MO040
Lymphocytic Leukemia
CT for Chronic
MO MO040
CT for Chronic
MO MO040
CT for Chronic
MO MO041
CT for Peripheral T - Cell

MO MO042
Lymphoma

MO MO042
Lymphoma

MO MO043
Lymphoma
CT for NK - T Cell
MO MO043
Lymphoma
CT for NK - T Cell
MO MO043
Lymphoma
CT for Hodgkin's
MO MO043
Lymphoma
CT for Hodgkin's
MO MO043
Lymphoma
CT for Hodgkin's
MO MO043
Lymphoma
CT for Relapsed Hodgkin

MO MO043
Lymphoma

MO MO044
Lymphoma

MO MO044
Lymphoma
CT for Relapsed NHL &

MO MO045
HL
CT for MM / Amyloidosis /
MO MO046
POEMS
CT for MM / Amyloidosis /
MO MO046
POEMS
MO MO047 CT for MM / Amyloidosis

CT for Chronic Myeloid

MO MO049
Leukemia
CT for Chronic Myeloid

MO MO049
Leukemia
CT for Myeloproliferative
MO MO050
Neoplasm
CT for Acute Myeloid

MO MO050
Leukemia
CT for Acute Myeloid

MO MO051
Leukemia
CT for Acute
MO MO051
Lymphoblastic Leukemia
CT for Acute
MO MO052
CT for Acute
MO MO053
CT for Lymphoblastic
MO MO054
Lymphoma
MO MO054
Lymphoma
MO MO055
Lymphoma
CT for Acute
MO MO055
Promyelocytic Leukemia
MO MO056 (High Risk)
CT for Acute
MO MO056
CT for Acute
MO MO057
CT for Acute
MO MO058
MO MO059 (Low Risk)
CT for Acute
MO MO059
MO MO060 (Low Risk)
MO MO061 Febrile Neutopenia

MO MO061 Febrile Neutopenia
Chemotherapy
MO MO061 Complications - Tumor
Lysis Syndrome
Granulocyte Colony
MO MO062
Stimulating Factor Use
CT for Langerhans Cell

MO MO062
Histiocytosis
CT for Langerhans Cell

MO MO062
Histiocytosis
MO MO062 CT for Low Grade Glioma
MO MO062 CT for Low Grade Glioma
CT for Medulloblastoma /
MO MO063
Brain PNET
CT for Medulloblastoma /
MO MO063
CNS PNET
MO MO063 CT for Neuroblastoma
MO MO064 CT for Retinoblastoma
CT for
MO MO065
Rhabdomyosarcoma
CT for
MO MO065
Rhabdomyosarcoma
CT for Relapse
MO MO065
Rhabdomyosarcoma
MO MO066 CT for Wilms Tumor
CT for Pediatric Acute

MO MO067

MO MO067
MO MO068
CT for Ph+ve Pediatric

Acute Lymphoblastic
MO MO068
Leukemia for adult and
paediatric
CT for Ph+ve Pediatric

MO MO068 Acute Lymphoblastic
Leukemia for adult and
MO MO068 paediatric
CT for Pediatric
MO MO069
Lymphoblastic Lymphoma
CT for Pediatric
MO MO070
CT for Pediatric
MO MO070

MO MO071
Myeloid Leukemia

MO MO071
Myeloid Leukemia

MO MO071
Myeloid Leukemia

MO MO071

MO MO071

MO MO071
CT for Pediatric Hodgkins

MO MO071
Lymphoma

MO MO071
Lymphoma

MO MO071
Lymphoma Relapse
MO MO071
Lymphoma Relapse

MO MO071
Lymphoma Relapse
CT for Pediatric Non

MO MO071
Hodgkins Lymphoma

MO MO071
Hodgkins Lymphoma

MO MO071
Hodgkins Lymphoma

MO MO071
Hodgkins Lymphoma
MO MO071 PEDIATRIC-GCT/JEB
CT for Pediatric
MO MO071
Hepatoblastoma
CT for Pediatric
MO MO071
Hepatoblastoma
MO MO071 CT for CA Lung


CT for CA Lung
MO SU060 CT for CA Lung
MO SU060 CT for CA Lung
CT for CA Lung
CT for CA Lung
MP MG074 CT for CA Lung

CT for CA Lung
CT for CA Lung

CT for CA Lung
MP MG099 CT for CA Cervix

CT for primary CNS
MR MR001
lymphoma
MR MR001 GCT Testis
CT for GCT of bone
GEP NET
Neuroendocrine
carcinoma
GEP NET high grade

MR MR001 Neuroendocrine
carcinoma
Intravesical BCG /
Mitomycin
Intravesical BCG /
Mitomycin
Blood transfusion
Blood transfusion
High end histopathology

(Biopsies) and advanced
serology investigations
PET scan
Platelet pheresis
Linear Accelerator,
External Beam
Radiotherapy 3D CRT (6
Fractions) (Inclusive of
Simulation & Planning
Cost)
2D External Beam
Radiotherapy
(Telecobalt / Strock LA)
(6 Fractions)
(Inclusive of Simulation &

Planning Cost)
2D External Beam
Radiotherapy
(Telecobalt / Strock LA)
(6 Fractions)
(Inclusive of Simulation &

Planning Cost)
PackageDescription
Cyclophosphamide + Adriamycin Cyclophosphamide - 600 mg /m2 D1 Adriamycin - 60mg/m2 D1 every 21 days

Cyclophosphamide + AdriamycinCyclophosphami de - 600 mg /m2 D1Adriamycin - 60mg/m2 D1 every 21 days
Fulvestrant Fulvestrant 500 mg D1 D15 D28 then every 28 days
FulvestrantFulvestrant 500 mg D1 D15 D28 then every 28 days.per dose13200 (39600 in cycle1 ) then 13200 per month
Paclitaxel Paclitaxel 175 mg/m2 D1 every 21 days
Exemestane Exemestane 25 mg orally daily
Exemestane Exemestane 25 mg orally daily (q 3 monthsly)
Zoledronic Acid Zoledronic acid 4 mg IV Monthly
Cisplatin + Irinotecan Cisplatin 60mg/m2 D1Irinotecan 60 mg/m2 D1 D8 D15 every 28 days

Lipodox + Carboplatin Lipopdox 30 mg/m2 D1 Carboplatin AUC 5-6 D1 every 28 days
Etoposide Etoposide 50 mg/m2 OD D1-D14 every 21 days
Etoposide 50 mg/m2 OD D1-D21 every 28 days
Irinotecan Irinotecan 60 -90 mg/m2 D1 D8 every 21 days
LipodoxLipodox 40 mg/m2 IV every 28 days
Carboplatin + GemcitabineGemcitabine - 1000mg/m2 D1 D8 Carboplatin AUC 2 D1 D8Gemcitabine - 1000mg/m2 D1
D8Carboplatin AUC 5-6 D1 only
Carboplatin + Paclitaxel Paclitaxel 175mg/m2 D1 Carboplatin AUC 5-6 D1 every 21 days
Cyclophosphamide 50 mg/m2 OD D1-D21 every 28 days
TamoxifenTamoxifem 20 mg orally daily (3 months)
LetrozoleLetrozole 2.5 mg orally daily (3 months)
Carboplatin (AUC 7)Carboplatin AUC 7 every 21 days
Bleomycin + Etoposide + CisplatinBleomycin 30 units D1 D8 D15Cisplatin 20 mg/m2 IV D1-D5Etoposide 100mg/m2 D1-D5 every
21 days
Etoposide + CisplatinCisplatin 20 mg/m2 IV D1-D5Etoposide 100mg/m2 D1-D5 every 21 days
Gemcitabine + Oxaliplatin Gemcitabine 1000mg/m2 D1 D8 Oxaiplatin 130mg/m2 D1 every 21 days
Gemcitabine + PaclitaxelGemcitabine 1000mg/m2 D1 D8 D15Paclitaxel 100 mg/m2 D1 D8 D15 every 28 days
Vinblastin + Ifosfamide + Cisplatin Vinblastine 0.11 mg/kg IV D1-D2Mesna 240mg/m2 0h 4h 8h D1- D5Ifosfamide 1200mg/m2 D1-
D5Cisplatin 20 mg/m2 D1-D5 every 21 days
Etoposide + Methotrexate + Dactinomycin- Cyclophosphamide + VincristineEtoposide 100mg/m2 IV D1 D2Dactinomycin 0.5 mg IV

push D1 D2Methotrexate 300 mg /m2 D1Leucovorin 15 mg PO every 12 hrs for 4 dosesCyclophosphamide 600mg/m2
D8Vincrstine 1 mg/m2 D8 ever
Etoposide + Methotrexate + Dactinomycin + CisplatinEtoposide 100mg/m2 IV D1 D2 D8Dactinomycin 0.5 mg IV push D1 D2

Methotrexate 300 mg /m2 D1Leucovorin 15 mg PO every 12 hrs for 4 doses Cisplatin 75mg/m2 D8 every 2 weeks
MethotrexateMethotrexate 1/mg/kg IM every other day x 4 days D1 3 D5 D7Alternating every other day withLeucovorin 15 mg PO
repeat every 14 days
DactinomycinInj Dactinomycin 0.5 mg D1- D5 every 14 days

Carboplatin + PaclitaxelPaclitaxel 175mg/m2 D1Carboplatin AUC 5-6 D1 every 21 days
Cisplatin Cisplatin 40 mg/m2 every week
Carboplatin + PaclitaxelPaclitaxel 175mg/m2 D1Carboplatin AUC 5 D1 every 21 days
Cisplatin + DoxorubicinDoxorubicin 60 mg/m2 D1Cisplatin 50mg/m2 every 3 weeks
Lipodox + CarboplatinLipopdox 30 mg/m2 D1Carboplatin AUC 5 D1 every 28 days
Carboplatin + GemcitabineGemcitabine - 1000mg/m2 D1 D8Carboplatin AUC 2 D1 D8Gemcitabine - 1000mg/m2 D1 D8

Carboplatin AUC 5-6 D1 only every 3 weeks
Anastrozole 1 mg orally daily (for 3 months)
Cisplatin + 5 FU5 FU 1000mg/m2 D1-D4Cisplatin 75mg/m2 D1 every 3 weeks
CisplatinCisplatin 40 mg/m2 every week
Carboplatin + PaclitaxelPaclitaxel 175mg/m2 D1Carboplatin AUC 5 D1 every 21 days
Vincristine + Topotecan + Cyclophosphamide + Irinotecan + TemozolamideVincristine 1.5mg/m2( day 1)Topotecan 1.5mg/m2 (day
5)Cyclophosphamide 250mg/m2 (days 5)Given every 3 weeksIrinotecan 10-50 mg/sqM days 5 and days 8-12 Temozolamide
100mg/m2 5 of each
Vincristine + Ifosfamide + EtoposideVincristine + Doxorubicin + CyclophosphamideVincristi ne + Cyclophosphamide +
Dactinomycin.4 cycles VIE, 6 cycles VAC, 4 cycles VCDVincristine 1.5mg/m2 (day 1, 8 and 15)Ifosfamide: 1800mg/m2
(days5)Etposide: 100mg/sq.m (
Vincristine + Adriamycin + CyclophosphamideIfosfami de + EtoposideIfosfamide: 1800mg/m2 (days5)Etposide: 100mg/sq.m (days
5)Given every 3 weeklyVincristine 1.5mg/m2 (day 1 and 8)Adriamyicn: 75mg/m2 (day 1)Cyclophosphamide 1200mg/m2 (day
1)Given 3 weekly
Doxorubicin + CisplatinCisplatin 100mg/m2Doxorubicin 75mg/m2 given every 3 weeks
Methotrexate + Doxorubicin+ Cisplatin for Relapsed Osteogenic SarcomaCisplatin 120mg/sq.mDoxorubicin 75mg/m2Methotrexate

8-12 gram/m2Each cycle for 5 weeks
OGS - 12 Ifosfamide 1800 mg/m2 D1-D5Mesna 600mg/m2 0h 3h 6h 9h D1- D5Adriamycin 25mg/m2 D1- D3Cisplatin 33 mg/m2
D1- D3 every 21 days
OGS - 12 Ifosfamide 1800 mg/m2 D1-D5Mesna 600mg/m2 0h 3h 6h 9h D1- D5Cisplatin 33 mg/m2 D1- D3 every 21 days
Gemcitabine + DocetaxelGemcitabine 900 mg/m2 D1 D8Docetaxel 100 mg/m2 D8 every 21 days
Ifosfamide + AdriamycinDoxorubicin 30mg/m2 D1 D2Ifosfamide 2000 to 3000mg/m2Mesna 400 to 600 mg/m2 0h 4h 8h D1 -

D3Every 21 days
Doxorubicin 60-75/m2, every 21 days
Dacarbazine + CisplatinDacarbazine 250mg/m2 D1-D5Cisplatin 75 mg/m2 Every 21 days
TemozolamideTemozolami de 200mg/m2 D1-D5 every 28 days
Imatinib Tab Imatinib 400/800 mg daily

5 Fluorouracil (FU)+ Mitomycin C5 Fluorouracil(FU) 1000mg/m2 D1-D4 D29-
D32Mitomycin 10mg/m2 D1
Capecitabine + Mitomycin C Capecitabine 825mg/m2 PO twice daily till completion of RTMitomycin 10mg/2 D1
Cisplatin + PaclitaxelPaclitaxel 175 mg/m2 D1Cisplatin 75mg/m2 D1 every 21 days
5 FU + Leucovorin5 FU 1200mg/m2 D1 D2Leucovorin 400mg/m2 D1 every 14 days
Capecitabine + IrinotecanCapecitabine 1000mg/m2 D1- D14Irinotecan 200 mg/m2 D1 every 21 days
5 FU + Leucovorin + Oxaliplatin5 FU 1200mg/m2 D1 D2Leucovorin 400mg/m2 D1Oxaliplatin 85 mg/m2 D1 every 14 days
5FU + Leucovorin + Irinotecan5 FU 1200mg/m2 D1 D2Leucovorin 400mg/m2 D1Irinotecan 180mg/m2 85 mg/m2 D1 every 14 days
Capecitabine + OxaliplatinCapecitabine 1000mg/m2 D1- D14Oxaliplatin 130 mg/m2 D1 every 21 days
Capecitabine along with RTCapecitabine 825 mg/m2 twice daily
CapecitabineCapecitabine 1000mg/m2 D1-D14 every 21 days
5FU + Leucovorin + Oxaliplatin + Irinotecan5 FU 1200mg/m2 D1 D2Leucovorin 400mg/m2 D1Oxaliplatin 85 mg/m2 D1Irinotecan
180mg/m2 every 14 days
Cisplatin + 5 FUCisplatin 75mg/m2 D1 D295FU
1000mg/m2 D1-D4 D29
D32 every 35
Paclitaxel + CarboplatinPaclitaxel 50mg/m2 D1Carboplatin AUC 2 D1 every week
Cisplatin + DocetaxelDocetaxel 40mg/m2 D1Cisplatin 40 mg/m2 D1Leucovorin 400mg/m2 D15FU 1000mg/m2 D1 D2 every 14
days
IrinotecanIrinotecan 60- 90 mg/m2 D1 D8 every 21 days
5 FU5 FU 250 mg/m2 D1-

D5 over 24 hrs every week
CapecitabineCapecitabine 825 mg/m2 twice daily
Capecitabine + OxaliplatinCapecitabine 1000mg/m2 D1- D14Oxaliplatin 130 mg/m2 D1 every 21 days
Docetaxel + Cisplatin + 5 FUDocetaxel 40mg/m2 D1Cisplatin 40 mg/m2 D1Leucovorin 400mg/m2 D15FU 1000mg/m2 D1 D2
every 14 days
Docetaxel + Cisplatin + CapecitabineDocetaxel 40mg/m2 D1Cisplatin 40 mg/m2 D1Capecitabine 825mg/m2 twice daily every 14
days
Docetaxel + Oxaliplatin + 5 FUDocetaxel 50mg/m2 D1Oxaliplatin 85 mg/m2 D1Leucovorin 400mg/m2 D15FU 1200mg/m2 D1 D2
every 14 days
Docetaxel + Oxaliplatin + CapecitabineDocetaxel 50mg/m2 D1Oxaliplatin 85
mg/m2 D1Capecitabine 825 mg/m2 Twice daily every 14 days
5FU + Leucovorin + Oxaliplatin5 FU 1200mg/m2 D1 D2Leucovorin 400mg/m2 D1Oxaliplatin 85 mg/m2 D1 every 14 days
PaclitaxelPaclitaxel 80mg/m2 every week
Doxorubicin (TACE)Doxorubicin 30-75 mg/m2 one course
SorafenibSorafenib 400mg PO twice daily
Lenvatinib 12 mg daily
Gemcitabine + NanopaclitaxelGemcitabine 1000mg/m2 D1 D8 D16Albumin bound Paclitaxel 125mg/m2 D1 D8 D15 every 28 days
Gemcitabine 1000mg /m2 D1 D8 every 21 days
Gemcitabine 300mg/m2 weekly
5FU + Leucovorin + Oxaliplatin + Irinotecan5 FU 1200mg/m2 D1 D2Leucovorin 400mg/m2 D1Oxaliplatin 85 mg/m2 D1Irinotecan
180mg/m2 every 14 days
CapecitabineCapecitabine 825 mg/m2 twice daily
Capecitabine + GemcitabineGemcitabine 1000mg/m2 D1 D8 D15Capecitabine 830mg/m2 twice daily D1- D21 every 28 days
CapecitabineCapecitabine 1000 - 1250 mg/m2 twice daily D1 -D14 every 21 days
Cisplatin + GemcitabineGemcitabine 1000 mg/m2 D1 D8Cisplatin 25 mg/m2 D1 D8 every 21 days
GemcitabineGemcitabine 300 mg/m2 D 1every week (till RT ends) - per week
GemcitabineGemcitabine 1000mg /m2 D1 D8 every 21 days
Oxaliplatin + GemcitabineGemcitabine 1000 mg/m2 D1Oxaliplatin
100 mg/m2 D1 every 14 days
Capecitabine + IrinotecanCapecitabine 1000mg/m2 D1- D14Irinotecan 200 mg/m2 D1 every 21 days
5FU + Leucovorin + Oxaliplatin5 FU 1200mg/m2 D1 D2Leucovorin 400mg/m2 D1Oxaliplatin 85 mg/m2 D1 every 14 days
ImatinibImatinib 400 mg once daily
SunitinibSunitinb 37.5 mg once daily
TemozolamideTemozolomi de 150 - 200 mg/m2 D1-D5

every 28 days
TemozolamideTemozolomi de 75mg/m2 once daily
Gemcitabine + CisplatinGemcitabine 1000 mg/m2 D1 D8Cisplatin 75 mg/m2 D1 every 21 days
Pemetrexed + CisplatinPemetrexed 500mg/m2 D1Cisplatin 75 mg/m2 D1 every 21 days
Pemetrexed + CarboplatinPemetrexed 500mg/m2 D1Carboplatin AUC 5-6 D1 every 21 days
Cisplatin + EtoposideEtoposide 100mg/m2 D1 - D3Cisplatin 75-100 mg/m2 D1 every 21 days
Cisplatin + Adriamycin + CyclophosphamideCisplatin 50 mg/m2 D1Doxorubicin
50 mg/m2
D1Cyclophosphamide 500 mg/m2 D1 every 21 days
Cisplatin + DocetaxelDocetaxel 75
mg/m2 D1Cisplatin 75 mg/m2 D1 every 21 days
CisplatinCisplatin 100mg/m2 every 21 days

Carboplatin + GemcitabineGemcitabine 1000 mg/m2 D1 D8Carboplatin AUC 5-6 D1 every 21 days
Docetaxel + Cisplatin + 5 FUDocetaxel 75 mg/m2 D1Cisplatin 75 mg/m2 D15 FU 750 mg/m2 D1- D5
every 21 days
DocetaxelDocetaxel 20mg/m2 every week
DocetaxelDocetaxel 75 mg/m2 D1 every 21 days
Etoposide + CarboplatinEtoposide 100mg/m2 D1 - D3Carboplatin AUC 5-6 D1 every 21 days
Etoposide + CisplatinEtoposide 100mg/m2 D1 - D3Cisplatin 75-100 mg/m2 D1 every 21 days
GemcitabineGemcitabine 1000 mg/m2 D1 D8 every 21 days
Gemcitabine + CisplatinGemcitabine 1000 mg/m2 D1 D8Cisplatin 75 mg/m2 D1 every 21 days
Paclitaxel + CarboplatinPaclitaxel 175mg/m2 every 21 days
PaclitaxelPaclitaxel 175mg/m2 every 21 days
CarboplatinCarboplatin AUC 2 every week
CisplatinCisplatin 40mg/m2 every week
Sunitinib50 mg once daily 4 weeks on 2 weeks off
Cabozantinib 60 mg od x 1
monthevery 4 weeks
Cisplatin + Methotrexate + VinblastinMethotrexate 30mg/m2 D1 D8Vinblastine 4 mg/m2 D1 D8Doxorubicin 30 mg/m2 D2Cisplatin

100
mg/m2 D2Leucovorin 15 mg PO D2 D9 every 21 days
Carboplatin + GemcitabineGemcitabine 1000 mg/m2 D1 D8Carboplatin AUC 5-6 D1 every 21 days
Cisplatin + GemcitabineGemcitabine 1000 mg/m2 D1 D8Cisplatin 75 mg/m2 D1 every 21 days
Cisplatin + PaclitaxelPaclitaxel 175 mg

/m2 D1Cisplatin 75 mg /m2 D1 every 21 days
Gemcitabine + PaclitaxelGemcitabine 2500
mg/m2 D1Paclitaxel 150 mg/m2 D1 every 14 days
Methotrexate + Vinblastin + Doxorubicin + CisplatinMethotrexate 30mg/m2 D1Vinblastine 3
mg/m2 D2Doxorubicin 30
mg/m2 D2Cuisplatin 70 mg/m2 D2 every 14 days
Paclitaxel + CarboplatinPaclitaxel 175mg/m2 D1Carboplatin AUC 5-6 D1 every 21 days
PaclitaxelPaclitaxel 80 mg/m2 D1 every week
Cisplatin + PaclitaxelPaclitaxel 175
mg/m2 D1Cisplatin 75 mg/m2 D1 every 21 days
5 FU + Cisplatin5 FU 1000mg/m2 D1-D4Cisplatin 75mg/m2 D1 every 4 weeks
CapecitabineCapecitabine 1000-1250 mg/m2 PO twice daily D1 -D14 every 21 days
PaclitaxelPaclitaxel 80 mg/m2 D1 every week
PaclitaxelPaclitaxel 175 mg/m2 D1 every 21 days
Paclitaxel + CarboplatinPaclitaxel 80 mg/m2 D1Carboplatin AUC 2 D1 every week
LHRH AgonistLeuprolide
22.5 ug every 3 months Mitoxantrone + PrednisoloneMitoxantrone 12mg/m2 every 3
CHOPCyclophosphamide 750mg/m2 D1Vincristine 1.4mg/m2 D1Adriamycin 50

mg/m2 D1Prednisolone 100 mg D5Every 21days. Total 6 cycles
weeksPrednsiolone 10 mg daily
DocetaxelDocetaxel 20mg/m2 D1 every week
Abiraterone 1000 mg + Prednisolone 10mg daily Once every month
Rituximab + Cyclophosphamide + Etoposide + PrednsioloneRituximab 375mg/m2Cyclophosphami de 750 mg/m2Vincristine
1.4 mg/m2, on Day1Etoposide 65mg/m2 Day 1 to 3Prednisolone 100 mg Day 5Total 6 cycles, repeat 21 days
Rituximab + Cyclophosphamide + Doxorubicin + PrednsioloneRituximab 375mg/m2Cyclophosphami de 750 mg/m2Doxorubicin
50mg/m2Vincristine 1.4 mg/m2 on Day1Prednisolone 100 mg Day 5Total 6 cycles, repeat 21 days
Rituxmab + Dexamethasone + High Dose Cytarabine + CisplatinRituximab 375mg/m2 Day 1Cytarabine 2g/m2 BD on day
2Dexamethasone 40 mg Day 1 - 4Cisplatin 75mg/m2 or Carboplatin AUC-5 on day 1Cycle to be repeated every 21days
GDP - RRituximab 375mg/m2 Day 1Gemcitabine 1000mg/m2 on day 1 and 8Dexamethasone 40 mg Day 1 - 4Cisplatin 75mg/m2
on day 1Cycle to be repeated every 21daysTotal- 6 cycles
ICE - RRituximab 375mg/m2Ifosfamide 1.66g/m2 on day 1 - 3Mesna 1.66g/m2 day 1 - 3Carboplatin AUC 5 on day 1Etoposide
100mg/m2 on day 1 - 3Cycle every 21days for 6 cycles
Etoposide + Prednsiolone + Vincristine + Cyclophosphamide + DoxorubicinRituximab 375mg/m2 Day 1Etoposide 50mg/m2VCR

0.4mg/m2Doxorubicin 10mg/m2 Day1 - 4Cyclophosphamide 750mg/m2 on day 5 Prednisolone 100 mg day 5Every 21 daysDose
adjustment each cycle dep
Codox - M - IVAC- cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate / ifosfamide, etoposide, high- dose
cytarabine)GMALL (German multicenter acute lymphoblastic leukemia)Berlin- Frankfurt - MunsterHyper CVAD
(cyclophosphamide, Vincristine,
Bendamustine + RituximabBendamustine 90mg/m2 on day 1, 2Rituximab 375mg/m2 on day 1Repeat every 28 days, Total 6 cycles
Lenalidomide + RituximabRituximab 375mg/m2 Day 1Lenlidomide 25 mg D1-28, for 8 cycles
RituximabRituximab 375mg/m2 per week for 6 weeks
Rituximab + Cyclophosphamide + Vincristine + PrednisoloneRituximab 375 mg/m2Cyclophosphamide 750mg/m2Vincristine

1.4mg/m2 Day 1Prednisolone 100 mg Day 1 - 5Repeat every 21days. Total 6 cycles
Fludarabine + CyclophosphamideFludarab ine 25mg/m2 D1- 3Cyclophosphamide 250 mg/m2 D1-3 every 28 days for 6 cycles
Rituxmab + ChlorambucilRituximab 375mg/m2 Day 1Chlorambucil 10 mg/m2 D1-7Repeat every 28 days for 12 cycles
Rituximab + Fludarabine + CyclophosphamideRituxima b 375mg/m2 on day 1Fludarabine 25mg/m2 D1 - 3Cyclophosphamide 250

mg/m2 D1 - 3Every 28 days for 6 cycles
Lenalidomidelenalidomide- 10-25 mg/day day 1 to 21
every 28 days
CHOEPCyclophosphamide 750mg/m2 D1Vincristine 1.4mg/m2 D1Adriamycin 50 mg/m2 D1Etoposide 100mg/m2 D1-

3Prednisolone 100 mg D5Every 21days. Total 6 cycles
CHOPCyclophosphamide 750mg/m2 D1Vincristine 1.4mg/m2 D1Adriamycin 50
mg/m2 D1Prednisolone 100 mg D5Every 21days. Total 6 cycles
SMILEMethotrexate 2gm/m2 D1Ifosfamide 1500mg/m2 D2-4Etoposide 100mg/m2 D2-4L-
asparginase 6000U/m2 D8,10,12,14,16,18,20Dexa
methasone 40mg D1-4 every 28 days
GELOXGemcitabine 1000mg/m2 D1 and D8Oxaliplatin 130mg/m2 D1L- asparginase 6000 U/m2 D1-7Repeat every 21 days
LVPL-asparginase 6000U/m2 D5Vincristine 1.4mg/m2 D1Prednisolone 100mg D5Repeat every 21 days
COPPCyclophosphamide 650mg/m2 D1, 8Vincristine 1.4mg/m2 D1, 8Procarbazine 100 mg/m2 D1-14Prednisolone 40mg/m2 D1-
14Every 28days. Total 6 - 8 cycles
ABVDAdriamycin 25mg/m2Bleomycin 10unit/m2Vinblastine 6mg/m2Dacarbazine 375 mg/m2 Day 1,15Every 28 days for 6 cycles
AEVDAdriamycin 25mg/m2Vinblastine 6mg/m2Dacarbazine 375 mg/m2 Day 1,15Etoposide 65mg/m2 Day 1-3, 15-
17Every 28 days for 6 cycles
ICEIfosfamide 1.5 mg/m2 D1-3Carboplatin AUC5 D2Etoposide 100mg/m2 D1- 3Every 3 weeks
MINEIfosfamide 4 gm/m2 over 3days (D1- 3)Mitoxantrone 8mg/m2Etoposide 65mg/m2 D1-3Every 3 weeks
PTCL - GDPGemcitabine 1000mg/m2 D1 and D8Dexamethasone 40mg D1-4Cisplatin 75mg/m2 D1 orCacrboplatin AUC-5Every 3
weeks
DHAPDexamethasone 40mg D1-4Cisplatin 100mg/m2 or Carboplatin AUC-5D1Cytarabine 2 gm/m2 BD D2Repeat every 21 days
Lenalidomide + DexamethasoneLenalidomi de 25 mg daily Day1- 21Dexamethasone 40mg Day 1, 8, 15, 22Every 28days
Pomalidomide + DexamethasonePomalidom ide 4 mg daily Day 1- 21Dexamethasone 40mg Day 1, 8, 15, 22Every 28 days
Cyclophosphamide + Thalidomide + DexamethasoneCyclophosp hamide 100mg D1- D14Thalidomide 100-200 mg daily Day 1-
28Dexamethasone 40mg Day 1, 8, 15, 22Every 28 days
Melphalan + Thalidomide + PrednisoloneMelphalan 9mg/m2 D1-D4Thalidomide 100mg D1-28Prednisolone 100mg Day1-4Every

28days
Bortezomib + Cyclophosphamide + Dexamethasone Cyclophosp hamide - 300 mg/m2 day 1,
8, 15, 22Dexamethasone
40mg Day 1, 8, 15,
22Bortezomib 1.3 mg/m2
Day1, 8, 15, 22Every 28 days
Bortezomib + Dexamethasone Bortezomib 1.3 mg/m2 Day1, 8, 15, 22Dexamethasone 40mg Day1, 8, 15, 22Every 28 day
Bortezomib + Melphalan + Prednsiolone Melphalan 9mg/m2 D1- D4Prednisolone 100mg Day 1-4Bortezomib 1.3
mg/m2 Day 1, 8, 15,
22Every 28 days
Bortezomib + Lenalidomide
+
Dexamethasone Lenalidomi de 25 mg daily Day 1 - 21Dexamethasone 40mg Day 1, 8, 15, 22Bortezomib
1.3 mg/m2 Day 1, 8, 15,
22Every 28 days
Bortezomib + Thalidomide
Dexamethasone Thalidomid e 100 mg daily Day 1 - 28 Dexamethasone 40 mg Day 1, 8, 15, 22Bortezomib 1.3
mg/m2 Day 1, 8, 15,
22Every 28 days
Imatinib Imatinib 400 mg,
600 mg, 800 mg(per month
X 5 years)
Dasatinib 100 mg once a day
Hydroxurea Hydroxurea daily(Dose will be based on blood counts)
Cytarabine 2 gm / M2 BD for 5Every 21 days for 3 cycles
Cytarabine 100 mg / M2 7 days Daunomycin 60 mg / M2 3 ( this does not include antibiotics, antifungals, blood and platelets
transfusion)
Berlin- Frankfurt -Munster- 90, Berlin- Frankfurt - Munster-95, Berlin- Frankfurt -Munster- 2000Hyper (cyclophosphamide,
Vincristine, Adriamycin ,Dexamethasone UKALL (United kingdom acute lymphoblasticleukaemia)
GMALL (German multicenter acute lymphoblastic
Berlin- Frankfurt -Munster- 90Berlin- Frankfurt -Munster 95Berlin- Frankfurt -Munster 2000Hyper (cyclophosphamide, Vincristine,
Adriamycin
,Dexamethasone UKALL (United kingdom acute lymphoblastic leukaemia)GMALL (German multicenter acute lymphoblastic
leukem
6 Mercaptopurine 50 mg /
M2 daily
Methotrexate 25 mg / M2 Weekly for 2 years
Berlin- Frankfurt -Munster- 90Berlin- Frankfurt -Munster 95Berlin- Frankfurt -Munster 2000Hyper CVAD (cyclophosphamide,
Vincristine, Adriamycin,
Dexamethasone UKALL (United kingdom acute lymphoblastic leukaemia)GMALL (German multicenter acute lymphoblastic
Berlin- Frankfurt -Munster- 90Berlin- Frankfurt -Munster 95 Berlin- Frankfurt - Munster-2000Hyper CVAD (cyclophosphamide,
Vincristine, Adriamycin,
Dexamethasone UKALL (United kingdom acute lymphoblastic leukaemia)GMALL (German multicenter acute lymphoblastic
6 Mercaptopurine 50 mg/M2 daily and Methotrexate 25 mg/M2 Weekly for 2 Years
Arsenic trioxide
ATRA
Daunomycin or Idarubcin
Cytarabine - multiagent - vary in each protocol
Arsenic trioxide
ATRADaunomycin or IdarubcinCytarabine - multiagent - vary on protocol
6 MP 50 mg / day
Daily
Methotrexate 15 mg WeeklyATRA 45 mg / M2 for 14 days Every three months for 18 Months

ATO: Arsenic trioxide 0.15 mg / kg day 1-Day 5, day 8- 12, day 15-19, day 22-26
every 56 days for 4 cyclesATRA : All trans retinoic acid 45 mg / M2 day 1-Day 14 and Day 29-
43 every 56 days for 4 cycles - (per 56 day cycle)
ATO: Arsenic trioxide 0.15 mg / kg day 1-45 or 60ATRA: All trans retinoic acid 45 mg / M2 - day 1-45 or 60
Cefoperazone + SulbactumPiperalicillin + TazobactumCefoperazoneP iperacillinAmikacinGentami cinCefipimeLevofloxacinAm

oxycillin and clavulanateTeicoplaninVanc omycin
MeropenemImipenemColisti nTigecyclinLinezolidVoricon azoleCaspfunginAmphoteri cin - B
RasburicaseFebuxostatAllo purinolSevelamer
5 microgram / kg / day(max 300 microgram per day) for 7 days orPEG - GCSF 6mg one single dose per chemotherapy cycle
Langerhans Cell Histiocytosis(Histiocytosis Protocol - Induction)
Langerhans Cell Histiocytosis(Histiocytosis Protocol - Maintenance)

Vincristine + CarboplatinVincristine 1.5mg/m2 (day 1, 8 and 15 for first 4 cycles and then only day 1 from cycle 5 to 17)Carboplatin
550mg/m2 every 3 weeks (all cycles)
VinblastinVinblastine 6 mg/m2 every week
PACKER
Cisplatin + Cyclophosphamide + VincristineCyclophosphami de 1000mg/m2 (2 every cycles)Vincristine 1.5mg/m2 (days 1 and
8)Cisplatin 100mg/m2 (1 day per cycle)Cycles given every 3 weekly
Cabroplatin + Etoposide + Cyclophosphamide + DoxorubicinCarboplatin 600mg/m2Etoposide 100mg/m2 (days
5)CyclophosphamideDoxor ubicin
Carboplatin + Cisplatin + Cyclophosphamide + Vincristine + Etoposide
13-cis retinoic acid 160mg/m2 per day for 2 weeksEach cycle given 4 weekly
Vincristine + Carboplatin + EtoposideCarboplatin 600mg/m2 day 1Etoposide 150mg/m2 1-3
Vincristine1.5mg/m2 day 1
Vincristine + Cyclophosphamide + DactinomycinVincristine 1.5mg/m2 (day 1, 8 and
15)Cyclophosphamie 1200 -
2200 mg/m2 (day 1)Dactinomycin 1.5mg / m2 (day 1)3 weekly cycle
Vincristine + Ifosfamide + EtoposideVincristine 1.5mg/m2 (days 1, 8 and 15)Ifosfamide 1.8gm/m2 (days 5)Etoposide 100mg/m2
(days 5)Each cycle every 3 weeks
Vincristine + Topotecan + Cyclophosphamide andVincristine + Adriamycin
+
CyclophosphamideVincristi ne 1.5mg/m2 (day 1)Topotecan 1.5mg/m2 (day 5)Cyclophosphamide 250mg/m2 (days 5)3 -
weeklyVincristine 1.5mg/m2Adriamyicn 60mg/m2Cyclophosphamid e 600mg/m2 (all
Vincristine + Actinomycin DVincristine 1.5 mg/m2 weekly for 12 weeks and then 3 weeklyActinomycin D 45 microgram / kg 3
weekly
for 24 weeks
Vincristine + Actinomycin D
+ DoxorubicinVincristine 1.5 mg/m2 weekly for 12 weeks and then 3
weeklyActinomycin D 45
microgram/kg 3 weeklyDoxorubicin 60mg/m2 for 24 weeks
Cyclophosphamide + Doxorubicin + Etoposide + Vincristine + DactinomycinVincristine 1.5
mg/m2Dactinomycin 45 microgram/kgAdriamyicn 60mg/m2Cyclophosphamid eEtoposideWeekly chemotherapy - varying hybrid

regimen
Consolidation (Phase II, CNS Therapy Reinduction)
India collaborative childhood leukaemia group Berlin- Frankfurt -Munster Kill acute lymphocytic leukemia cells
Mitroxantrone,Chlorambucil, Prednisolone: 841
6 - Mercaptopurine 75mg/m2 dailyMethotrexate 20mg/m2 weeklyVincristine 1.5mg/m2 monthlyIntrathecal methotrexate 12 mg 3
monthly
Dasatinib + chemo (to be used only with ALL therapy)- Permonth
Imatinib + chemo ((to be used only with ALL therapy)

-permonth
Consolidation (Phase II, CNS Therapy Reinduction)
India collaborative childhood leukaemia group Berlin- Frankfurt -Munster Kill acute lymphocytic leukemia
cellsMitroxantrone,Chloram bucil,Prednisolone: 841
6 - Mercaptopurine 75mg/m2 dailyMethotrexate 20mg/m2 weeklyVincristine 1.5mg/m2 monthlyIntrathecal methotrexate 12 mg 3
monthly
Cytrabine 3 gram/m2 twice a dayDays 1, 3 and 5
Cytrabine 200mg/m2/day days 1-10 and

Daunorubicin 50mg/m2 1, 3 and 5Etposide 100mg/m2 5
Cytrabine 100-
200mg/m2/day days 1-7 and Daunorubicin 50mg/m2 1, 3 and 5
Consolidation
Induction
Maintenance (18 months total cost)
COPDAC:
Cyclophosphamide, Vincristine sulfate,Prednisone,Dacarba zine
Oncovin,Etoposide,Prednis one,doxorubicin hydrochloride
ifosfamide, carboplatin, etoposide
DECA:
Dexamethasone,Etoposide, Cytarabine,Cisplatin
IGVD: Need to check
Lymphoma malign B 89-96 Consolidation (second month)
Lymphoma malign B 89-96 Consolidation (First month)
Lymphoma malign B 89-96 - Maintenance
Mitroxantrone,Chlorambucil, Prednisolone: 842
PEDIATRIC-GCT/JEB
Carboplatin + Cisplatin + Doxorubicin
Cisplatin
ErlotinibErlotinib 150 mg once daily
GefitnibGefitinib 250 mg once daily
Pemetrexed + CarboplatinPemetrexed 500mg/m2 D1Carboplatin AUC 5-6 D1 every 21 days
TopotecanTopotecan 1.5 mg/m2 D1-D5 every 21 days
DocetaxelDocetaxel 20 mg/m2 D1 every week
Etoposide + CisplatinEtoposide 100mg/m2 D1 - D3Cisplatin 75-100 mg/m2 D1 every 21 days
Gemcitabine + CarboplatinGemcitabine 1000 mg/m2 D1 D8Carboplatin AUC 5-6 D1 every 21 days
Gemcitabine + CisplatinGemcitabine 1000 mg/m2 D1 D8Cisplatin 75 mg/m2 D1 D8 every 21 days
PaclitaxelPaclitaxel 175mg/m2 every 21 days
Paclitaxel + CisplatinPaclitaxel 175 mg/m2 D1Cisplatin 75mg/m2 D1 every 21 days
Pemetrexed + CisplatinPemetrexed 500mg/m2 D1Cisplatin 75 mg/m2 D1 every 21 days
PemetrexedPemetrexed 500mg/m2 D1 every 21 days
Vinorelbine + CarboplatinVinorelbine 25mg/m2 D1 D8CarboplatinAUC 5-6 D1
every 21 days
Vinorelbine + CisplatinVinorelbine 25mg/m2 D1 D8Cisplatin 75mg/m2 D1 every 21 days
Carboplatin Carboplatin AUC 2 every week
De-Angelis/Methotrexate
SA Carboplatin AUC 7 once every 3 weeks - Max 4 cycles (price per cycle)
Denosumab Denosumab 120 mg s/c D1, 8, 15 then
every 28 days- 19800 per
dose. Max 6 dose
Temozolamide 150mg/m2 D9-14 + Capecitabine 1gm/me D1-14 every 28 days
Carboplatin AUC 5 + Etoposide 100mg/m2 D1- D3 every 21 days
Induction cycles (PC)Rate per dose -Rs 5000 max no- 06 (including drug)
Maintenance
Whole Blood transfusion

Blood component including platelet transfusion (RDP, PC, SDP)
High end histopathology (Biopsies) and advanced serology investigations
PET scan
Platelet pheresis
Radical
Adjuvant
Neoadjuvant
PackageID
PackageId
- Amount
- PMJAY
HIMCARE
MO001L MO001L1 4500
MO001L MO001L2 5000
MO001M MO001M1 11000
MO001M MO001M2 13200
MO001N MO001N1 13000
MO001O MO001O1 10400
MO001O MO001O2 4300
MO002A MO002A1 3900
MO003A MO003A1 14400

MO003B MO003B1 19000
MO003C MO003C1 3400
MO003C MO003C2 3800
MO003D MO003D1 12100
MO003E MO003E1 19800
MO003F MO003F1 15300
MO003G MO003G1 16400

MO003H MO003H1 3100
MO003I MO003I1 1400
MO003J MO003J1 4300
MO004A MO004A1 8100
MO004B MO004B1 13600
MO004C MO004C1 12000
MO004D MO004D1 19300
MO004E MO004E1 19300
MO004G MO004G1 15000
MO005A MO005A1 13300
MO005B MO005B1 14100
MO005C MO005C1 1400
MO005D MO005D1 7700

MO006A MO006A1 16400
MO006B MO006B1 2600
MO007A MO007A1 16400
MO007B MO007B1 4900
MO007C MO007C1 19000
MO007D MO007D1 15300
MO007E MO007E1 4300
MO008A MO008A1 9100
MO008B MO008B1 2600
MO008C MO008C1 16000
MO009A MO009A1 25500
MO009B MO009B1 10900
MO009C MO009C1 14000
MO010A MO010A1 13200
MO010B MO010B1 29700
MO010C MO010C1 32600
MO010D MO010D1 31500
MO011A MO011A1 26400
MO011B MO011B1 15100
MO011C MO011C1 4400
MO012A MO012A1 7900
MO012B MO012B1 5500
MO012C MO012C1 5500

MO013A MO013A1 12100
MO013B MO013B1 18600
MO013C MO013C1 9000
MO013D MO013D1 16400
MO013E MO013E1 14700
MO014A MO014A1 6100
MO014B MO014B1 13800
MO014C MO014C1 15100
MO014D MO014D1 10600
MO014E MO014E1 13800
MO014F MO014F1 8000
MO014G MO014G1 8100
MO014H MO014H1 20700
MO015A MO015A1 16400
MO015B MO015B1 10700
MO015C MO015C1 15600
MO015D MO015D1 29900
MO015E MO015E1 29900
MO016A MO016A1 15300
MO016B MO016B1 12100
MO016C MO016C1 10400
MO016D MO016D1 8000
MO016E MO016E1 13800
MO016F MO016F1 16000

MO016G MO016G1 16000
MO016H MO016H1 20400
MO016I MO016I1 20400
MO016J MO016J1 10600
MO016K MO016K1 15100
MO016L MO016L1 6600
MO017A MO017A1 24800
MO017B MO017B1 9900
MO017C MO017C1 18700
MO018A MO018A1 31300
MO018B MO018B1 9900
MO018C MO018C1 4400
MO018D MO018D1 20800
MO018E MO018E1 8000
MO018F MO018F1 37600
MO019A MO019A1 8100
MO019B MO019B1 13400
MO019C MO019C1 10600
MO019D MO019D1 4400
MO019E MO019E1 9900

MO019F MO019F1 19200
MO019G MO019G1 13800
MO019H MO019H1 15100
MO020A MO020A1 16500
MO020B MO020B1 11000
MO021A MO021A1 5500
MO021B MO021B1 33000
MO022A MO022A1 13400
MO022B MO022B1 10400
MO022C MO022C1 11200
MO023A MO023A1 7800
MO023B MO023B1 6500
MO024A MO024A1 13700
MO024B MO024B1 10800

MO024C MO024C1 15300
MO024D MO024D1 16000
MO024E MO024E1 3600
MO024F MO024F1 9400
MO024G MO024G1 8500
MO024H MO024H1 10200
MO024I MO024I1 9900
MO024J MO024J1 13400
MO024K MO024K1 8500
MO024L MO024L1 16000
MO024M MO024M1 6600
MO024N MO024N1 13000

MO024O MO024O1 3000
MO024P MO024P1 2600
MO025A MO025A1 11000
MO025B MO025B1 14300
MO026A MO026A1 7500
MO026B MO026B1 15300
MO026C MO026C1 13400
MO026D MO026D1 9000
MO026E MO026E1 14700
MO026F MO026F1 9400
MO026G MO026G1 17100
MO026H MO026H1 9900
MO026I MO026I1 8300
MO026J MO026J1 16000
MO026K MO026K1 7100
MO027A MO027A1 14700
MO027B MO027B1 9000
MO027C MO027C1 8100
MO027D MO027D1 16000
MO027E MO027E1 6600
MO027F MO027F1 13000
MO027G MO027G1 8500
MO028A MO028A1 8800
MO028B MO028B1 9400

MO028C MO028C1 8500
MO028D MO028D1 16900
MO028E MO028E1 4700
MO028F MO028F1 8500
MO028G MO028G1 16000
MO028H MO028H1 3600
MO028I MO028I1 14300

MO029A MO029A1 28900
MO029B MO029B1 29700
MO030A MO030A1 38400
MO031A MO031A1 38900
MO031B MO031B1 35100
MO032A MO032A1 34900
MO033A MO033A1 38000
MO034A MO034A1 27500
MO034B MO034B1 24800
MO035A MO035A1 17600
MO035B MO035B1 19300
MO036A MO036A1 20000
MO036B MO036B1 18900
MO036C MO036C1 44800
MO036D MO036D1 5300
MO037A MO037A1 5800
MO037B MO037B1 5700
MO037C MO037C1 21700
MO038A MO038A1 21300
MO038B MO038B1 8800
MO039A MO039A1 4300
MO039B MO039B1 11300
MO039C MO039C1 11300
MO040A MO040A1 11600

MO040B MO040B1 11600
MO040C MO040C1 16300
MO041A MO041A1 13800
MO042A MO042A1 5800
MO042B MO042B1 7900
MO043A MO043A1 4500
MO043B MO043B1 4600
MO043C MO043C1 16100
MO043D MO043D1 14700
MO043E MO043E1 13900
MO043F MO043F1 19600
MO043G MO043G1 16500
MO044A MO044A1 16500
MO044B MO044B1 5500
MO045A MO045A1 2500
MO046A MO046A1 78400
MO046B MO046B1 116200
MO047A MO047A1 176000
MO047B MO047B1 136200
MO047C MO047C1 4400
MO048A MO048A1 176000
MO048B MO048B1 136200
MO048C MO048C1 4400

MO049A MO049A1 79200
MO049B MO049B1 106500
MO049C MO049C1 8800
MO050A MO050A1 60500
MO050B MO050B1 89100
MO051A MO051A1 36600
MO051B MO051B1 86700
MO052A MO052A1 26400
MO053A MO053A1 5000
MO054A MO054A1 27900
MO054B MO054B1 31800
MO055A MO055A1 6500
MO055B MO055B1 3700
MO056A MO056A1 7000
MO056B MO056B1 9200
MO057A MO057A1 9500
MO057B MO057B1 8400
MO057C MO057C1 2300
MO058A MO058A1 8200
MO059A MO059A1 6300
MO059B MO059B1 17900
MO060A MO060A1 13700
MO061A MO061A1 4200

MO061B MO061B1 5500
MO061C MO061C1 16800
MO062A MO062A1 263700
MO062B MO062B1 95700
MO062C MO062C1 3000
MO062D MO062D1 5500
MO062E MO062E1 5500
MO063A MO063A1 263700
MO063B MO063B1 95700
MO063C MO063C1 3000
MO064A MO064A1 63400
MO064B MO064B1 115800
MO064C MO064C1 115400
MO065A MO065A1 64700
MO065B MO065B1 142400
MO065C MO065C1 43300
MO066A MO066A1 10400
MO066B MO066B1 14300
MO067A MO067A1 15400
MO067B MO067B1 15400
MO067C MO067C1 37400

MO068A MO068A1 46900
MO068B MO068B1 46700
MO068C MO068C1 72400
MO068D MO068D1 108600
MO069A MO069A1 11800
MO070A MO070A1 6200
MO070B MO070B1 6200
MO071A MO071A1 9400
MO071B MO071B1 5000
MO071C MO071C1 2800
MO071D MO071D1 16000
MO071E MO071E1 11200
MO071F MO071F1 27100
MO071G MO071G1 3500
MO071H MO071H1 8500
MO071I MO071I1 7500

MO071J MO071J1 9900
MO071K MO071K1 15300
MO071L MO071L1 13400
MO071M MO071M1 6600
MO071N MO071N1 13000
MO071O MO071O1 8500
MO071P MO071P1 14700
MO071Q MO071Q1 10400
MO071R MO071R1 8400
MO071S MO071S1 18700
MO071T MO071T1 18700
MO072A MO072A1 3000

MO073A MO073A1 39600
MO074A MO074A1 6600
MO075A MO075A1 19800
MO076A MO076A1 8800

MO076B MO076B1 14800
SU060A SU060A1 3200

SU060B SU060B1 30000
MG074A MG074A1 2000
MG074B MG074B1 2000
MG076A MG076A1 5000
Per Day
Bed
MG098A MG098A1 Category-
HDU(3300)
,,Bed
Category-
ICU -
Without
Ventilator(
8500),Bed
Category-
ICU - With
Ventilator(
9000),Bed
Category-
Routine
Ward(2100
)
MG099A MG099A1 11000
MR001A MR001A1 23100
MR001B MR001B1 12100
MR001C MR001C1 12100

2D Additional
External fractions -
Beam 18 Max
Radiothera upto (Every
1018 MR MR001 MR001D MR001D1 M 18900 Y
py additional
(Telecobalt fraction at
/ Strock Rs.500 per
LA) Fraction)
2D
External
Beam
Radiothera
py -
Palliative
(Telecobalt
/ Strock
1019 MR MR002 Palliative MR002A MR002A1 M 11000 Y
LA) (Upto
10
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
2D
External
Beam
Radiothera
1020 MR MR003 Radical MR003A MR003A1 M 22000 Y
py
(Telecobalt
/ Strock
LA)
(25
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
2D
External
Beam
Radiothera
1021 MR MR003 Adjuvant MR003B MR003B1 M 22000 Y
py
(Telecobalt
/ Strock
LA)
(25
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
2D
External
Beam
1022 MR MR003 MR003C MR003C1 M 22000 Y
py nt
(Telecobalt
/ Strock
LA)
(25
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Additional
2D fractions -
External 10 Max
Beam upto
Radiothera (additional
1023 MR MR003 MR003D MR003D1 M 10500 Y
py fraction at
(Telecobalt Rs.500 per
/ Strock Fraction
LA) upto a
max)
(25
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
2D
External
Beam
Radiothera
py
(Telecobalt
/ Strock
LA)
(6
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
, External
Beam
Radiothera
py 3D CRT
1025 MR MR004 (6 Adjuvant MR004B MR004B1 M 23100 Y
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
, External
Beam
Radiothera
py 3D CRT
Neoadjuva
1026 MR MR004 (6 MR004C MR004C1 M 23100 Y
nt
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
Beam fractions -
Radiothera 18 Max
1027 MR MR004 (6 additional MR004D MR004D1 M 37800 Y
(Inclusive Rs.1000
of per
& Planning
Cost)
Linear
Accelerator
, External
Beam
Radiothera
py 3D CRT
1028 MR MR005 (25 Radical MR005A MR005A1 M 44000 Y
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
, External
Beam
Radiothera
py 3D CRT
1029 MR MR005 (25 Adjuvant MR005B MR005B1 M 44000 Y
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
, External
Beam
Radiothera
py 3D CRT
Neoadjuva
1030 MR MR005 (25 MR005C MR005C1 M 44000 Y
nt
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
Beam fractions -
Radiothera 10 Max
1031 MR MR005 (25 additional MR005D MR005D1 M 21000 Y
(Inclusive Rs.1000
of per
& Planning
Cost)
Linear
Accelerator
, External
Beam
Radiothera
py IMRT
(Intensity
Modulated
Radiothera
py)
(20
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
, External
Beam
Radiothera
py IMRT
(Intensity
Modulated
Radiothera
py)
(20
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
, External
Beam
1034 MR MR006 MR006C MR006C1 M 77000 Y
py IMRT nt
(Intensity
Modulated
Radiothera
py)
(20
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator Additional
, External fractions -
Beam 15 (Every
Radiothera additional
1035 MR MR006 MR006D MR006D1 M 63000 Y
py IMRT fraction at
(Intensity Rs.2000
Modulated per
Radiothera Fraction)
py)
(20
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
, External
Beam
Radiothera
py IMRT
(Intensity
Modulated
Radiothera
py)
(6
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
, External
Beam
Radiothera
py IMRT
(Intensity
Modulated
Radiothera
py)
(6
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
, External
Beam
1038 MR MR007 MR007C MR007C1 M 46200 Y
py IMRT nt
(Intensity
Modulated
Radiothera
py)
(6
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Additional
Accelerator
fractions -
, External
18 Max
Beam
upto (Every
Radiothera
1039 MR MR007 additional MR007D MR007D1 M 75600 Y
py IMRT
fraction at
(Intensity
Rs.2000
Modulated
per
Radiothera
Fraction)
py)
(6
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
External
Beam
Radiothera
py IGRT
(Image
Guided
radiotherap
y) with 3D
CRT or
IMRT
(20
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
External
Beam
Radiothera
py IGRT
(Image
Guided
radiotherap
y) with 3D
CRT or
IMRT
(20
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
External
Beam
Radiothera
py IGRT Neoadjuva
1042 MR MR008 MR008C MR008C1 M 99000 Y
(Image nt
Guided
radiotherap
y) with 3D
CRT or
IMRT
(20
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
Additional
External
fractions -
Beam
15 Max
Radiothera
upto(Every
py IGRT
(Image
fraction at
Guided
Rs.2500
radiotherap
per
y) with 3D
Fraction)
CRT or
IMRT
(20
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
External
Beam
Radiothera
py IGRT
(Image
Guided
radiotherap
y) with 3D
CRT or
IMRT
(6
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
External
Beam
Radiothera
py IGRT
(Image
Guided
radiotherap
y) with 3D
CRT or
IMRT
(6
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
External
Beam
Radiothera
py IGRT Neoadjuva
1046 MR MR009 MR009C MR009C1 M 60500 Y
(Image nt
Guided
radiotherap
y) with 3D
CRT or
IMRT
(6
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
Linear
Accelerator
Additional
External
fractions -
Beam
18 Max
Radiothera
uptoEvery
py IGRT
(Image
fraction at
Guided
Rs.2500
radiotherap
per
y) with 3D
Fraction
CRT or
IMRT
(6
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
SRT /
SRT /
SBRT with
SBRT with
IGRT
IGRT
(Stereotac
1048 MR MR010 (Stereotac MR010A MR010A1 M 90200 Y
atic
atic
radiotherap
radiotherap
y) (4
y)
Fractions)
(Inclusive
of
Simulation
& Planning
Cost)
SRT / Additional
SBRT with fractions -
IGRT 4Every
(Stereotac additional
1049 MR MR010 MR010B MR010B1 M 92400 Y
atic fraction at
radiotherap Rs.11000
y) (4 per
Fractions) Fraction
(Inclusive
of
Simulation
& Planning
Cost)
SRS with
IGRT
(Stereotac
SRS with
atic
IGRT
radiotherap
(Stereotac
1050 MR MR011 y) MR011A MR011A1 M 77000 Y
atic
(Inclusive
radiotherap
of
y)
Simulation
& Planning
Cost)
Respiratory
Gating
along with
Linear Respiratory
Accelerator Gating
planning (5 along with
1051 MR MR012 MR012A MR012A1 M 71500 Y
Fractions) Linear
(Inclusive Accelerator
of planning
Simulation
& Planning
Cost)
Respiratory
Gating
Additional
along with
fractions -
Linear
10 Max
Accelerator
uptoEvery
planning (5
1052 MR MR012 additional MR012B MR012B1 M 73500 Y
Fractions)
fraction at
(Inclusive
Rs.3500
of
per
Simulation
Fraction
& Planning
Cost)
Brachyther
apy High
Dose
Radiation Intracavitor
1053 MR MR013 MR013A MR013A1 M 3900 Y
(2D/X-ray) y
(Maximum
of 4
session)
Brachyther
apy High
Dose
Radiation Intralumina
1054 MR MR013 MR013B MR013B1 M 3900 Y
(2D/X-ray) l
(Maximum
of 4
session)
Brachyther
apy High
Dose
Radiation
1055 MR MR013 Endobiliary MR013C MR013C1 M 3900 Y
(2D/X-ray)
(Maximum
of 4
session)
Brachyther
apy High
Dose
Radiation Endobronc
1056 MR MR013 MR013D MR013D1 M 3900 Y
(2D/X-ray) hial
(Maximum
of 4
session)
Brachyther
apy High
Dose
Radiation
1057 MR MR013 CVS MR013E MR013E1 M 3900 Y
(2D/X-ray)
(Maximum
of 4
session)
Brachyther
apy High
Dose
Radiation Interstitial /
(5 doses) Intracavitar
(Inclusive y complex
1058 MR MR014 MR014A MR014A1 M 46200 Y
of planning
Simulation, like CT or
Planning MR
Cost, OT &
other
charges )
Brachyther
apy High
Dose
Surface
Radiation
Mould /
(5 doses)
Intracavitar
(Inclusive
1059 MR MR014 y complex MR014B MR014B1 M 46200 Y
of
planning
Simulation,
like CT or
Planning
MR
Cost, OT &
other
charges )
Brachyther
apy High
Dose
Radiation
(5 doses)
Additional
(Inclusive
1060 MR MR014 fractions - MR014C MR014C1 M 39450 Y
of
11
Simulation,
Planning
Cost, OT &
other
charges )
large Dose
iodine scan/ Pre
1061 MR MR015 treatment 3 Ablation - MR015A MR015A1 M 11400 Y
mCi calculation
of
treatment
Ablation of
iodine
residual
1062 MR MR015 treatment MR015B MR015B1 M 16900 Y
disease
30 mCi
any risk
Ablation of
residual
Iodine
neck
1063 MR MR016 treatment MR016A MR016A1 M 18000 Y
disease
50 mCi
low/interm
ediate
Ablation for
Iodine
metastatic
1064 MR MR020 treatment MR020A MR020A1 M 40000 Y
disease,
250 mCi
High risk
Chemo
Chemo
Port
1393 SC SC076 Port SC076A SC076A2 S 49000 Y
Insertion
Insertion
(Pediatric)
Clinical
notes with
planned
line of
treatment
Detailed
(document
Discahrge
s
Summary
confirming
N (with RT
the
treatment
Procedure
and doses
indicated
given)
and details
of RT
treatment
plan),HPE
report
Clinical
notes with
Indications
(such as
patient
age,
general
condition,
staging,
tumour
size, nodal
Detailed
status,
Discahrge
presence
Summary
of enlarged
N (with RT
internal
treatment
mammary
and doses
nodes at
given)
baseline,
Neoadjuva
nt CT
received,
Margin
status,
pre-/ post-
surgery),
planned
line of
treatment (
Clinical
notes with
Indications
(such as
patient
age,
general
condition,
staging,
tumour
size, nodal
Detailed
status,
Discahrge
presence
Summary
of enlarged
N (with RT
internal
treatment
mammary
and doses
nodes at
given)
baseline,
Neoadjuva
nt CT
received,
Margin
status,
pre-/ post-
surgery),
planned
line of
treatment (
Clinical
notes with
Indications
(such as
patient
age,
general
condition,
staging,
tumour
size, nodal
Detailed
status,
Discahrge
presence
Summary
of enlarged
N (with RT
internal
treatment
mammary
and doses
nodes at
given)
baseline,
Neoadjuva
nt CT
received,
Margin
status,
pre-/ post-
surgery),
planned
line of
treatment (
Clinical
notes with
Indications
(such as
patient
age,
general
condition,
staging,
tumour
size, nodal
Detailed
status,
Discahrge
presence
Summary
of enlarged
N (with RT
internal
treatment
mammary
and doses
nodes at
given)
baseline,
Neoadjuva
nt CT
received,
Margin
status,
pre-/ post-
surgery),
planned
line of
treatment (
Clinical
notes with
planned
line of
treatment
Detailed
(document
Discahrge
s
Summary
confirming
N (with RT
the
treatment
Procedure
and doses
indicated
given)
and details
of RT
treatment
plan),HPE
report
Clinical
notes with
planned
line of
treatment
Detailed
(document
Discahrge
s
Summary
confirming
N (with RT
the
treatment
Procedure
and doses
indicated
given)
and details
of RT
treatment
plan),HPE
report
Clinical
notes with
Indications
(such as
patient
age,
general
condition,
staging,
tumour
size, nodal
Detailed
status,
Discahrge
presence
Summary
of enlarged
N (with RT
internal
treatment
mammary
and doses
nodes at
given)
baseline,
Neoadjuva
nt CT
received,
Margin
status,
pre-/ post-
surgery),
planned
line of
treatment (
Clinical
notes with
planned
line of
treatment
Detailed
(document
Discahrge
s
Summary
confirming
N (with RT
the
treatment
Procedure
and doses
indicated
given)
and details
of RT
treatment
plan),HPE
report
Clinical
notes with
planned
line of
treatment
Detailed
(document
Discahrge
s
Summary
confirming
N (with RT
the
treatment
Procedure
and doses
indicated
given)
and details
of RT
treatment
plan),HPE
report
Clinical
notes with
planned
line of
treatment
Detailed
(document
Discahrge
s
Summary
confirming
N (with RT
the
treatment
Procedure
and doses
indicated
given)
and details
of RT
treatment
plan),HPE
report
Clinical
notes with
Indications
(such as
patient
age,
general
condition,
staging,
tumour
size, nodal
Detailed
status,
Discahrge
presence
Summary
of enlarged
N (with RT
internal
treatment
mammary
and doses
nodes at
given)
baseline,
Neoadjuva
nt CT
received,
Margin
status,
pre-/ post-
surgery),
planned
line of
treatment (
Clinical
notes with
Indications
(such as
patient
age,
general
condition,
staging,
tumour
size, nodal
Detailed
status,
Discahrge
presence
Summary
of enlarged
N (with RT
internal
treatment
mammary
and doses
nodes at
given)
baseline,
Neoadjuva
nt CT
received,
Margin
status,
pre-/ post-
surgery),
planned
line of
treatment (
Clinical
notes with
planned
line of
treatment
Detailed
(document
Discahrge
s
Summary
confirming
N (with RT
the
treatment
Procedure
and doses
indicated
given)
and details
of RT
treatment
plan),HPE
report
Clinical
notes with
planned
line of
treatment
Detailed
(document
Discahrge
s
Summary
confirming
N (with RT
the
treatment
Procedure
and doses
indicated
given)
and details
of RT
treatment
plan),HPE
report
Clinical
notes with
Indications
(such as
patient
age,
general
condition,
staging,
tumour
size, nodal
Detailed
status,
Discahrge
presence
Summary
of enlarged
N (with RT
internal
treatment
mammary
and doses
nodes at
given)
baseline,
Neoadjuva
nt CT
received,
Margin
status,
pre-/ post-
surgery),
planned
line of
treatment (
Clinical
notes with
Indications
(such as
patient
age,
general
condition,
staging,
tumour
size, nodal
Detailed
status,
Discahrge
presence
Summary
of enlarged
N (with RT
internal
treatment
mammary
and doses
nodes at
given)
baseline,
Neoadjuva
nt CT
received,
Margin
status,
pre-/ post-
surgery),
planned
line of
treatment (
Clinical
notes with
planned
line of
treatment
Detailed
(document
Discahrge
s
Summary
confirming
N (with RT
the
treatment
Procedure
and doses
indicated
given)
and details
of RT
treatment
plan),HPE
report
Clinical
notes with
planned
line of
treatment
Detailed
(document
Discahrge
s
Summary
confirming
N (with RT
the
treatment
Procedure
and doses
indicated
given)
and details
of RT
treatment
plan),HPE
report
Clinical
notes with
Indications
(such as
patient
age,
general
condition,
staging,
tumour
size, nodal
Detailed
status,
Discahrge
presence
Summary
of enlarged
N (with RT
internal
treatment
mammary
and doses
nodes at
given)
baseline,
Neoadjuva
nt CT
received,
Margin
status,
pre-/ post-
surgery),
planned
line of
treatment (
Clinical
notes with
planned
line of
treatment
Detailed
(document
Discahrge
s
Summary
confirming
N (with RT
the
treatment
Procedure
and doses
indicated
given)
and details
of RT
treatment
plan),HPE
report
Clinical
notes with
planned
line of
treatment
Detailed
(document
Discahrge
s
Summary
confirming
N (with RT
the
treatment
Procedure
and doses
indicated
given)
and details
of RT
treatment
plan),HPE
report
Clinical
notes with
Indications
(such as
patient
age,
general
condition,
staging,
tumour
size, nodal
Detailed
status,
Discahrge
presence
Summary
of enlarged
N (with RT
internal
treatment
mammary
and doses
nodes at
given)
baseline,
Neoadjuva
nt CT
received,
Margin
status,
pre-/ post-
surgery),
planned
line of
treatment (
Clinical
notes with
Indications
(such as
patient
age,
general
condition,
staging,
tumour
size, nodal
Detailed
status,
Discahrge
presence
Summary
of enlarged
N (with RT
internal
treatment
mammary
and doses
nodes at
given)
baseline,
Neoadjuva
nt CT
received,
Margin
status,
pre-/ post-
surgery),
planned
line of
treatment (
Clinical
notes with
Indications
(such as
patient
age,
general
condition,
staging,
tumour
size, nodal
Detailed
status,
Discahrge
presence
Summary
of enlarged
N (with RT
internal
treatment
mammary
and doses
nodes at
given)
baseline,
Neoadjuva
nt CT
received,
Margin
status,
pre-/ post-
surgery),
planned
line of
treatment (
Clinical
notes with
planned
line of
treatment
Detailed
(document
Discahrge
s
Summary
confirming
N (with RT
the
treatment
Procedure
and doses
indicated
given)
and details
of RT
treatment
plan),HPE
report
Clinical
notes with
planned
line of
treatment
Detailed
(document
Discahrge
s
Summary
confirming
N (with RT
the
treatment
Procedure
and doses
indicated
given)
and details
of RT
treatment
plan),HPE
report
Clinical
notes with
Indications
(such as
patient
age,
general
condition,
staging,
tumour
size, nodal
Detailed
status,
Discahrge
presence
Summary
of enlarged
N (with RT
internal
treatment
mammary
and doses
nodes at
given)
baseline,
Neoadjuva
nt CT
received,
Margin
status,
pre-/ post-
surgery),
planned
line of
treatment (
Clinical
notes with
planned
line of
treatment
Detailed
(document
Discahrge
s
Summary
confirming
N (with RT
the
treatment
Procedure
and doses
indicated
given)
and details
of RT
treatment
plan),HPE
report
Clinical
notes with
planned
line of
treatment
Detailed
(document
Discahrge
s
Summary
confirming
N (with RT
the
treatment
Procedure
and doses
indicated
given)
and details
of RT
treatment
plan),HPE
report
Clinical
notes with
Indications
(such as
patient
age,
general
condition,
staging,
tumour
size, nodal
Detailed
status,
Discahrge
presence
Summary
of enlarged
N (with RT
internal
treatment
mammary
and doses
nodes at
given)
baseline,
Neoadjuva
nt CT
received,
Margin
status,
pre-/ post-
surgery),
planned
line of
treatment (
Clinical
notes with
planned
line of
treatment
Detailed
(document
Discahrge
s
Summary
confirming
N (with RT
the
treatment
Procedure
and doses
indicated
given)
and details
of RT
treatment
plan),HPE
report
Biopsy/
HPE report
of
malignancy
,Clinical
notes with
Indications
of SRS
(such as
patient
age,
general Detailed
condition, Discahrge
staging, Summary
N tumour (with RT
size, nodal treatment
status, and doses
presence given)
of enlarged
internal
mammary
nodes at
baseline,
Neoadjuva
nt CT
received,
Margin
status,
pre-/ pos
Clinical
notes and
Documenta
ry evidence
confirming
the need of
Respiratory
-gated
radiotherap
Detailed
y (tumours
Discahrge
that move
Summary
with
N (with RT
respiration
treatment
during
and doses
radiotherap
given)
y (lung,
breast and
upper
abdominal
tumpurs),C
linical
notes and
documenta
ry evidence
confirming
the need of
Clinical
notes and
Documenta
ry evidence
confirming
the need of
Respiratory Detailed
-gated Discahrge
radiotherap Summary
N y (tumours (with RT
that move treatment
with and doses
respiration given)
during
radiotherap
y (lung,
breast and
upper
abdominal
tumpurs)
Clinical
notes with
planned
line of
treatment
Detailed
(document
Discahrge
s
Summary
confirming
N (with RT
the
treatment
Procedure
and doses
indicated
given)
and details
of RT
treatment
plan),HPE
report
Clinical
notes with
planned
line of
treatment
Detailed
(document
Discahrge
s
Summary
confirming
N (with RT
the
treatment
Procedure
and doses
indicated
given)
and details
of RT
treatment
plan),HPE
report
Clinical
notes with
planned
line of
treatment
Detailed
(document
Discahrge
s
Summary
confirming
N (with RT
the
treatment
Procedure
and doses
indicated
given)
and details
of RT
treatment
plan),HPE
report
Clinical
notes with
planned
line of
treatment
Detailed
(document
Discahrge
s
Summary
confirming
N (with RT
the
treatment
Procedure
and doses
indicated
given)
and details
of RT
treatment
plan),HPE
report
Clinical
notes with
planned
line of
treatment
Detailed
(document
Discahrge
s
Summary
confirming
N (with RT
the
treatment
Procedure
and doses
indicated
given)
and details
of RT
treatment
plan),HPE
report
Clinical
notes with
Indications
(such as
patient
age,
general
condition,
staging,
tumour
size, nodal
Detailed
status,
Discahrge
presence
Summary
of enlarged
N (with RT
internal
treatment
mammary
and doses
nodes at
given)
baseline,
Neoadjuva
nt CT
received,
Margin
status,
pre-/ post-
surgery),
planned
line of
treatment (
Clinical
notes with
Indications
(such as
patient
age,
general
condition,
staging,
tumour
size, nodal
Detailed
status,
Discahrge
presence
Summary
of enlarged
N (with RT
internal
treatment
mammary
and doses
nodes at
given)
baseline,
Neoadjuva
nt CT
received,
Margin
status,
pre-/ post-
surgery),
planned
line of
treatment (
Clinical
notes with
planned
line of
treatment
Detailed
(document
Discahrge
s
Summary
confirming
N (with RT
the
treatment
Procedure
and doses
indicated
given)
and details
of RT
treatment
plan),HPE
report
Biopsy/
HPE,Radio
Biopsy/
N iodine
FNAC
original
treatment
chart,THY
ROID
SCAN
Biopsy/
HPE,Radio
Biopsy/
N iodine
FNAC
original
treatment
chart,THY
ROID
SCAN
Biopsy/
Biopsy/
N HPE,Radio
FNAC
iodine
original
treatment
chart,THY
ROID
SCAN
Biopsy/
Biopsy/
N HPE,Radio
FNAC
iodine
original
treatment
chart,THY
ROID
SCAN
Discharge
summary,I
nvoice of
Clinical Chemo
notes with port
N planned used,Proce
line of dure /
treatment Operative
Notes,Proc
edure /
Operative
Notes

Himcare Excel Sheet

Uploaded by

Copyright:

Available Formats

You might also like

Himcare Excel Sheet

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Himcare Excel Sheet

Uploaded by

Copyright:

Available Formats

Package Package PackageID Governme

Category Category PackageN PackageD PackageId IsMedSur PreAuthS

627 MO MO019 MO019F MO019F1 S 19200 Y N

684 MO MO029 1.4 mg/m2, MO029A MO029A1 S 28900 Y N

685 MO MO029 MO029B MO029B1 S 29700 Y N

731 MO MO049 MO049A MO049A1 S 79200 Y N

913 MP MG098 PET scan PET scan MG098A MG098A1 M Y N

1761 SG SG096 Biopsy Vulval SG096E SG096E1 S 2500 Y N

abdomen and Pelvis,HPE or cytology suggestive NFUSION

abdomen and Pelvis,HPE or cytology suggestive NFUSION

abdomen and Pelvis,HPE or cytology suggestive NFUSION

Thorax, abdomen,Clinical notes with DEPARTM

Thorax, abdomen, Pelvis,Clinical notes with DEPARTM

Thorax, abdomen, Pelvis,CECT Thorax,

Thorax, abdomen, Pelvis,CECT Thorax,

abdomen and Pelvis,histopathology,LFT,M NFUSION

,CBC,CECT Abdomen &Pelvis ,CECT Thorax,

,CBC,CECT Abdomen &Pelvis ,CECT Thorax,

,CBC,CECT Abdomen &Pelvis ,CECT Thorax,

,Chest X-ray,Ckit-mutation (not mandatory),C-kit

,Chest X-ray,Ckit-mutation (not mandatory),C-kit

Thorax, abdomen and NFUSION

HbsAg , HCV and HIV,CECT (chest +abdomen

HbsAg , HCV and HIV,CECT (chest +abdomen

+abdomen +Pelvis) or PET- CT,Clinical notes

Viral markers . HbsAg , HCV and HIV,CECT RADIOLO

Viral markers . HbsAg , HCV and HIV,CECT RADIOLO

,Bone marrow studies,CBC,CBC, ESR,

+abdomen +Pelvis) or PET- CT report,Clinical RADIOLO

+abdomen +Pelvis) or PET- CT report,Clinical RADIOLO

Biopsy,BONE MARROW,Bone marrow

LFT, RFT, Viral markers . HbsAg , HCV and

+abdomen +Pelvis) or PET- CT,Clinical notes

All investigations reports including ,,Discharge

confirming the need of

MO MO001 CT for CA Breast

CT for Metastatic bone

MO MO003 CT for CA Ovary

MO MO003 CT for CA Ovary

MO MO003 CT for CA Ovary

MO MO004 CT for Germ Cell Tumor

MO MO004 CT for Germ Cell Tumor

MO MO004 CT for Germ Cell Tumor

MO MO004 CT for Germ Cell Tumor

MO MO004 CT for Germ Cell Tumor

MO MO004 CT for Germ Cell Tumor

MO MO006 CT for Cervical Cancer

MO MO008 CT for Vulvar Cancer

MO MO008 CT for Vulvar Cancer

MO MO008 CT for Vulvar Cancer

MO MO009 CT for Ewing Sarcoma

MO MO009 CT for Ewing Sarcoma

MO MO009 CT for Ewing Sarcoma

CT for Soft Tissue

MO MO013 CT for Anal Cancer

MO MO013 CT for Anal Cancer

MO MO013 CT for Anal Cancer

MO MO013 CT for Anal Cancer

MO MO014 CT for Colorectal Cancer